

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 July 2001 (12.07.2001)

PCT

(10) International Publication Number
WO 01/49854 A2

- (51) International Patent Classification⁷: C12N 15/52, 15/54, 15/31, 9/12, C12P 13/04, 13/08 // (C12P 13/04, C12R 1:15)
- (71) Applicant: ARCHER-DANIELS-MIDLAND COMPANY [US/US]; 4666 Faries Parkway, Decatur, IL 62526 (US).
- (21) International Application Number: PCT/US00/35617
- (71) Applicants and
- (72) Inventors: HANKE, Paul, D. [US/US]; 2565 Autumn Grove Court, Aurora, IL 60504 (US). LI-D'ELIA, Lhing-Yew [—/US]; 1903 Oak Park Drive, Champaign, IL 61821 (US). RAYAPATI, John [US/US]; 949 Pine Hill Drive, Decatur, IL 62521 (US).
- (22) International Filing Date:
29 December 2000 (29.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (27) Agents: LUDWIG, Steven, R. et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., Suite 600, 1100 New York Avenue, Washington, DC 20005-3934 (US).
- (30) Priority Data:
60/173,707 30 December 1999 (30.12.1999) US
60/184,130 22 February 2000 (22.02.2000) US
09/722,441 28 November 2000 (28.11.2000) US
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

[Continued on next page]

(54) Title: INCREASED LYSINE PRODUCTION BY GENE AMPLIFICATION

SEQUENCE ID

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2



LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

Published:

— *Without international search report and to be republished
upon receipt of that report.*

- (84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Increased Lysine Production by Gene Amplification

5

10

Background of the Invention

Field of the Invention

15

The invention relates to the areas of microbial genetics and recombinant DNA technology. The invention provides gene sequences, vectors, microorganisms, promoters and regulatory proteins useful for the production of L-lysine. The invention further provides a method to increase the production of L-lysine.

Related Art

20

L-lysine is an important economic product obtained principally by industrial-scale fermentation utilizing the Gram positive *Corynebacterium glutamicum*, *Brevibacterium flavum* and *Brevibacterium lactofermentum* (Kleemann, A., et. al., Amino Acids, in ULLMANN'S ENCYCLOPEDIA OF INDUSTRIAL CHEMISTRY, vol. A2, pp.57-97, Weinham: VCH-Verlagsgesellschaft (1985)).

25

The stereospecificity of the amino acids produced by fermentation makes the process advantageous compared with synthetic processes; generally L-form

-2-

amino acids are produced by the microbial fermentation process. The production of L-lysine and other amino acids through fermentation, utilizing cheap carbon sources such as molasses, glucose, acetic acid and ethanol, is a relatively inexpensive means of production.

5 Microorganisms employed in microbial processes for amino acid production may be divided into 4 classes: wild-type strain, auxotrophic mutant, regulatory mutant and auxotrophic regulatory mutant (K. Nakayama *et al.*, in NUTRITIONAL IMPROVEMENT OF FOOD AND FEED PROTEINS, M. Friedman, ed., (1978), pp. 649-661).

10 Several fermentation processes utilizing various strains isolated for auxotrophic or resistance properties are known in the art for the production of L-lysine: U.S. Patent No. 2,979,439 discloses mutants requiring amino acid supplementation (homoserine, or L-methionine and L-threonine); U.S. Patent No. 3,700,557 discloses mutants having a nutritional requirement for L-threonine, L-methionine, L-arginine, L-histidine, L-leucine, L-isoleucine, L-phenylalanine, L-cystine, or L-cysteine; U.S. Patent No. 3,707,441 discloses a mutant having a resistance to an L-lysine analog; U.S. Patent No. 3,687,810 discloses a mutant having both an ability to produce L-lysine and a resistance to bacitracin, penicillin G or polymyxin; U.S. Patent No. 3,708,395 discloses mutants having a nutritional requirement for homoserine, L-threonine, L-threonine and L-methionine, L-leucine, L-isoleucine or mixtures thereof and a resistance to L-lysine, L-threonine, L-isoleucine or analogs thereof; U.S. Patent No. 3,825,472 discloses a mutant having a resistance to an L-lysine analog; U.S. Patent No. 4,169,763 discloses mutant strains of *Corynebacterium* that produce L-lysine and are resistant to at least one of aspartic analogs and sulfa drugs; U.S. Patent No. 5,846,790 discloses a mutant strain able to produce L-glutamic acid and L-lysine in the absence of any biotin action-suppressing agent; and U.S. Patent No. 5,650,304 discloses a strain belonging to the genus *Corynebacterium* or *Brevibacterium* for the production of L-lysine that is resistant to 4-N-(D-alanyl)-2,4-diamino-2,4-dideoxy-L-arabinose 2,4-dideoxy-L-arabinose or a derivative thereof.

25

30

A considerable amount is known regarding the biochemical pathway for L-lysine synthesis in *Corynebacterium* species (recently reviewed by Sahm *et al.*, *Ann. N. Y. Acad. Sci.* 782: 25-39 (1996)). Entry into the L-lysine pathway begins with L-aspartate (see Figure 1), which itself is produced by transamination of oxaloacetate. A special feature of *C. glutamicum* is its ability to convert the L-lysine intermediate piperidine 2,6-dicarboxylate to diaminopimelate by two different routes, i.e. by reactions involving succinylated intermediates or by the single reaction of diaminopimelate dehydrogenase. Overall, carbon flux into the pathway is regulated at two points: first, through feedback inhibition of aspartate kinase by the levels of both L-threonine and L-lysine; and second through the control of the level of dihydrodipicolinate synthase. Therefore, increased production of L-lysine may be obtained in *Corynebacterium* species by deregulating and increasing the activity of these two enzymes.

More recent developments in the area of L-lysine fermentative production in *Corynebacterium* species involve the use of molecular biology techniques to augment L-lysine production. The following examples are provided as being exemplary of the art: U. S. Patent Nos. 4,560,654 and 5,236,831 disclose an L-lysine producing mutant strain obtained by transforming a host *Corynebacterium* or *Brevibacterium* species microorganism which is sensitive to S-(2-aminoethyl)-cysteine with a recombinant DNA molecule wherein a DNA fragment conferring both resistance to S-(2-aminoethyl)-cysteine and L-lysine producing ability is inserted into a vector DNA; U. S. Patent No. 5,766,925 discloses a mutant strain produced by integrating a gene coding for aspartokinase, originating from coryneform bacteria, with desensitized feedback inhibition by L-lysine and L-threonine, into chromosomal DNA of a *Corynebacterium* species bacterium harboring leaky type homoserine dehydrogenase or a *Corynebacterium* species deficient in homoserine dehydrogenase gene; increased L-lysine production is obtained by gene amplification by way of a plasmid vector or utilizing a gene replacement strategy. European Patent Applications EP 0 811 682 A2 and EP 0 854 189 A2

both provide for increased production of L-lysine in *Corynebacterium* species by way of gene amplification based on plasmid copy number.

Summary of the Invention

5 It is an object of the invention to provide a method to increase the production of an amino acid in *Corynebacterium* species by amplifying, i.e., increasing, the number of a gene or genes of an amino acid biosynthetic pathway in a host cell. Particularly preferred *Corynebacterium* species include *Corynebacterium glutamicum*, *Brevibacterium flavum*, and *Brevibacterium lactofermentum*.

10 It is an object of the invention to provide an isolated feed back resistant aspartokinase enzyme wherein the naturally occurring threonine amino acid residue 380 in the feedback sensitive form is changed to isoleucine in the *ask* gene of ATCC 21529. It is an object of the invention to provide an isolated *ask* polypeptide comprising the amino acid sequence of SEQ ID NO:2. It is another object of the invention to provide an isolated polynucleotide molecule
15 comprising a nucleotide sequence encoding the polypeptide sequence of SEQ ID NO:2. It is another object of the invention to provide an isolated polynucleotide molecule comprising a nucleic acid having the sequence of SEQ ID NO:1.

20 It is another object of the invention to provide a method comprising transforming a *Corynebacterium* species host cell with a polynucleotide molecule comprising a nucleotide sequence encoding a polypeptide comprising amino acid SEQ ID NO:2, wherein said isolated polynucleotide molecule is integrated into said host cell's chromosome thereby increasing the total number of said amino acid biosynthetic pathway genes in said host cell chromosome, and selecting a
25 transformed host cell. It is a further object of the invention to provide a method comprising screening for increased amino acid production. The method may further comprise growing said transformed host cell in a medium and purifying an amino acid produced by said transformed host cell.

In another embodiment, a method to increase the production of an amino acid is a method comprising transforming a *Corynebacterium* species host cell with an isolated nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:2, wherein said isolated nucleic acid molecule is integrated into said host cell's chromosome thereby increasing the total number of said amino acid biosynthetic pathway genes in said host cell chromosome, and wherein said isolated nucleic acid molecule further comprises at least one of the following: a polynucleotide encoding a *Corynebacterium* species lysine pathway *asd* amino acid sequence; a polynucleotide encoding a *Corynebacterium* species lysine pathway *dapA* amino acid sequence; a polynucleotide encoding a *Corynebacterium* species lysine pathway *dapB* amino acid sequence; a polynucleotide encoding a *Corynebacterium* species lysine pathway *ddh* amino acid sequence; a polynucleotide encoding a *Corynebacterium* species lysine pathway *lysA* amino acid sequence; a polynucleotide encoding a *Corynebacterium* species lysine pathway *lysA* amino acid sequence; a polynucleotide encoding a *Corynebacterium* species lysine pathway *ORF2* amino acid sequence, and selecting a transformed host cell. The method may further comprise growing said transformed host cell in a medium and purifying an amino acid produced by said transformed host cell.

The term " *lysA* " refers to a truncated *lysA* gene or amino acid sequence used by Applicants and described *infra*. The term "*lysA*" refers to the full length *lysA* gene or amino acid sequence used by Applicants and described *infra*.

It is another object of the invention to provide an isolated polynucleotide molecule comprising a nucleic acid molecule encoding the *Corynebacterium glutamicum* lysine pathway *ask* amino acid sequence of SEQ ID NO:2; and at least one additional *Corynebacterium* species lysine pathway gene selected from the group consisting of a nucleic acid molecule encoding the *asd* polypeptide, a nucleic acid molecule encoding the *dapA* polypeptide, a nucleic acid molecule encoding the *dapB* polypeptide, a nucleic acid molecule encoding the *ddh* polypeptide, a nucleic acid molecule encoding the *lysA* polypeptide, a nucleic acid molecule encoding the *lysA* polypeptide and a nucleic acid molecule

encoding the *ORF2* polypeptide. In a preferred embodiment of the invention, the isolated polynucleotide molecule comprises pK184-KDABH'L. In another preferred embodiment of the invention, the isolated nucleic acid molecule comprises pK184-KDAB. In another preferred embodiment of the invention, the isolated nucleic acid molecule comprises pD2-KDABHL. In another preferred embodiment of the invention, the isolated nucleic acid molecule comprises pD11-KDABHL.

It is another object of the invention to provide a host cell transformed with an isolated polynucleotide molecule comprising a nucleotide sequence encoding an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the isolated nucleic acid molecule is integrated into the host cell's chromosome thereby increasing the total number of amino acid biosynthetic pathway genes in the host cell chromosome. In one embodiment the polynucleotide further comprises at least one additional *Corynebacterium* species lysine pathway gene selected from the group consisting of: a nucleic acid molecule encoding an *asd* polypeptide; a nucleic acid molecule encoding a *dapA* polypeptide; a nucleic acid molecule encoding a *dapB* polypeptide; a nucleic acid molecule encoding a *ddh* polypeptide; a nucleic acid molecule encoding a *lysA* polypeptide; a nucleic acid molecule encoding a *lysA* polypeptide; and a nucleic acid molecule encoding an *ORF2* polypeptide.

In another embodiment, the polynucleotide further comprises a nucleic acid molecule encoding a polypeptide wherein said *asd* polypeptide is SEQ ID NO:4; said *dapA* polypeptide is SEQ ID NO:6; said *dapB* polypeptide is SEQ ID NO:8; said *ddh* polypeptide is SEQ ID NO:10; said *lysA* polypeptide is SEQ ID NO:21; said *lysA* polypeptide is SEQ ID NO:14; and said *ORF2* polypeptide is SEQ ID NO:16.

In another embodiment, the polynucleotide further comprises a nucleic acid molecule wherein said *asd* polypeptide is SEQ ID NO:4; said *dapA* polypeptide is SEQ ID NO:6; said *dapB* polypeptide is SEQ ID NO:8; said *ddh* polypeptide is SEQ ID NO:10; said *lysA* polypeptide is SEQ ID NO:21; said

lysA polypeptide is SEQ ID NO:14; and said *ORF2* polypeptide is SEQ ID NO:16.

In another embodiment, the polynucleotide further comprises a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4; a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6; a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8; and a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

In another embodiment, the polynucleotide further comprises a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4; a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6; a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8; a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10; and a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

In another embodiment, the polynucleotide further comprises a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4; a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6; a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8; a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10; a nucleic acid molecule encoding the *lysA* amino acid sequence of SEQ ID NO:21; and a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

In another embodiment, the polynucleotide further comprises a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4; a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6; a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8; a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10; a nucleic acid molecule encoding the *lysA* amino acid sequence of SEQ ID NO:14; and a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

-8-

In one embodiment, the transformed host cell is a *Brevibacterium* selected from the group consisting of *Brevibacterium flavum* NRRL-B30218, *Brevibacterium flavum* NRRL-B30219, *Brevibacterium lactofermentum* NRRL-B30220, *Brevibacterium lactofermentum* NRRL-B30221, *Brevibacterium lactofermentum* NRRL-B30222, *Brevibacterium flavum* NRRL-30234 and *Brevibacterium lactofermentum* NRRL-30235. In another embodiment, the host cell is *Escherichia coli* DH5 α MCR NRRL-B30228. In another embodiment, the host cell is a *C. glutamicum* selected from the group consisting of *C. glutamicum* NRRL-B30236 and *C. glutamicum* NRRL-B30237.

It is another object of the invention to provide a method of producing lysine comprising culturing the host cells comprising the amino acid sequence of SEQ ID NO: 2 wherein said host cells comprise one or more of (a) increased enzyme activity of one or more lysine biosynthetic pathway enzymes compared to the genetically unaltered nonhuman host cell; (b) one or more copies of each gene encoding a lysine biosynthetic pathway enzyme; and, (c) alteration of one or more transcription factors regulating transcription of one or more genes encoding a lysine biosynthetic pathway enzyme, wherein said host cell produces lysine in said culture medium. In one embodiment of the invention, the increased enzyme activity comprises overexpressing one or more genes encoding one or more lysine biosynthetic pathway enzymes. In another embodiment of the invention the increased enzyme activity results from the activity of one or more modified lysine biosynthetic pathway enzymes wherein said enzyme modification results in a change in kinetic parameters, allosteric regulation, or both, compared to the enzyme lacking the modification. In another embodiment of the invention, alteration of one or more transcription factors comprises one or more mutations in transcription inhibitor proteins, one or more mutations in transcription activator proteins, or both, wherein said one or more mutations increases transcription of the target nucleotide sequence compared to the transcription by said one or more transcription factors lacking said alteration(s).

It is an object of the invention to provide an isolated polypeptide, wherein said polypeptide comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:19. It is a further object of the invention to provide an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:19. It is a further object of the invention to provide an isolated polynucleotide comprising a nucleic acid having the sequence of SEQ ID NO:18. It is another object of the invention to provide host cell NRRL B30360.

It is an object of the invention to provide an isolated polypeptide wherein said polypeptide comprises a polypeptide having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:21. It is a further object of the invention to provide an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:21. It is a further object of the invention to provide a polynucleotide molecule comprising a nucleic acid having the sequence of SEQ ID NO:20.

It is an object of the invention to provide an isolated polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:2, further comprising a promoter sequence where said promoter sequence has at least 95% sequence identity to SEQ ID NO:17. It is a further object of the invention to provide an isolated polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polynucleotide molecule further comprises the sequence of SEQ ID NO:17. It is a further object of the invention to provide a host cell NRRL B30359.

Further objects and advantages of the present invention will be clear from the description that follows.

Brief Description of the Figures

Figure 1. A schematic of the L-lysine biosynthetic pathway in *Corynebacterium glutamicum* (Sahm *et al.*).

Figure 2. The nucleotide sequence of *ask* (ATCC 21529 sequence) (SEQ ID NO:1).

Figure 3 A, B. The amino acid sequence of *ask* (ATCC 21529 sequence) (SEQ ID NO:2).

Figure 4. The nucleotide sequence of *asd* (ATCC 21529 sequence) (SEQ ID NO:3).

Figure 5 A, B. The amino acid sequence of *asd* (ATCC 21529 sequence) (SEQ ID NO:4).

Figure 6. The nucleotide sequence of *dapA* (NRRL-B11474) (SEQ ID NO:5).

Figure 7. The amino acid sequence of *dapA* (NRRL-B11474) (SEQ ID NO:6).

Figure 8. The nucleotide sequence of *dapB* (NRRL-B11474) (SEQ ID NO:7).

Figure 9. The amino acid sequence of *dapB* (NRRL-B11474) (SEQ ID NO:8).

Figure 10. The nucleotide sequence of *ddh* (NRRL-B11474) (SEQ ID NO:9).

Figure 11 A, B. The amino acid sequence of *ddh* (NRRL-B11474) (SEQ ID NO:10).

Figure 12. The nucleotide sequence of full length *lysA* (NRRL-B11474) (SEQ ID NO:11) used to obtain the truncated *lysA* ('*lysA*') nucleotide sequence. Underlined region annealed with *lysA* primer.

Figure 13. The amino acid sequence of full length *lysA* (NRRL-B11474) (SEQ ID NO:12) comprising the truncated *lysA* ('*lysA*') amino acid sequence (SEQ ID NO: 21). Underlined L: the last amino acid residue of *lysA* encoded in the truncated PCR product.

Figure 14. The nucleotide sequence of full length *lysA* (pRS6) (SEQ ID NO:13).

Figure 15 A, B, C. The amino acid sequence of full length *lysA* (pRS6) (SEQ ID NO:14).

5 **Figure 16.** The nucleotide sequence of ORF2 (NRRL-B11474) (SEQ ID NO:15).

Figure 17. The amino acid sequence of ORF2 (NRRL-B11474) (SEQ ID NO:16).

10 **Figure 18.** A schematic depiction of the construction of the 5 and 6 lysine pathway gene constructs of the invention.

Figure 19. Comparison of the aspartokinase (*ask*) amino acid sequence from ATCC13032, N13 and ATCC21529.

Figure 20. The nucleotide sequence of the HpaI-PvuII fragment from pRS6 (SEQ ID NO:17) comprising the P1 promoter.

15 **Figure 21 A, B.** A schematic depiction of the construction of the pDElia2-KDABHP1L construct.

Figure 22. A schematic depiction of the construction of the pDElia2_{FC5}-KDBHL construct.

Figure 23. The nucleotide sequence of truncated ORF2 (SEQ ID NO:18).

20 **Figure 24.** The amino acid sequence of truncated ORF2 (SEQ ID NO:19).

Figure 25. The nucleotide sequence of truncated LysA ('lysA')(NRRL-B11474) (SEQ ID NO:20).

25 **Figure 26.** The amino acid sequence of truncated LysA ('LysA')(NRRL-B11474) (SEQ ID NO:21).

Detailed Description of the Preferred Embodiments

A. Definitions

In order to provide a clear and consistent understanding of the specification and claims, including the scope to be given such terms, the following definitions are provided. It is also to be noted that the term "a" or "an" entity, refers to one or more of that entity; for example, "a polynucleotide," is understood to represent one or more polynucleotides.

Allosteric Regulation. As used herein, the term refers to regulation of enzyme activity through the binding of one or more ligands (allosteric effectors) to one or more binding sites. The ligands may be the same molecule or different molecules. The molecules bind to sites on the enzyme other than the enzyme active site. As a result of the binding, a conformational change is induced in the enzyme which regulates affinity of the active site for its substrate or other ligands. Allosteric effectors may serve to enhance catalytic site substrate affinity (allosteric activators) or to reduce affinity (allosteric repressors). Allosteric effectors form the basis of metabolic control mechanisms such as feedback loops, for example (See, Copeland, Robert A., in *Enzymes. A Practical Introduction to Structure, Mechanism, and Data Analysis*, pages 279-296, Wiley-VCH, New York (1996)).

Amino Acid Biosynthetic Pathway Genes. As used herein, the term "amino acid biosynthetic pathway gene(s)" is meant to include those genes and genes fragments encoding peptides, polypeptides, proteins, and enzymes, which are directly involved in the synthesis of amino acids. These genes may be identical to those which naturally occur within a host cell and are involved in the synthesis of any amino acid, and particularly lysine, within that host cell. Alternatively, there may be modifications or mutations of such genes, for example, the genes may contain modifications or mutations which do not significantly affect the biological activity of the encoded protein. For example, the natural gene may be modified by mutagenesis or by introducing or

-13-

substituting one or more nucleotides or by removing nonessential regions of the gene. Such modifications are readily performed by standard techniques.

Auxotroph. As used herein, the term refers to a strain of microorganism requiring for growth an external source of a specific metabolite that cannot be synthesized because of an acquired genetic defect.

Amino Acid Supplement. As used herein, the term refers to an amino acid required for growth and added to minimal media to support auxotroph growth.

Chromosomal Integration. As used herein, the term refers to the insertion of an exogenous DNA fragment into the chromosome of a host organism; more particularly, the term is used to refer to homologous recombination between an exogenous DNA fragment and the appropriate region of the host cell chromosome.

Enhancers. As used herein, the term refers to a DNA sequence which can stimulate promoter activity and may be an endogenous element or a heterologous element inserted to enhance the level, i.e., strength of a promoter.

High Yield Derivative. As used herein, the term refers to strain of microorganism that produces a higher yield from dextrose of a specific amino acid when compared with the parental strain from which it is derived.

Host Cell. As used herein, the term "host cell" is intended to be interchangeable with the term "microorganism." Where a difference is intended, the difference will be made clear.

Isolated Nucleic Acid Molecule. As used herein, the term is intended to mean a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, recombinant DNA molecules contained in a vector are considered isolated for the purposes of the present invention. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the DNA molecules of the present invention. Isolated nucleic acid

molecules according to the present invention further include such molecules produced synthetically.

Lysine Biosynthetic Pathway Protein. As used herein, the term "lysine biosynthetic pathway protein" is meant to include those peptides, polypeptides, proteins, and enzymes, which are directly involved in the synthesis of lysine from aspartate. Also included are amino acid sequences as encoded by open reading frames (ORF), where the ORF is associated with a lysine biosynthetic pathway operon. These proteins may be identical to those which naturally occur within a host cell and are involved in the synthesis of lysine within that host cell. Alternatively, there may be modifications or mutations of such proteins, for example, the proteins may contain modifications or mutations which do not significantly affect the biological activity of the protein. For example, the natural protein may be modified by mutagenesis or by introducing or substituting one or more amino acids, preferably by conservative amino acid substitution, or by removing nonessential regions of the protein. Such modifications are readily performed by standard techniques. Alternatively, lysine biosynthetic proteins may be heterologous to the particular host cell. Such proteins may be from any organism having genes encoding proteins having the same, or similar, biosynthetic roles.

Mutagenesis. As used herein, the term refers to a process whereby a mutation is generated in DNA. With "random" mutagenesis, the exact site of mutation is not predictable, occurring anywhere in the genome of the microorganism, and the mutation is brought about as a result of physical damage caused by agents such as radiation or chemical treatment. rDNA mutagenesis is directed to a cloned DNA of interest, and it may be random or site-directed.

Mutation. As used herein, the term refers to a one or more base pair change, insertion or deletion, or a combination thereof, in the nucleotide sequence of interest.

Operably Linked. As used herein, the term "operably linked" refers to a linkage of polynucleotide elements in a functional relationship. A nucleic acid is "operably linked" when it is placed into a functional relationship with another

-15-

nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence. Operably linked means that the DNA sequences being linked are typically contiguous and, where necessary, join two protein coding regions, contiguous and in reading frame. However, since enhancers generally function when separated from the promoter by several kilobases and intronic sequences may be of variable lengths, some polynucleotide elements may be operably linked but not contiguous.

Operon. As used herein, the term refers to a contiguous portion of a transcriptional complex in which two or more open reading frames encoding polypeptides are transcribed as a multi-cistronic messenger RNA, controlled by a cis-acting promoter and other cis-acting sequences necessary for efficient transcription, as well as additional cis acting sequences important for efficient transcription and translation (*e.g.*, mRNA stability controlling regions and transcription termination regions). The term generally also refers to a unit of gene expression and regulation, including the structural genes and regulatory elements in DNA.

Parental Strain. As used herein, the term refers to a strain of host cell subjected to some form of treatment to yield the host cell of the invention.

Percent Yield From Dextrose. As used herein, the term refers to the yield of amino acid from dextrose defined by the formula $[(\text{g amino acid produced} / \text{g dextrose consumed}) * 100] = \% \text{ Yield}$.

Phenotype. As used herein, the term refers to observable physical characteristics dependent upon the genetic constitution of a host cell.

Promoter. As used herein, the term "promoter" has its art-recognized meaning, denoting a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription and thus refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes. In general, a coding sequence is located 3' to a promoter sequence. Sequence elements within promoters that function in the

-16-

initiation of transcription are often characterized by consensus nucleotide sequences. The promoter sequence consists of proximal and more distal upstream elements (enhancers). As used herein, the term "endogenous promoter" refers to a promoter sequence which is a naturally occurring promoter sequence in that host microorganism. The term "heterologous promoter" refers to a promoter sequence which is a non-naturally occurring promoter sequence in that host microorganism. The heterologous occurring promoter sequence may be from any prokaryotic or eukaryotic organism. A synthetic promoter is a nucleotide sequence, having promoter activity, and not found naturally occurring in nature.

Promoters may be derived in their entirety from a native gene, or be hybrid promoters. Hybrid promoters are composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. Hybrid promoters may be constitutive, inducible or environmentally responsive.

Useful promoters include constitutive and inducible promoters. Many such promoter sequences are known in the art. See, for example, U.S. Pat. Nos. 4,980,285; 5,631,150; 5,707,828; 5,759,828; 5,888,783; 5,919,670, and, *Sambrook, et al., Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Press (1989). Other useful promoters include promoters which are neither constitutive nor responsive to a specific (or known) inducer molecule. Such promoters may include those that respond to developmental cues (such as growth phase of the culture), or environmental cues (such as pH, osmoticum, heat, or cell density, for example).

Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions, elevated temperature, or the presence of light. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different cell types, or in response to different environmental conditions. Promoters which cause a gene to be expressed in most cell types at most times are commonly referred to as "constitutive promoters." It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined,

-17-

DNA fragments of different lengths may have identical or similar promoter activity.

Relative Growth. As used herein, the term refers to a measurement providing an assessment of growth by directly comparing growth of a parental strain with that of a progeny strain over a defined time period and with a defined medium.

Transcription factor. As used herein, the term "transcription factor" refers to RNA polymerases, and other proteins that interact with DNA in a sequence-specific manner and exert transcriptional regulatory effects. Transcriptional factors may be transcription inhibitory proteins or transcription activator proteins. In the context of the present invention, binding sites for transcription factors (or transcription complexes) are often included in the transcriptional regulatory element(s).

Transcription factor recognition site. As used herein, a "transcription factor recognition site" and a "transcription factor binding site" refer to a polynucleotide sequence(s) or sequence motif(s) which are identified as being sites for the sequence-specific interaction of one or more transcription factors, frequently taking the form of direct protein-DNA binding. Typically, transcription factor binding sites can be identified by DNA footprinting, gel mobility shift assays, and the like, and/or can be predicted on the basis of known consensus sequence motifs, or by other methods known to those of skill in the art.

Transcriptional Complex. As used herein, the term "transcriptional unit" or "transcriptional complex" refers to a polynucleotide sequence that comprises a structural gene (one or more exons), a cis-acting linked promoter and one or more other cis-acting sequences necessary for efficient transcription of the structural sequences, distal regulatory elements necessary for appropriate transcription of the structural sequences, and additional cis sequences important for efficient transcription and translation (e.g., polyadenylation site, mRNA stability controlling sequences). See, for example U.S. Patent No. 6,057,299.

-18-

Transcriptional Regulatory Element. As used herein, the term "transcriptional regulatory element" refers to a DNA sequence which activates transcription alone or in combination with one or more other DNA sequences. A transcriptional regulatory element can, for example, comprise a promoter, response element, negative regulatory element, silencer element, gene suppressor, and/or enhancer. See, for example, U.S. Patent No. 6,057,299.

B. Microbiological and Recombinant DNA Methodologies

The invention as provided herein utilizes some methods and techniques that are known to those skilled in the arts of microbiology and recombinant DNA technologies. Methods and techniques for the growth of bacterial cells, the introduction of isolated DNA molecules into host cells, and the isolation, cloning and sequencing of isolated nucleic acid molecules, etc., are a few examples of such methods and techniques. These methods and techniques are described in many standard laboratory manuals, such as Davis *et al.*, *Basic Methods In Molecular Biology* (1986), J.H. Miller, *Experiments in Molecular Genetics*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1972); J.H. Miller, *A Short Course in Bacterial Genetics*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1992); M. Singer and P. Berg, *Genes & Genomes*, University Science Books, Mill Valley, California (1991); J. Sambrook, E.F. Fritsch and T. Maniatis, *Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989); P.B. Kaufman *et al.*, *Handbook of Molecular and Cellular Methods in Biology and Medicine*, CRC Press, Boca Raton, Florida (1995); *Methods in Plant Molecular Biology and Biotechnology*, B.R. Glick and J.E. Thompson, eds., CRC Press, Boca Raton, Florida (1993); and P.F. Smith-Keary, *Molecular Genetics of Escherichia coli*, The Guilford Press, New York, NY (1989), all of which are incorporated herein by reference in their entireties.

Unless otherwise indicated, all nucleotide sequences newly described herein were determined using an automated DNA sequencer (such as the Model

373 from Applied Biosystems, Inc.). Therefore, as is known in the art, for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art.

In certain embodiments, polynucleotides of the invention comprise a nucleic acid, the sequence of which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:18; and SEQ ID NO:20, or a complementary sequence thereof.

By a polynucleotide comprising a nucleic acid, the sequence of which is at least, for example, 95% "identical" to a reference nucleotide sequence is intended that the nucleic acid sequence is identical to the reference sequence except that the nucleic acid sequence may include up to five mismatches per each 100 nucleotides of the reference nucleic acid sequence. In other words, to obtain a nucleic acid, the sequence of which is at least 95% identical to a reference nucleic acid sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The reference (query) sequence may be any one of the entire nucleotide sequences shown in SEQ ID NO:17, SEQ ID NO:18, or SEQ ID NO:20, or any fragment of any of these sequences, as described *infra*.

As a practical matter, whether any particular nucleic acid sequence is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, for instance, a nucleotide sequence consisting of SEQ ID NO:17; SEQ ID NO:18, or SEQ ID NO:20, or a complementary sequence thereof, can be determined conventionally using sequence analysis computer programs such as a OMIGA® Version 2.0 for Windows, available from Oxford Molecular, Ltd. (Oxford, U.K.).

OMIGA uses the CLUSTAL W alignment algorithm using the slow full dynamic programming alignment method with default parameters of an open gap penalty of 10 and an extend gap penalty of 5.0, to find the best alignment between two nucleotide sequences. When using CLUSTAL W or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference nucleotide sequence such that gaps, mismatches, or insertions of up to 5% of the total number of nucleotides in the reference sequence are allowed. Other sequence analysis programs, known in the art, can be used in the practice of the invention.

This embodiment of the present invention is directed to polynucleotides comprising a nucleic acid, the sequence of which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a nucleic acid sequence of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:20, or a complementary sequence thereof, irrespective of whether they have functional activity. This is because even where a particular polynucleotide does not have functional activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe, an S1 nuclease mapping probe, or a polymerase chain reaction (PCR) primer.

Preferred, however, are polynucleotides comprising a nucleic acid, the sequence of which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a nucleic acid sequence of SEQ ID NO:17, SEQ ID NO:18 or SEQ ID NO:20, or a complementary sequence thereof, which do, in fact, have functional activity in *Corynebacterium* species.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a reference amino acid sequence of a polypeptide is intended that the amino acid sequence of the claimed polypeptide is identical to the reference sequence except that the claimed polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of the polypeptide. In other words, to obtain a polypeptide having an amino

acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence shown in SEQ ID NO:2 or to the amino acid sequence encoded by a nucleic acid sequence can be determined conventionally using known computer programs such the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acid residues in the reference sequence are allowed.

In a specific embodiment, the identity between a reference sequence (query sequence, a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, is determined using the FASTDB computer program based on the algorithm of Brutlag *et al.* (Comp. App. Biosci. 6:237-245 (1990)). Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

-22-

According to this embodiment, if the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction is made to the results to take into consideration the fact that the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. A determination of whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of this embodiment. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence. For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not

-23-

manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are made for the purposes of this embodiment.

5 **C. *Methods and Processes of the Invention***

Various embodiments of the invention provide methods to increase the production of an amino acid and processes for the production of an amino acid from a *Corynebacterium* species host cell. Particularly preferred *Corynebacterium* species of the methods and processes of the invention include:
10 *Corynebacterium glutamicum*, *Brevibacterium flavum*, *Brevibacterium lactofermentum* and other *Corynebacteria* and *Brevibacteria* species known in the art.

As will be understood by those skilled in the art, the term "Corynebacterium species" includes those organisms previously identified in the
15 literature as "Brevibacterium species," for example *Brevibacterium flavum* and *Brevibacterium lactofermentum* which have now been reclassified into the genus *Corynebacterium* (*Int. J. Syst. Bacteriol.* 41: 255 (1981)).

Amino acid biosynthetic pathway genes embodied by the methods and processes described herein include those for L-glycine, L-alanine, L-methionine,
20 L-phenylalanine, L-tryptophan, L-proline, L-serine, L-threonine, L-cysteine, L-tyrosine, L-asparagine, L-glutamine, L-aspartic acid, L-glutamic acid, L-lysine, L-arginine, L-histidine, L-isoleucine, L-leucine, and L-valine biosynthesis. Particularly preferred embodiments are drawn to biosynthetic pathway genes for L-lysine (Sahm *et al.*, *Ann. N. Y. Acad. Sci.* 782: 25-39
25 (1996)), L-threonine, L-isoleucine, L-tryptophan, and L-valine.

By way of example, the amino acid pathway for L-lysine biosynthesis is well known to skilled artisans of amino acid production in *Corynebacterium* species. Genes encoding the enzymes important for the conversion of L-aspartate to L-lysine include the *ask*, *asd*, *dapA*, *dapB*, *ddh* and *lysA* genes

(Figure 1). Thus, the invention provides herein for exemplary purposes only, specific embodiments utilizing L-lysine biosynthetic pathway genes. Other embodiments drawn to the use of biosynthetic pathway genes for the synthesis of other amino acids are also encompassed by the invention described herein.

5 The methods to increase the production of an amino acid and the processes for the production of an amino acid of the invention both utilize a step requiring the transformation of an isolated nucleic acid molecule into a *Corynebacterium* species host cell. As known to one skilled in the art, transformation of an isolated nucleic acid molecule into a host cell may be
10 effected by electroporation, transduction or other methods. These methods are described in the many standard laboratory manuals referenced and incorporated herein.

 The methods to increase the production of an amino acid and the processes for the production of an amino acid of the invention both utilize a step
15 requiring amplification of at least one amino acid biosynthesis pathway gene. As known to one skilled in the art, the term amplification means increasing the number of a gene or genes of an amino acid biosynthetic pathway by any means known in the art. Particularly preferred means of amplification include: (1) the
20 addition an isolated nucleic acid molecule comprising copies of a gene or genes of a biosynthetic pathway by insertion into the chromosome of a host cell, for example by homologous recombination, and (2) the addition an isolated nucleic acid molecule comprising copies of a gene or genes of a biosynthetic pathway into a host cell by way of a self-replicating, extra-chromosomal vector, for example, a plasmid.

25 Another method of the invention to increase the production of an amino acid comprises increasing the expression of at least one amino acid biosynthetic pathway gene. Preferred methods of increasing expression comprise using heterologous promoters, regulated promoters, unregulated promoters and combinations thereof.

30 Methods of inserting an isolated nucleic acid molecule into the chromosome of a host cell are known to those skilled in the art. For example,

insertion of isolated nucleic acid molecules into the chromosome of *Corynebacterium* species may be done utilizing the pK184 plasmid described by Jobling, M. *et al.*, *Nucleic Acids Research* 18(17): 5315-5316 (submitted 1990). Because these vectors lack a *Corynebacterium* species origin of replication and contain a selectable marker such as kanamycin (*kan*), cells will only be capable of growing under selection if the vector has been inserted into the host cell chromosome by homologous recombination.

In alternative embodiments, the invention also provides methods for increasing amino acid production and processes for the production of an amino acid wherein biosynthetic pathway gene amplification is accomplished through the introduction into a host cell of a self-replicating, extra-chromosomal vector, *e.g.*, a plasmid, comprising an isolated nucleic acid molecule encoding an amino acid biosynthetic pathway gene or genes. Suitable plasmids for these embodiments include pSR1 and other derivatives of pSR1 (Archer, J. *et al.*, *J. Gen. Microbiol.* 139: 1753-1759 (1993)).

For various embodiments of the invention drawn to a method to increase production of an amino acid, screening for increased production of an amino acid, for example L-lysine, may be determined by directly comparing the amount of L-lysine produced in culture by a *Corynebacterium* species host strain to that of a *Corynebacterium* species transformed host strain in which an amino acid biosynthesis gene or genes are amplified. The level of production of the amino acid of choice may conveniently be determined by the following formula to calculate the percent yield from dextrose: $[(\text{g amino acid/L} / (\text{g dextrose consumed/L})) * 100]$.

In one embodiment, the invention provides a method to increase the production of an amino acid comprising: (a) transforming a *Corynebacterium* species host cell with an isolated polynucleotide molecule comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2; (b) amplifying the number of at least one of the biosynthetic pathway genes for said amino acid in the chromosome of said host cell;

(c) selecting a transformed host cell; and (d) screening for increased production of said amino acid from said transformed host cell relative to said host cell.

In a particularly preferred embodiment, the invention provides a method to increase the production of an amino acid comprising transforming a *Corynebacterium* species host cell with an isolated polynucleotide molecule comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2; and further comprising at least one of the following: a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *asd* amino acid sequence; a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *dapA* amino acid sequence; a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *dapB* amino acid sequence; a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *ddh* amino acid sequence; a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *lysA* amino acid sequence; a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *lysA* amino acid sequence; and a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *ORF2* amino acid sequence.

In another particular embodiment of the method, the isolated polynucleotide molecule further comprises at least one of the following: a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4; a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6; a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8; a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10; a nucleic acid molecule encoding the *lysA* amino acid sequence of SEQ ID NO:21; a nucleic acid molecule encoding the *lysA* amino acid sequence of SEQ ID NO:14; and a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

In another particular embodiment of the method, the isolated polynucleotide molecule further comprises the following: a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4; a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6; a nucleic acid

-27-

molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8; and a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

5 In another particular embodiment of the method, the isolated polynucleotide molecule further comprises the following: a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4; a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6; a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8; a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10; and a
10 nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

In another particular embodiment of the method, the isolated polynucleotide molecule further comprises the following: a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4; a nucleic acid molecule
15 encoding the *dapA* amino acid sequence of SEQ ID NO:6; a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8; a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10; a nucleic acid molecule encoding the *lysA* amino acid sequence of SEQ ID NO:21; and a nucleic acid molecule encoding the *ORF2* amino acid sequence of
20 SEQ ID NO:16.

In another particular embodiment of the method, the polynucleotide molecule further comprises the following: a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4; a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6; a nucleic acid molecule encoding
25 the *dapB* amino acid sequence of SEQ ID NO:8; a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10; a nucleic acid molecule encoding the *lysA* amino acid sequence of SEQ ID NO:14; and a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

-28-

In another embodiment of the method, the method further comprises growing said transformed host cell in a medium; and purifying an amino acid produced by said transformed host cell.

5 It is another object of the invention to provide an isolated polynucleotide molecule comprising the polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:2; and at least one additional *Corynebacterium* species lysine pathway gene selected from the group consisting of a nucleic acid molecule encoding an *asd* polypeptide; a nucleic acid molecule encoding a *dapA* polypeptide; a nucleic acid molecule encoding a *dapB* polypeptide; a nucleic acid molecule encoding a *ddh* polypeptide; a nucleic acid molecule encoding a *lysA* polypeptide; a nucleic acid molecule encoding a *lysA* polypeptide; and a nucleic acid molecule encoding an *ORF2* polypeptide. In a preferred embodiment, said *asd* polypeptide is SEQ ID NO:4; said *dapA* polypeptide is SEQ ID NO:6; said *dapB* polypeptide is SEQ ID NO:8; said *ddh* polypeptide is SEQ ID NO:10; said *lysA* polypeptide is SEQ ID NO:21; said *lysA* polypeptide is SEQ ID NO:14; and said *ORF2* polypeptide is SEQ ID NO:16.

20 It is another object of the invention to provide an isolated polynucleotide molecule comprising the polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO 2; a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4; a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6; a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8; and a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

25 It is another object of the invention to provide an isolated polynucleotide molecule comprising the polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO: 2; a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4; a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6; a nucleic acid molecule encoding the *dapB* amino acid

30

-29-

sequence of SEQ ID NO:8; a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10; and a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

It is another object of the invention to provide an isolated polynucleotide molecule comprising the polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:2; a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4; a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6; a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8; a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10; a nucleic acid molecule encoding the *lysA* amino acid sequence of SEQ ID NO:21; and a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

It is another object of the invention to provide an isolated polynucleotide molecule comprising the polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:2; a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4; a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6; a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8; a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10; a nucleic acid molecule encoding the *lysA* amino acid sequence of SEQ ID NO:14; and a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

It is a further object of the invention to provide an isolated polynucleotide molecule comprising pK184-KDAB. It is a further object of the invention to provide an isolated polynucleotide molecule comprising pK184-KDABH'L. It is a further object of the invention to provide an isolated polynucleotide molecule comprising pD11-KDABH'L. It is a further object of the invention to provide an isolated polynucleotide molecule comprising pD2-KDABHL.

It is a further object of the invention to provide a vector comprising the isolated polynucleotide molecule comprising a nucleotide sequence encoding a

polypeptide comprising the amino acid sequence of SEQ ID NO 2; and further comprising at least one additional *Corynebacterium* species lysine pathway gene selected from the group consisting of a nucleic acid molecule encoding an *asd* polypeptide; a nucleic acid molecule encoding a *dapA* polypeptide; a nucleic acid molecule encoding a *dapB* polypeptide; a nucleic acid molecule encoding a *ddh* polypeptide; a nucleic acid molecule encoding a *lysA* polypeptide; a nucleic acid molecule encoding a *lysA* polypeptide; and a nucleic acid molecule encoding an *ORF2* polypeptide.

It is a further object to provide a host cell comprising a vector comprising the isolated polynucleotide molecule comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO 2; and further comprising at least one additional *Corynebacterium* species lysine pathway gene selected from the group consisting of a nucleic acid molecule encoding an *asd* polypeptide; a nucleic acid molecule encoding a *dapA* polypeptide; a nucleic acid molecule encoding a *dapB* polypeptide; a nucleic acid molecule encoding a *ddh* polypeptide; a nucleic acid molecule encoding a *lysA* polypeptide; a nucleic acid molecule encoding a *lysA* polypeptide; and a nucleic acid molecule encoding an *ORF2* polypeptide.

It is a further object to provide a host cell wherein said host cell is a *Brevibacterium* selected from the group consisting of *Brevibacterium flavum* NRRL-B30218, *Brevibacterium flavum* NRRL-B30219, *Brevibacterium lactofermentum* NRRL-B30220, *Brevibacterium lactofermentum* NRRL-B30221, *Brevibacterium lactofermentum* NRRL-B30222, *Brevibacterium flavum* NRRL-30234 and *Brevibacterium lactofermentum* NRRL-30235. In another embodiment, the host cell is *Escherichia coli* DH5 α MCR NRRL-B30228. In another embodiment, the host cell is a *C. glutamicum* selected from the group consisting of *C. glutamicum* NRRL-B30236 and *C. glutamicum* NRRL-B30237.

The invention provides processes for the production of an amino acid. In one embodiment, the invention provides a process for producing an amino acid comprising: (a) transforming a *Corynebacterium* species host cell with an isolated nucleic acid molecule; (b) amplifying the number of chromosomal

-31-

copies of at least one of the biosynthetic pathway genes for said amino acid; (c) selecting a transformed host cell; (d) growing said transformed cell in a medium; and (e) purifying said amino acid.

5 The invention is also directed to an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:19. In one embodiment of the invention, the polypeptide has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:19. The invention is also directed to an isolated polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:19. In one embodiment, the isolated polynucleotide comprises a nucleic acid
10 having the sequence of SEQ ID NO:18.

The invention is also directed to a vector comprising the polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:19. In one embodiment, the invention is directed to a host cell comprising a vector encoding a polypeptide comprising
15 the amino acid sequence of SEQ ID NO:19. In one embodiment, the host cell is NRRL B30360.

The invention is also directed to a method comprising transforming a *Corynebacterium* species host cell with the polynucleotide molecule comprising a nucleotide sequence encoding a polypeptide comprising the amino acid
20 sequence of SEQ ID NO:19, and selecting a transformed host cell. In one embodiment, the method further comprises screening for increased amino acid production. In a preferred embodiment, the amino acid screened for is lysine. In one embodiment, the polynucleotide molecule is integrated into said host cell's chromosome, thereby increasing the total number of said amino acid biosynthetic
25 pathway genes in said host cell chromosome.

In another embodiment, the polynucleotide molecule further comprises at least one of the following: (a) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *ask* amino acid sequence; (b) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *asd* amino
30 acid sequence; (c) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *dapA* amino acid sequence; (d) a nucleic acid molecule encoding

a *Corynebacterium species* lysine pathway *dapB* amino acid sequence; (e) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *ddh* amino acid sequence; (f) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *lysA* amino acid sequence; (g) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *lysA* amino acid sequence; and, (h) a nucleic acid molecule encoding an ORF2 polypeptide having SEQ ID NO:16. In this embodiment, the method further comprises screening for increased amino acid production. In another embodiment, the amino acid screened for is lysine.

In another embodiment of the method, the polynucleotide molecule further comprises: (a) a nucleic acid molecule encoding the *ask* amino acid sequence having SEQ ID NO:2; (b) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *asd* amino acid sequence; (c) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *dapB* amino acid sequence; (d) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *ddh* amino acid sequence; and, (e) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *lysA* amino acid sequence. In one embodiment of this method, the method further comprises screening for increased amino acid production.

The invention is also directed to an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:21. In one embodiment, the polypeptide has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:21. The invention also comprises an isolated polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide comprising the amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:21. The invention is further comprises a polynucleotide molecule comprising a nucleic acid having the sequence of SEQ ID NO:20. In one embodiment the invention comprises a vector comprising the polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide comprising the amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:21. The invention further comprises a host cell

comprising the vector comprising the polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide comprising the amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:21.

5 In one embodiment, the invention comprises a host cell selected from the group consisting of NRRL B30218, NRRL B30220 and NRRL B30222.

10 The invention is further directed to a method comprising transforming a *Corynebacterium* species host cell with a polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide comprising the amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 21, and selecting a transformed host cell. The method further comprises screening for increased amino acid production; in particular, for lysine production. In one embodiment, the polynucleotide molecule is integrated into said host cell's chromosome, thereby increasing the total number of said amino acid biosynthetic pathway genes in said host cell chromosome. In one
15 embodiment the method further comprises a polynucleotide molecule further comprising at least one of the following: (a) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *ask* amino acid sequence; (b) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *ask* amino acid sequence having SEQ ID NO. 2; (c) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *asd* amino acid sequence; (d) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *dapA* amino acid sequence; (e) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *dapB* amino acid sequence; (f) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *ddh* amino acid sequence; (g) a
20 nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *ORF2* amino acid sequence; and, (h) a nucleic acid molecule encoding a truncated *Corynebacterium species* lysine pathway *ORF2* amino acid sequence. In one embodiment, the method further comprises screening for increased amino acid
25 production. In another embodiment, the amino acid screened for is lysine.
30

Another embodiment of the invention is also directed to an isolated polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polynucleotide molecule further comprises a promoter sequence having SEQ ID
5 NO:17. In one embodiment, the promoter sequence has at least 95% sequence identity to SEQ ID NO:17. In one embodiment, the promoter sequence having at least 95% sequence identity to SEQ ID NO:17 is operably directly linked to the LysA gene. In another embodiment of the invention, there is a vector comprising the isolated polynucleotide molecule comprising a nucleotide
10 sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polynucleotide molecule further comprises a promoter sequence wherein said promoter sequence has at least 95% sequence identity to SEQ ID NO:17. In another aspect of the invention, there is a host cell comprising the vector comprising the isolated polynucleotide molecule
15 comprising a nucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polynucleotide molecule further comprises a promoter sequence having at least 95% sequence identity to SEQ ID NO:17. In one embodiment, the host cell is NRRL B30359.

The invention is also directed to a method comprising transforming a
20 *Corynebacterium* species host cell with the polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polynucleotide molecule further comprises a promoter sequence having at least 95% sequence identity to SEQ ID NO:17, and selecting a transformed host cell. In one embodiment, the method
25 further comprises screening for increased amino acid production. In another embodiment, the amino acid screened for is lysine. In another embodiment of the method, the polynucleotide molecule is integrated into said host cell's chromosome, thereby increasing the total number of amino acid biosynthetic pathway genes in said host cell chromosome. In another embodiment of the
30 method, the polynucleotide molecule further comprises at least one of the following: (a) a nucleic acid molecule encoding a *Corynebacterium* species

lysine pathway *asd* amino acid sequence; (b) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *dapA* amino acid sequence; (c) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *dapB* amino acid sequence; (d) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *ddh* amino acid sequence; (e) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *ORF2* amino acid sequence; (f) a nucleic acid molecule encoding a truncated *Corynebacterium species* lysine pathway *ORF2* amino acid sequence; (g) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *lysA* amino acid sequence; and, (h) a nucleic acid molecule encoding a truncated *Corynebacterium species* lysine pathway *lysA* amino acid sequence. In this embodiment, the method further comprises screening for increased amino acid production; in particular, for lysine production.

In a different embodiment of the method, the polynucleotide molecule comprises: (a) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *asd* amino acid sequence; (b) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *dapA* amino acid sequence; (c) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *dapB* amino acid sequence; (d) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *ddh* amino acid sequence; (e) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *ORF2* amino acid sequence; and, (f) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *lysA* amino acid sequence. In this embodiment, the method further comprises screening for increased amino acid production. In a preferred embodiment, the amino acid is lysine.

A variety of media known to those skilled in the art may be used to support cell growth for the production of an amino acid. Illustrative examples of suitable carbon sources include, but are not limited to: carbohydrates, such as glucose, fructose, sucrose, starch hydrolysate, cellulose hydrolysate and molasses; organic acids, such as acetic acid, propionic acid, formic acid, malic acid, citric acid, and fumaric acid; and alcohols, such as glycerol. Illustrative

examples of suitable nitrogen sources include, but are not limited to: ammonia, including ammonia gas and aqueous ammonia; ammonium salts of inorganic or organic acids, such as ammonium chloride, ammonium phosphate, ammonium sulfate and ammonium acetate; and other nitrogen-containing sources, including
5 meat extract, peptone, corn steep liquor, casein hydrolysate, soybean cake hydrolysate, urea and yeast extract.

A variety of fermentation techniques are known in the art which may be employed in processes of the invention drawn to the production of amino acids. Generally, amino acids may be commercially produced from the invention in
10 fermentation processes such as the batch type or of the fed-batch type. In batch type fermentations, all nutrients are added at the beginning of the fermentation. In fed-batch or extended fed-batch type fermentations one or a number of nutrients are continuously supplied to the culture, right from the beginning of the fermentation or after the culture has reached a certain age, or when the nutrient(s)
15 which are fed were exhausted from the culture fluid. A variant of the extended batch of fed-batch type fermentation is the repeated fed-batch or fill-and-draw fermentation, where part of the contents of the fermenter is removed at some time, for instance when the fermenter is full, while feeding of a nutrient is continued. In this way a fermentation can be extended for a longer time.

20 Another type of fermentation, the continuous fermentation or chemostat culture, uses continuous feeding of a complete medium, while culture fluid is continuously or semi-continuously withdrawn in such a way that the volume of the broth in the fermenter remains approximately constant. A continuous fermentation can in principle be maintained for an infinite time.

25 In a batch fermentation an organism grows until one of the essential nutrients in the medium becomes exhausted, or until fermentation conditions become unfavorable (*e.g.*, the pH decreases to a value inhibitory for microbial growth). In fed-batch fermentations measures are normally taken to maintain favorable growth conditions, *e.g.*, by using pH control, and exhaustion of one or
30 more essential nutrients is prevented by feeding these nutrient(s) to the culture. The microorganism will continue to grow, at a growth rate dictated by the rate

-37-

of nutrient feed. Generally a single nutrient, very often the carbon source, will become limiting for growth. The same principle applies for a continuous fermentation, usually one nutrient in the medium feed is limiting, all other nutrients are in excess. The limiting nutrient will be present in the culture fluid at a very low concentration, often unmeasurably low. Different types of nutrient limitation can be employed. Carbon source limitation is most often used. Other examples are limitation by the nitrogen source, limitation by oxygen, limitation by a specific nutrient such as a vitamin or an amino acid (in case the microorganism is auxotrophic for such a compound), limitation by sulphur and limitation by phosphorous.

The amino acid may be recovered by any method known in the art. Exemplary procedures are provided in the following: Van Walsem, H.J. & Thompson, M.C., *J. Biotechnol.* 59:127-132 (1997), and U.S. Pat. No. 3,565,951, both of which are incorporated herein by reference.

The invention described herein provides isolated nucleic acid molecules comprising at least one L-lysine amino acid biosynthesis gene. Unless otherwise indicated, all nucleotide sequences described herein were determined using an automated DNA sequencer (such as the Model 373 from Applied Biosystems, Inc.), and all amino acid sequences of polypeptides encoded by DNA molecules described herein were predicted by translation of the relative DNA sequence. Therefore, as is known in the art, for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art.

As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely

-38-

different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.

The invention provides several isolated nucleic acid molecules encoding comprising at least one L-lysine amino acid biosynthesis pathway gene of *Corynebacterium glutamicum*. More specifically, the invention provides the following isolated nucleic acid molecules: the nucleotide sequence of the *ask* gene from the strain ATCC 21529 (SEQ ID NO:1); the nucleotide sequence of the *asd* gene from the strain ATCC 21529 (SEQ ID NO:3); the nucleotide sequence of the *dapA* gene from the strain NRRL-B11474 (SEQ ID NO:5); the nucleotide sequence of the *dapB* gene from the strain NRRL-B11474 (SEQ ID NO:7); the nucleotide sequence of the *ddh* gene from the strain NRRL-B11474 (SEQ ID NO:9) and the nucleotide sequence of the *ORF2* gene from the strain NRRL-B11474 (SEQ ID NO:15). In addition, also provided herein is the nucleotide sequence of *lysA* (SEQ ID NO:13) gene from plasmid pRS6 (Marcel, T., *et al.*, *Molecular Microbiology* 4: 1819-1830 (1990)).

It is known in the art that amino acids are encoded at the nucleic acid level by one or more codons (code degeneracy). It is also known in the art that choice of codons may influence expression of a particular amino acid sequence (protein, polypeptide; etc.). Thus, the invention is further directed to nucleic acid molecules encoding the *ask* amino acid sequence of SEQ ID NO:2 wherein the nucleic acid molecule comprises any codon known to encode a particular amino acid. The invention is also further directed to nucleic acid sequences (SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 18 and 20) which comprise alternative codons in order to optimize expression of the protein or polypeptide.

In addition to the above described isolated nucleic acid molecules, the invention also provides isolated nucleic acid molecules comprising more than one L-lysine *Corynebacterium glutamicum* biosynthesis gene. Such isolated nucleic acid molecules are referred to as "cassette" constructs. These cassette constructs simplify for the practitioner the number of recombinant DNA manipulations required to achieve gene amplification of L-lysine biosynthesis genes.

In one embodiment drawn to a cassette construct, the invention provides an isolated nucleic acid molecule comprising: (a) a polynucleotide encoding the *Corynebacterium glutamicum* L-lysine pathway amino acid sequence of SEQ ID NO:2; and (b) at least one additional *Corynebacterium* species L-lysine pathway gene selected from the group consisting of: (1) a polynucleotide encoding the *asd* polypeptide; (2) a polynucleotide encoding the *dapA* polypeptide; (3) a polynucleotide encoding the *dapB* polypeptide; (4) a polynucleotide encoding the *ddh* polypeptide; (5) a polynucleotide encoding the *lysA* polypeptide, and (6) a polynucleotide encoding the *ORF2* polypeptide.

The isolated nucleic acid molecules of the invention are preferably propagated and maintained in an appropriate nucleic acid vector. Methods for the isolation and cloning of the isolated nucleic acid molecules of the invention are well known to those skilled in the art of recombinant DNA technology. Appropriate vectors and methods for use with prokaryotic and eukaryotic hosts are described by Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor, N.Y., 1989, the disclosure of which is hereby incorporated by reference.

A great variety of vectors can be used in the invention. Such vectors include chromosomal, episomal and virus-derived vectors, *e.g.*, vectors derived from bacterial plasmids and from bacteriophage, as well as vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids, all may be used in accordance with this aspect of the present invention. Generally, any vector suitable to maintain and propagate a polynucleotide in a bacterial host may be used in this regard.

A large numbers of suitable vectors and promoters for use in bacteria are known, many of which are commercially available. Preferred prokaryotic vectors include plasmids such as those capable of replication in *E. coli* (such as, for example, pBR322, ColEI, pSC101, pACYC 184, π VX). Such plasmids are, for example, disclosed by Maniatis, T., *et al.*, *In: Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor, NY (1982)).

The following vectors are provided by way of example: pET (Novagen), pQE70, pQE60, pQE-9 (Qiagen), pBs, phagescript, psiXI74, pBlueScript SK, pBsKS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene), pTrec99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia).

5 Preferred vectors for the isolated nucleic acid molecules of the invention include the pFC1 to pFC7 novel family of combinatorial cloning vectors (Lonsdale, D.M., *et al.*, *Plant Molecular Biology Reporter* 13: 343-345 (1995)), the pK184 vector (Jobling, M.G. and Homes, R.K., *Nucleic Acid Research* 18: 5315-5316 (1990)).

10 Another group of preferred vectors are those that are capable of autonomous replication in *Corynebacterium* species. Such vectors are well known to those skilled in the art of amino acid production by way of microbial fermentation, examples of which include pSR1, pMF1014a and vectors derived therefrom.

15 The invention provides an isolated amino acid sequence of the *ask* polypeptide of the strain ATCC 21529 (SEQ ID NO:2). The isolated *ask* amino sequence disclosed herein possesses unique properties with respect to feedback resistance of *ask* enzyme activity to accumulated levels of L-lysine and L-threonine in the culture medium. When compared to the DNA sequences of
20 other *Corynebacterium glutamicum ask-asd* gene sequences, the invention discloses a threonine to isoleucine change at amino acid residue 380 which results in resistance to feedback inhibition. The invention also includes other amino acid changes at residue 380 which result in decreased *ask* enzyme sensitivity to L-threonine and/or L-lysine.

25 In addition, and as described in more detail herein, the vector may contain control regions that regulate as well as engender expression. Generally, such regions will operate by controlling transcription, such as inducer or repressor binding sites and enhancers, among others.

30 Vectors of the present invention generally will include a selectable marker. Such markers also may be suitable for amplification or the vectors may contain additional markers for this purpose. In this regard, vectors preferably

-41-

contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells. Such markers include, but are not limited to, an antibiotic resistance gene such as a chloramphenicol, ampicillin, or kanamycin resistance gene, or an autotrophic gene which allows the host cell to grow in the absence of a nutrient for which the host cell strain is normally auxotrophic.

If the vector is intended to be maintained in the host cell extrachromosomally, it will contain, in addition an origin of replication which will allow it to replicate in the *Corynebacterium* species host cell. Alternatively, if it is desired that the vector integrate into the *Corynebacterium* species chromosome, the vector is constructed such that it cannot replicate in *Corynebacterium*. For example, such a vector might be capable of propagation in another organism, for example, *E. coli*, but lack the proper origin of replication to be propagated in *Corynebacterium*. In another aspect of this embodiment, the vector is a shuttle vector which can replicate and be maintained in more than one host cell species, for example, such a shuttle vector might be capable of replication in a *Corynebacterium* host cell such as a *C. glutamicum* host cell, and also in an *E. coli* host cell.

The invention further provides the following isolated the amino acid sequences: the amino acid sequence of the *asd* polypeptide of the strain ATCC 21529 (SEQ ID NO:4); the amino acid sequence of the *dapA* polypeptide of the strain NRRL-B11474 (SEQ ID NO:6); the amino acid sequence of the *dapB* polypeptide of the strain NRRL-B11474 (SEQ ID NO:8); the amino acid sequence of the *ddh* polypeptide of the strain NRRL-B11474 (SEQ ID NO:10) and the amino acid sequence of the *ORF2* polypeptide of the strain NRRL-B11474 (SEQ ID NO:16). In addition, also provided herein is the amino acid sequence of *lysA* (pRS6) (Marcel, T., *et al.*, *Mol. Microbiol.* 4: 819-830 (1990)) (SEQ ID NO:14).

In addition to the isolated polypeptide sequences defined by the specific sequence disclosures disclosed above, the invention also provides the amino acid sequences encoded by the deposited clones.

It will be recognized in the art that some amino acid sequences of the invention can be varied without significant effect of the structure or function of the proteins disclosed herein. Variants included may constitute deletions, insertions, inversions, repeats, and type substitutions so long as enzyme activity is not significantly affected. Guidance concerning which amino acid changes are likely to be phenotypically silent can be found in Bowie, J.U., *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990).

The strains of the invention may be prepared by any of the methods and techniques known and available to those skilled in the art. Introduction of gene constructs of the invention into the host cell can be effected by electroporation, transduction or other methods. These methods are described in the many standard laboratory manuals referenced and incorporated herein.

Various embodiments of the invention provide strains with increased L-lysine production as a result of gene amplification. By gene amplification is meant increasing the number of copies above the normal single copy number of an L-lysine biosynthesis pathway gene by a factor of 2, 3, 4, 5, 10, or more copies.

In one embodiment of the invention, the additional copies of the L-lysine biosynthesis pathway gene(s) may be integrated into the chromosome. Another embodiment of the invention provides that the additional copies of the L-lysine biosynthesis pathway gene(s) are carried extra-chromosomally. Amplifications by a factor of 5 or less may be obtained by introducing the additional gene copies into the chromosome of the host strain by way of single event homologous recombination. In a most preferred embodiment, the recombination event results in the introduction of one additional copy of the copy of the gene or genes of interest. If more than 5 copies of the genes are desired, then the invention also provides for the use of multicopy plasmids carrying the recombinant DNA construct of the invention.

Representative examples of appropriate hosts for isolated nucleic acid molecules of the invention include, but are not limited to, bacterial cells, such as

C. glutamicum, *Escherichia coli*, *Streptomyces* and *Salmonella typhimurium* cells; and fungal cells, such as yeast cells. Appropriate culture media and conditions for the above-described host cells are known in the art.

Particularly preferred host cells of the invention include:
5 *Corynebacterium glutamicum*, *Brevibacterium flavum* and *Brevibacterium lactofermentum*.

Applicants have deposited clones carrying the pK184-KDABH'L multi-gene constructs at an acceptable International Depositary Authority in accordance with the Budapest Treaty on the International Recognition of the Deposit of
10 Microorganisms for the Purposes of Patent Procedure. The deposits have been made with the Agricultural Research Service, Culture Collection (NRRL), 1815 North University Street, Peoria, Illinois 61604. Deposits made in which the pK184-KDAB or pK184-KDABH'L multi-gene constructs have been integrated into the chromosome of a host cell include the following: (1) the pK184-KDAB
15 plasmid, integrated into the chromosome, deposited as NRRL-B30219 and NRRL-B30221 and (2) the pK184-KDABH'L plasmid, integrated into the chromosome, deposited as NRRL-B30218, NRRL-B30220, and NRRL-B30222. In addition, the pK184-KDABH'L multigene construct in a plasmid configuration, carried in *E. coli* DH5 α MCR, was deposited as NRRL-B30228.
20 The six gene construct (pDElia2-KDABHL) was deposited in *E. coli* (NRRL-B30233). *C. glutamicum* comprising pK184-KDABH'L was deposited as NRRL-B30236. *C. glutamicum* comprising pK184-KDABHL was deposited as NRRL-B30237. *Brevibacterium flavum* comprising pDElia2-KDABHL was deposited as NRRL-B30234. *Brevibacterium lactofermentum* comprising
25 pDElia2-KDABHL was deposited as NRRL-B30235.

It is an object of the invention to provide a method of producing lysine comprising culturing the host cells comprising the amino acid sequence of SEQ ID NO:2 wherein said host cells comprise one or more of: (a) increased enzyme activity of one or more lysine biosynthetic pathway enzymes compared to the
30 genetically unaltered host cell; (b) one or more copies of each gene encoding a lysine biosynthetic pathway enzyme; and, (c) alteration of one or more

transcription factors regulating transcription of one or more genes encoding a lysine biosynthetic pathway enzyme, wherein said host cell produces lysine in said culture medium. In one embodiment of the method, said increased enzyme activity comprises overexpressing one or more genes encoding one or more lysine biosynthetic pathway enzymes. In one embodiment of the method, said one or more genes are operably linked directly or indirectly to one or more promoter sequences. In another embodiment of the method, said operably linked promoter

sequences are heterologous, endogenous, or hybrid. In a preferred embodiment of the method, said promoter sequences are one or more of: a promoter sequence from the 5' end of genes endogenous to *C. glutamicum*, a promoter sequence from plasmids that replicate in *C. glutamicum*, and, a promoter sequence from the genome of phage which infect *C. glutamicum*. In a preferred embodiment of the method, one or more of said promoter sequences are modified. In another preferred embodiment, said modification comprises truncation at the 5' end, truncation at the 3' end, non-terminal insertion of one or more nucleotides, non-terminal deletion of one or more nucleotides, addition of one or more nucleotides at the 5' end, addition of one or more nucleotides at the 3' end, and, combinations thereof.

In another embodiment of the method, said increased enzyme activity results from the activity of one or more modified lysine biosynthetic pathway enzymes wherein said enzyme modification results in a change in kinetic parameters, allosteric regulation, or both, compared to the enzyme lacking the modification. In one embodiment of the method, said change in kinetic parameters is a change in K_m , V_{max} or both. In another embodiment of the method, said change in allosteric regulation is a change in one or more enzyme allosteric regulatory sites. In one embodiment, said change in allosteric regulation is a change in the affinity of one or more enzyme allosteric regulatory sites for the ligand or ligands. The ligands may be the same or different. In one embodiment, said enzyme modification is a result of a change in the nucleotide sequence encoding said enzyme. In one embodiment, said change in said

-45-

nucleotide sequence is an addition, insertion, deletion, substitution, or a combination thereof, of one or more nucleotides.

In another embodiment of the method, said alteration of one or more transcription factors comprises one or more mutations in transcription inhibitor proteins, one or more mutations in transcription activator proteins, or both, wherein said one or more mutations increases transcription of the target nucleotide sequence compared to the transcription by said one or more transcription factors lacking said alteration. In one embodiment, said one or more mutations is a change in said nucleotide sequence encoding said transcription factor. In another embodiment, said change in said nucleotide sequence is an addition, insertion, deletion, substitution, or a combination thereof, of one or more nucleotides.

All patents and publications referred to herein are expressly incorporated by reference in their entirety.

Examples

Example 1

Preparation of L-Lysine Pathway Multi-gene Constructs pK184-KDAB and pK184-KDABH'L

Applicants have created L-lysine amino acid biosynthetic pathway multi-gene constructs for the purpose of amplifying the number of one or more of the genes of this pathway in the chromosome of *Corynebacterium* species. Also, through careful study of the L-lysine biosynthesis genes of strain ATCC 21529, Applicants have identified an amino acid change of threonine to isoleucine at amino acid residue 380 of the *ask* gene of ATCC 21529. Compared to the DNA sequences of other *Corynebacterium glutamicum ask* genes, a threonine to isoleucine change at amino acid residue 380 was observed (Figure 19), which is responsible for the unusual feedback resistant properties with respect to aspartate kinase enzyme regulation.

-46-

The isolated nucleic acid molecules encoding L-lysine, amino acid biosynthesis pathway genes utilized in the present invention are from the following sources:

	Gene(s)	Source
5	<i>ask-asd</i>	Strain ATCC 21529;
	<i>dapA</i>	Strain NRRL B11474;
	<i>dapB</i>	Strain NRRL B11474;
	<i>ddh</i>	Strain NRRL B11474;
	<i>lysA</i>	Plasmid pRS6 (Marcel, T., <i>et al.</i> , <i>Mol. Microbiol.</i> 4: 819-830 (1990)) carrying the <i>lysA</i> gene isolated from strain AS019, which was derived from ATCC 13059;
10	<i>lysA</i>	NRRL B11474;
	<i>lysA</i>	NRRL B11474 (full length); and,
	<i>ORF2</i>	Strain NRRL B11474.

As one skilled in the art would know, the invention is not limited to the specific strain origins that Applicants present for the isolated nucleic acid molecules of the invention. Any strain of *Corynebacterium* species, particularly that of *Corynebacterium glutamicum*, may be utilized for the isolation of nucleic acid molecules that will be used to amplify the number of chromosomally located amino acid biosynthetic pathway genes. Particularly preferred strains include: NRRL-B11474, ATCC 21799, ATCC 21529, ATCC 21543, and B12.

Methods and techniques common to the art of recombinant DNA technology were used in making the multi-gene constructs of the invention, as may be found in the many laboratory manuals cited and incorporated herein, for example as found in J. Sambrook, E.F. Fritsch and T. Maniatis, *Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989).

The polymerase chain reaction (PCR) technique is used extensively in the making of the multi-gene constructs of the invention. In a typical reaction, the

-47-

standard 10X stock solution (100 mM Tris-HCL, pH 8.3, 500 mM KCL, 1.5 mM MgCl₂) is diluted to 1X for use. Typical reaction conditions were used for PCR amplification: 10 mM Tris, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.01% gelatin, 200 μ M deoxynucleotides, 0.2-1.0 μ M primers and 2.5 U/100 μ l pfu polymerase. Standard cycling parameters were also employed in PCR reactions: For 30 cycles, template denaturation was performed at 94 °C for 1 min; 55 °C annealing temperature was performed for 1 min (or annealing temperature appropriate for particular primer pair); product extension was performed at 72 °C for 1 min (if product is <500 bp), 3 min (if product is >500 bp); and at the end of cycling, a final extension at 72 °C for 7 min was performed.

The primers utilized for cloning experiments included:

ask: 5'-GGGTACCTCGCGAAGTAGCACCTGTCAC-3';

asd: 5'-GCGGATCCCCCATCGCCCCTCAAAGA-3';

dapB: 5'-AACGGGCGGTGAAGGGCAACT-3';

dapA: 5'-TGAAAGACAGGGGTATCCAGA-3';

ddh 5'-CCATGGTACCAAGTGCGTGGCGAG-3';

5'-CCATGGTACCACACTGTTTCCTTGC-3';

argS: 5'-CTGGTTCCGGCGAGTGGAGCCGACCATTCCGCGAGG-3'; and

lysA: 5'-CTCGCTCCGGCGAGGTCGGAGGCAACTTCTGCGACG-3', a primer that anneals internally to *lysA* (about 500bp upstream to the end of *lysA*).

'*LysA*' is a truncated form obtained from *lysA*.

Applicants utilized standard PCR and subcloning procedures in cloning the coding regions of *ask-asd*, *dapB-ORF2-dapA*, *ddh*, '*lysA*', and *lysA*. Construction procedures and intermediate plasmids are described in Figure 18.

Applicants performed the following steps (Figure 18) in constructing the following vectors used in the L-lysine biosynthetic pathway:

1. pGEMT-*ask-asd*: an approximately 2.6 Kb PCR product containing the *ask-asd* operon of ATCC21529 using primers *ask* and *asd* was cloned into pGEM-T (Promega pGEM-T vector systems);

-48-

2. pADM21: an approximately 1.3Kb PCR product (with an engineered KpnI site on both primers) of NRRL-B11474 *ddh* coding region was cloned into pADM20;

3. pUC 18-*ddh*: an approximately 1.3Kb KpnI fragment of pADM21 containing *ddh* (NRRL-B11474) was subcloned into pUC 18 at the KpnI site;

4. pLIC1.7-*argS*-*lysA*: PCR product using template NRRL-B11474 genomic DNA and primers *argS* and *lysA* was cloned into pPMG-LIC cloning vector (PharMingen);

5. pM4-*dapB*-*ORF2*-*dapA*: an approximately 3 Kb PCR product using primers *dapB* and *dapA* was cloned into pM4 at the XbaI site;

6. pFC3-*ask*-*asd*: an approximately 2.6 Kb NsiI-ApaI fragment of pGEMT-*ask*-*asd* was cloned into pFC3 cut with PstI and ApaI;

7. pFC1-*ddh*: ~1.3 Kb Sall-EcoRI fragment of pUC18-*ddh* was cloned into pFC1 cut with Sall and EcoRI;

8. pFC1-*ddh*-*lysA*: an approximately 1.5 Kb EcoRI fragment (containing the truncated *lysA* DNA) of pLIC1.7-*argS*-*lysA* was cloned into pFC1-*ddh* at the EcoRI site;

9. pFC5-*dapB*-*ORF2*-*dapA*: an approximately 3.4 Kb BamHI-BglII fragment of pM4-*dapB*-*ORF2*-*dapA* was cloned into pFC5 at the BamHI site;

10. pFC5-*dapB*-*ORF2*-*dapA*-*ddh*-*lysA*: ~2.8 Kb NheI fragment of pFC1-*ddh*-*lysA* was cloned into pFC5-*dapB*-*ORF2*-*dapA* at the NheI site;

11. pFC-3-*ask*-*asd*-*dapB*-*ORF2*-*dapA*-*ddh*-*lysA*: ~6.2 Kb NotI fragment of pFC5-*dapB*-*ORF2*-*dapA*-*ddh*-*lysA* was cloned into pFC3-*ask*-*asd* at the NotI site;

12. pDElia9-*ask*-*asd*-*dapB*-*ORF2*-*dapA*-*ddh*-*lysA* (pDElia9-KDABHL): ~8.8 Kb PmeI fragment of pFC3-*ask*-*asd*-*dapB*-*ORF2*-*dapA*-*ddh*-*lysA* was cloned into pDElia9 at the EcoRV site; and

13. pK184-*ask*-*asd*-*dapB*-*ORF2*-*dapA*-*ddh*-*lysA* (pK184-KDABHL): an approximately 8.8 Kb PmeI fragment of pFC3-*ask*-*asd*-*dapB*-*ORF2*-*dapA*-*ddh*-*lysA* was cloned into pK184 at the HincII or SmaI site.

14. pFC5-*ask-asd-dapB-ORF2-dapA* (pFC5-KDAB): ~2.6 Kb KpnI-SmaI fragment of pFC3-*ask-asd* was cloned into pFC5-*dapB-ORF2-dapA* cut with KpnI and SmaI.

5 15. pK184-*ask-asd-dapB-ORF2-dapA* (pK184-KDAB): ~7 Kb KpnI-PmeI fragment of pFC5-*ask-asd-dapB-ORF2-dapA* was cloned into pK184 cut with KpnI and HincII.

Thus, Applicants have made the following L-lysine multi-gene constructs:

10 1. pK184-KDABHL, wherein "K" represents a nucleotide sequence encoding the *ask* polypeptide; "D" represents a nucleotide sequence encoding the *asd* polypeptide; "A" represents a nucleotide sequence encoding the *dapA* polypeptide; "B" represents a nucleotide sequence encoding the *dapB* polypeptide; "H" represents a nucleotide sequence encoding the *ddh* polypeptide; and "L" represents a nucleotide sequence encoding part of the *lysA* polypeptide. This construct is referred to as a truncated 6 gene construct. The
15 pK184-KDABHL construct, constructed *infra*, is referred to, as a full length 6 gene construct.

20 2. pK184-KDAB, wherein "K" represents a nucleotide sequence encoding the *ask* polypeptide; "D" represents a nucleotide sequence encoding the *asd* polypeptide; "A" represents a nucleotide sequence encoding the *dapA* polypeptide; and "B" represents a nucleotide sequence encoding the *dapB* polypeptide. This construct is referred to as a 4 gene construct.

Both pK184-KDABHL and pK184-KDAB, as do the other constructs discussed herein, comprise the nucleotide sequence encoding the *ORF2* polypeptide.

25 It should be noted that in addition to the indicated polypeptide sequences encoded by the isolated nucleic acid sequences represented by "K", "D", "A", "B", "H", "L" and "L", these isolated nucleic acid sequences also include native promoter elements for the operons represented therein. Thus, the *ask-asd* sequences have been cloned in a fashion that includes the respective native promoter elements; the *dapA* and *dapB* sequences, representing the operon *dapB-ORF2-dapA*, have been cloned in a fashion that includes the respective promoter
30

-50-

elements; the *ddh* sequence has been cloned in a fashion that includes the respective native promoter elements, and the *lysA* and *'lysA* sequences have been cloned in a fashion that includes a native promoter element.

Alternative gene promoter elements may be utilized in the constructs of the invention. For example, known bacterial promoters suitable for this use in the present invention include the *E. coli lacI* and *lacZ* promoters, the *T3* and *T7* promoters, the *gpt* promoter, the lambda *PR* and *PL* promoters, the *trp* promoter, or promoters endogenous to the bacterial cells of the present invention. Other promoters useful in the invention include regulated promoters, unregulated promoters and heterologous promoters. Many such promoters are known to one of skill in the art. See Sambrook, E.F. *et al.*, *Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989).

Example 2

Two-Fold Amplification of L-lysine Amino Acid Biosynthesis Pathway Genes

For exemplary purposes only, Applicants provide herein an example wherein at least one L-lysine amino acid biosynthesis pathway gene is amplified by a factor of 2 by way of (a) the introduction of an isolated nucleic acid molecule into a *Corynebacterium glutamicum* host cell, and (b) the subsequent single crossover homologous recombination event introducing said isolated nucleic acid molecule into said *Corynebacterium glutamicum* host cell chromosome.

As will be understood by those in the art, at least one or two or three or four or five or six or seven or eight or nine or ten or more amino acid biosynthesis pathway genes may be amplified, *i.e.*, increased in number, by a factor of at least one or two or three or four or five or six or seven or eight or nine or ten fold with minor variations of the example presented herein.

-51-

pK184-KDAB, pK184-KDABHL and pD2-KDABHL(a full length 6 gene construct constructed in Example 4) plasmids were used in the construction of high yield derivative cell lines of the invention. This was accomplished by way of introducing plasmid pK184-KDAB, pK184-KDABHL and pD2-KDABHL DNAs into a *Corynebacterium* species resulting in incorporation of pK184-KDAB, pK184-KDABHL or pD2-KDABHL into the host cell chromosome via a single crossover homologous recombination event. Amplification of the amino acid biosynthetic pathway genes by way of chromosomal integration of the plasmid constructs of the invention provided increased L-lysine production in several *Corynebacterium* species strains.

For cell transformation experiments with the isolated nucleic acid molecules of the invention, the growth and preparation of competent cells may be done according to the following procedure: (1) picking a fresh, single colony of *Corynebacterium glutamicum* and growing a culture overnight in 10 mL CM (SM1) in a 250 mL shake flask at 30 degrees Celsius with agitation; (2) inoculating 200 mL of "Growth Media" with the overnight culture to an optical density (O.D.) of 660 nm of 0.1 in a 500 mL shake flask; (3) growing the culture at 30 degrees Celsius with agitation for 5-6 hours; (4) pouring the culture into a chilled, sealed, sterile 250 mL centrifuge bottle; Spin at 8-10K for ten minutes in Refrigerated Sorvall at 4 degrees Celsius; (5) pouring off the supernatant thoroughly and resuspending the cell pellet in an equal volume of ice-cold, sterile, deionized water; (6) centrifuging the sample again under the same conditions; (7) repeating the water wash remembering to keep everything ice-cold; (8) pouring off the supernatant thoroughly and resuspending the cell pellet in 1 mL of ice-cold, sterile 10% glycerol and transferring the cells to a chilled, sterile, 1.5 mL microcentrifuge tube; (9) spin the sample for 10 minutes in a refrigerated centrifuge; (10) pipetting off and discarding the supernatant, and resuspending the pellet in two to three times the pellet volume (200-400 μ L) of 10% glycerol; and (11) aliquoting, if necessary, the cells into chilled tubes and freezing at -70 Celsius.

pK184-KDAB, pK184-KDABHL and pD2-KDABHL plasmid DNAs were introduced into *Corynebacterium glutamicum* host cells by the following electroporation procedure: (1) pipetting 35 μ L cell/glycerol solution onto the side wall of a chilled 0.1cm electrocuvette; (2) pipetting about 2-4 μ L of plasmid into the solution and mixing the sample by gentle pipetting up and down; (3) bringing the entire solution to the bottom of the electrocuvette by gentle tapping, avoiding the creation of bubbles; (4) keeping the sample on ice until ready for the electroschock step, wiping off any moisture on the outside of the electrocuvette prior to the electroschock administration, and shocking the cells one time at 1.5kV, 200 Ω , 25 μ F.

Cells are allowed to recover from electroporation by: (1) immediately pipetting 1 mL of warm "Recovery Media" into the electrocuvette and thoroughly mixing the solution by pipetting; (2) incubating the solution (in the electrocuvette) at 30 degrees Celsius for at least three hours for antibiotic resistance expression and cell recovery and (3) plating on selection media and incubating at 30 degrees Celsius for 3 days.

Example 3

Screening and Selection of Strains with Improved L-Lysine Production

After 3 days of growth, single colonies of antibiotic resistant cells are individually selected to determine if there is increased L-lysine production over that which is produced by the parental host cell strain.

Recipes for all media used in these experiments are found in Tables 1 and 2. L-lysine production is determined on cultures of transformed, antibiotic resistant cells grown in shaker flasks. Briefly, seed media (Table 1), was dispensed in 20ml aliquots into deep baffled 250ml Bellco shake flasks and autoclaved for 20 minutes. After cooling to room temperature, these seed flasks were then inoculated with the strain to be tested and placed on a rotary shaker. They were incubated at 30 degrees Celsius, shaking, overnight. The following morning, the optical density (wavelength = 660nm) of each seed was recorded,

-53-

and 2ml of the culture from each seed flask was transferred to a 21 ml aliquot of FM3 media, also in a deep baffled shake flask. These "main" flasks were then returned to the shaker and incubated at 30 degrees Celsius.

After 48 hours of incubation, 1 ml of main culture was removed from each flask, and the flasks were promptly returned to the shaker. From the 1 ml sample, optical density was determined by diluting 1:50 in 0.1N HCl to dissolve the calcium carbonate present in the media. The remainder of each sample was then centrifuged to pellet cells and calcium carbonate. A 1:50 dilution of the supernatant was made in water and from this dilution the dextrose concentration was determined. Extracellular L-lysine concentrations were also determined at this time by HPLC.

High yield derivative cells may be conveniently identified by determining the percent yield from dextrose, i.e., the yield of amino acid from dextrose, defined by the formula $[(g \text{ amino acid produced} / g \text{ dextrose consumed}) * 100] = \% \text{ yield}$. Results are presented below in which the parental strains E12, NRRL-B11474 and ATCC 21799 are transformed with the L-lysine multi-gene isolated nucleic acid molecules of the invention identified as pK184-KDA, pK184-KDABH'L and pD(Elia)2-KDABHL. The pD2-KDABHL construct was made as in Example 4.

20	Strain Tested	lysine titer (g/L)	L-lysine yield (%)	Cell Deposit
	NRRL-B11474	31	44	
	NRRL-B11474::pK184-KDAB	32	45.7	NRRL-B-30219
	NRRL-B11474::pK184-KDABH'L	36	51.8	NRRL-B-30218
	NRRL-B11474::pDElia2-KDABHL	38	54.6	NRRL-B-30234
25	E12	1.4	0.9	
	E12::pK184-KDABH'L	26.8	38	NRRL-B-30236
	E12::pDElia2-KDABHL	29.8	42.5	NRRL-B-30237
	ATCC21799	26.8	36.9	
	ATCC21799:: pK184-KDAB	28.5	39	NRRL-B-30221
30	ATCC21799:: pK184-KDABH'L	31	43	NRRL-B-30220
	ATCC21799:: pDElia2-KDABHL	36	50	NRRL-B-30235

Once high yield derivative cell lines are identified, the cell lines are further screened to determine that amplification of the amino acid biosynthetic pathway genes has occurred. Amplification screening may be conveniently accomplished either by (1) standard southern blot methodology to determine gene copy number or (2) by a determination of the total enzyme activity for enzymes encoded by the respective biosynthetic pathway genes of the isolated nucleic acid molecule introduced into the host cell.

A determination of gene copy number by Southern blot methodology may be done utilizing standard procedures known in the art of recombinant DNA technology, as described in the laboratory manuals referenced and incorporated herein, for example as found in J. Sambrook, E.F. Fritsch and T. Maniatis, *Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989).

Table 1. Seed Media, SM1

Ingredient	Concentration (g/L)
Sucrose	50
Potassium Phosphate, Monobasic	0.5
Potassium Phosphate, Dibasic	1.5
Urea	3.0
Magnesium Sulfate	5.0×10^{-1}
Polypeptone	20
Beef Extract	5.0
Biotin	7.56×10^{-4}
Thiamine	3.0×10^{-3}
Niacinamide	1.25×10^{-1}
L-Methionine	5.0×10^{-1}
L-Threonine	2.5×10^{-1}
L-Alanine	5.0×10^{-1}
pH	7.3

-55-

Table 2. Main Media, FM3	
Ingredient	Concentration (g/L)
Dextrose*	60
Ammonium Sulfate	50
Potassium Phosphate, Monobasic	1.0
Magnesium Sulfate	4.0×10^{-1}
Manganese Sulfate	1.0×10^{-2}
Ferrous Sulfate	1.0×10^{-2}
Biotin	3.0×10^{-4}
Calcium Carbonate	50
Corn Steep Liquor (dissolved solids)	20
pH (adjusted with KOH)	7.4

*Dextrose was added after autoclaving

Example 4

Preparation of L-Lysine Pathway Multi-Gene Constructs

The invention further comprises additional L-lysine multi-gene constructs constructed using the PCR technique. Standard PCR and subcloning procedures were utilized, as described above, to generate 5-gene constructs similar to those in Example 1. The constructs of this example comprise the antibiotic resistance gene, chloramphenicol acyl transferase (CAT). The CAT gene was operably linked to a *Corynebacteria* phosphofructokinase promoter for expression in *Corynebacteria*.

The following steps were performed in constructing the following constructs containing the CAT gene:

1. pGEMT-*ask-asd*: ~2.6 Kb PCR product containing the *ask-asd* operon of ATCC21529 using primers *ask* and *asd* was cloned into pGEM-T (Promega pGEM-T vector systems);
2. pUC18-*ddh*: ~1.3Kb KpnI fragment of pADM21 containing *ddh* (NRRL B11474) was subcloned into pUC18 at the KpnI site;
3. pLIC1.7-*argS-lysA*: ~3Kb PCR product using template BF100

-56-

genomic DNA and primers *argS* and *lysA* was cloned into pPMG-LIC cloning vector (PharMingen);

4. pM4-*dapB-ORF2-dapA*: ~3 Kb PCR product using primers *dapB* and *dapA* was cloned into pM4 at the blunted XbaI site;

5. pFC3-*ask-asd*: ~2.6 Kb NsiI-ApaI fragment of pGEMT-*ask-asd* was cloned into pFC3 cut with PstI and ApaI;

6. pFC1-*ddh*: ~1.3 Kb SalI-EcoRI fragment of pUC18-*ddh* was cloned into pFC1 cut with SalI and EcoRI;

7. pFC1-*ddh-lysA*: ~1.5 Kb EcoRI fragment (containing the truncated *lysA* DNA) of pLIC1.7-*argS-lysA* was cloned into pFC1-*ddh* at the EcoRI site;

8. pFC1-*ddh-lysA*: ~2.1 Kb EcoRI-PstI fragment (containing the intact *lysA* DNA) of pRS6 was cloned into pFC1-*ddh* cut with EcoRI and PstI;

9. pFC5-*dapB-ORF2-dapA*: ~3.4 Kb BamHI-BglII fragment of pM4-*dapB-ORF2-dapA* was cloned into pFC5 at the BamHI site;

10. pFC5-*dapB-ORF2-dapA-ddh-lysA*: ~2.8 Kb NheI fragment of pFC1-*ddh-lysA* was cloned into pFC5-*dapB-ORF2-dapA* at the NheI site;

11. pFC5-*dapB-ORF2-dapA-ddh-lysA*: ~3.4 Kb NheI fragment of pFC1-*ddh-lysA* was cloned into pFC5-*dapB-ORF2-dapA* at the NheI site;

12. pFC3-*ask-asd-dapB-ORF2-dapA-ddh-lysA* (pFC3-KDABH'L): ~6.2 Kb NotI fragment of pFC5-*dapB-ORF2-dapA-ddh-lysA* was cloned into pFC3-*ask-asd* at the NotI site;

13. pFC3-*ask-asd-dapB-ORF2-dapA-ddh-lysA* (pFC3-KDABHL): ~6.8 Kb NotI fragment of pFC5-*dapB-ORF2-dapA-ddh-lysA* was cloned into pFC3-*ask-asd* at the NotI site;

14. pK184-*ask-asd-dapB-ORF2-dapA-ddh-lysA* (pK184-KDABH'L): ~8.8 Kb PmeI fragment of pFC3-*ask-asd-dapB-ORF2-dapA-ddh-lysA* was cloned into pK184 at the HincII or SmaI site;

-57-

15. pDElia2-*ask-asd-dapB-ORF2-dapA-ddh-lysA* (pD2-KDABHL): ~9.4 Kb PmeI fragment of pFC3-*ask-asd-dapB-ORF2-dapA-ddh-lysA* was cloned into pDElia2 at the HincII site (contains the *kan* gene; is a full length 6 gene construct);

5 16. pDElia11-*ask-asd-dapB-ORF2-dapA-ddh-lysA* (pD11-KDABH'L): ~8.8 Kb PmeI fragment of pFC3-*ask-asd-dapB-ORF2-dapA-ddh-lysA* was cloned into pDElia11 at the HincII or SmaI site (contains the *CAT* gene; is a truncated 6 gene construct);

10 17. pDElia11-*ask-asd-dapB-ORF2-dapA-ddh-lysA* (pD11-KDABHL): ~9.4 Kb PmeI fragment of pFC3-*ask-asd-dapB-ORF2-dapA-ddh-lysA* was cloned into pDElia11 at the HincII site (contains the *CAT* gene; is a full length 6 gene construct);

18. pDElia2: ~1.24Kb blunted PstI fragment of pUC4K ligated with the ~1.75Kb DraI-SspI fragment of pUC 19;

15 19. pDElia11: ~1Kb PCR product containing the chloramphenicol acyl-transferase gene expressed by the *C. glutamicum fda* promoter was obtained using primers UCdraI and UCsspI and pM4 as template and was ligated with the ~1.75Kb DraI-SspI fragment of pUC19;

The primers utilized for the cloning procedures included:

20 *ask*: 5'-GGGTACCTCGCGAAGTAGCACCTGTCAC-3'

asd: 5'-GCGGATCCCCCATCGCCCCTCAAAGA-3'

dapB: 5'-AACGGGCGGTGAAGGGCAACT-3'

dapA: 5'-TGAAAGACAGGGGTATCCAGA-3'

ddh1 5'-CCATGGTACCAAGTGCGTGGCGAG-3'

25 *ddh2* 5'-CCATGGTACCACACTGTTTCCTTGC-3' Kpn I sites:GGTACC

argS: 5'-CTGGTTCCGGCGAGTGGAGCCGACCATTCGCGAGG-3'

lysA: 5'-CTCGCTCCGGCGAGGTCGGAGGCAACTTCTGCGACG-3'

-58-

a primer that anneals internally to *lysA* (about 500bp upstream to the end of *lysA*).

UCdraI 5'-GGATCTTCACCTAGATCC

UCsspI 5'-CCCTGATAAATGCTTC

5 "K", "D", "A", "B", "H", "L" and "L" have the same designations as set forth above.

Example 5

Three-Fold Amplification of L-lysine Amino Acid Biosynthesis Pathway Genes

10 For exemplary purposes only, Applicants provide herein an example wherein at least one L-lysine amino acid biosynthesis pathway gene is amplified by a factor of 3.

Plasmid pD11-KDABH'L (constructed in Example 4) was used in the construction of high yield derivative cell lines of the invention. For cell
15 transformation experiments with the isolated nucleic acid molecules of the invention, the growth preparation of competent cells, and determining of relative growth may be done according to the procedure set forth above.

Plasmid pD11-KDABH'L DNA was introduced into NRRL-B30220 (comprising pK184-KDABH'L), using the electroporation method above.
20 Introduction of the pD11-KDABH'L plasmid DNA into NRRL-B30220 resulted in incorporation of one copy of pD11-KDABH'L into the host cell chromosome via a single crossover homologous recombination event. The host cell comprising two copies of five genes (pD11-KDABH'L and pK184-KDABH'L) has been deposited as NRRL-B30222.

25 The amount of lysine produced by *C. glutamicum* ATCC 21799 host cells having 3 copies of 5 genes (one endogenous copy and one copy of each of pD11-KDABH'L and pK184-KDABH'L) is shown below.

-59-

L-lysine Production

Strains	L-lysine titer (g/L)	L-lysine yield (%)
ATCC 21799	26.6	45.0
NRRL-B30222	32.0	56.0

Example 6

This example describes changing the promoter to increase the level of expression of each of these 6 genes described above. Six genes encoding six different enzymes of the biosynthetic pathway from L-aspartate to L-lysine have been inserted onto the chromosome of *Corynebacterium glutamicum*. The additional copy of each gene is from a *C. glutamicum* strain. The nucleotide sequences that regulate the level of expression (promoter) for each gene were the same as found on the *C. glutamicum* chromosome at the native loci.

Increased expression can result in increased specific activities of the enzymes and improved flux of carbon from aspartate to lysine. The yield of lysine from glucose can be improved by this technique.

The level of expression from a promoter sequence is referred to as strength. A strong promoter gives higher expression than a weak one. The mechanisms that determine the strength of a promoter have been described (Record, M.T., *et al.*, "Escherichia coli RNA Polymerase, Promoters, and the Kinetics of the Steps of Transcription Initiation," in *Escherichia coli and Salmonella: Cellular and Molecular Biology*, ASM Press (1996), pp. 792-881). Sources of promoters include nucleotide sequences from the 5' end of genes native to the *C. glutamicum* chromosome, from sequences on plasmids that replicate in *C. glutamicum*, from sequences in the genome of phage that infect *C. glutamicum*, or from sequences assembled by humans (*tac*, *trc*) and are not found in nature. Genes of ribosomal proteins, ribosomal RNAs and elongation factors show high levels of expression. The promoters of these genes are candidates for increasing expression of amino acid biosynthetic pathway genes.

-60-

Another reason for changing promoters of genes in biosynthetic pathways is to make the pathway independent of factors that control the pathway in the wild type organism. For example the native promoter of the operon that contains diaminopimelate decarboxylase of the lysine biosynthetic pathway of *C. glutamicum* can respond to arginine or lysine in the growth medium. Arginine increased transcription three-fold and lysine decreased transcription by one third (Oguiza, *et al.*, *J Bact.* 175:7356-7362 (1993)). Diaminopimelate decarboxylase activity decreased 60% in cells grown in minimal medium supplemented with 10mM lysine (Cremer *et al.*, *J Gen Microbiol.* 134:3221-3229 (1988)). Replacing the promoter of *lysA* which encodes the diaminopimelate decarboxylase is one way to make lysine biosynthesis independent of arginine and lysine levels in media.

Example 6A

Shown below are examples of promoters that are stronger than the *askPI* promoter which regulates the gene for aspartate kinase, the first enzyme in the pathway from aspartate to lysine.

Beta-Galactosidase Assay of Candidate Promoters

Candidate	Specific Activity micromol/min/mg	Origin
E12	0.20	no promoter
E12/pTAC	49.80	pKK223-3
BF100	0.08	no promoter
BF100/pAD151.1	2.22	aspartokinase P1
E12	0.11	no promoter
E12/pAD151.1	1.96	aspartokinase P1
E12/5	3.46	BF100 genome
E12/7	8.60	BF100 genome
E12/10	6.56	BF100 genome
E12/32	3.11	BF100 genome
E12/3	22.00	corynephage
E12/39	11.57	corynephage

-61-

E12/42	10.90	corynephage
--------	-------	-------------

E12 is a *C. glutamicum* strain that does not produce lysine. E12 is a laboratory strain derived from ATCC 13059. BF100 is a high level lysine producer (NRRL-B11474). *TAC* is commercially available promoter that has been used as an example of a strong promoter. Four promoters from the *C. glutamicum* chromosome and three from a phage have been identified that are stronger than the native aspartokinase promoter.

Example 6B

Examples of strong promoters increasing specific enzyme activity of aspartokinase when expressed in *C. glutamicum* are shown below.

Influence of IPTG on Aspartokinase activity

Strain	Regulator/promoter-gene	Inducer	nmol/min/mg
BF100	none	none	110
PD9 <trc-ask< td=""><td>lacI/trc-ask</td><td>none</td><td>103</td></trc-ask<>	lacI/trc-ask	none	103
PD9 <trc-ask< td=""><td>lacI/trc-ask</td><td>+IPTG (30 mg/L)</td><td>269</td></trc-ask<>	lacI/trc-ask	+IPTG (30 mg/L)	269
131-2	lacI/trc-ask	none	59
131-2	lacI/trc-ask	+IPTG (30 mg/L)	117
131-5	lacI/trc-ask	none	59
131-5	lacI/trc-ask	+IPTG (30 mg/L)	123
pD9 is a plasmid that replicates in <i>C. glutamicum</i> .			
131 strains have the <i>trc-ask</i> construct integrated into the genome.			
IPTG induces genes controlled by the <i>TRC</i> promoter.			

-62-

Example 6C

Examples of the influence of *lacI/trc-ask* on lysine production in shake flasks are shown below.

Strain	Induction	O.D.	Titre	Yield	S.P.
BF100	none	46	26	43	58
PD9 <i>trc-ask</i>	none	49	30	49	61
PD9 <i>trc-ask</i>	+IPTG	45	30	50	68
BF100	none	43	23	39	53
131-2	none	34	27	46	82
131-5	none	35	28	47	82
O.D. = optical density at 660nm					
Titre = grams Lysine/liter					
Yield = grams lysine made/grams dextrose consumed					
S.P. = grams lysine/O.D.					

The production of lysine by BF100 was improved by increasing the strength of the aspartokinase promoter.

Example 7

This example demonstrates the use of vector pDElia2-*ask-asd-dapA-ORF2-dapB-ddh-P1lysA* (pDElia2KDABHP1L) in the construction of the high yield cell lines of the invention. The HpaI-PvaII fragment containing the P1 promoter was prepared as described in Marcel T., *et al.*, *Molecular Microbiology* 4:1819-1830 (1990). Applicants utilized standard PCR and subcloning procedures as set forth above. For cell transformation experiments with the isolated nucleic acid molecules of the invention, the growth preparation of competent cells, and determining or relative growth may be done according to the procedure set forth above.

-63-

Applicants performed the following steps in constructing the following vectors used in the L-lysine biosynthetic pathway.

1. pGEMT-*ask-asd*: ~2.6 Kb PCR product containing the *ask-asd* operon of ATCC21529 using primers *ask* and *asd* was cloned into pGEM-T (Promega pGEM-T vector systems).

2. pUC18-*ddh*: ~1.3 KpnI fragment of pADM21 containing *ddh* (BF100 locus) was subcloned into pUC18 at the KpnI site.

3. pFC3-*ask-asd*: ~2.6 Kb NsiI-ApaI fragment of pGEMT-*ask-asd* was cloned into pFC3 cut with PstI and ApaI.

4. pFC3-*dapB-ORF2-dapA*: ~2.9 Kb PCR product of NRRL-B11474 *dapB-ORF2-dapA* coding region was cloned into pFC3 at the EcoRV site.

5. pFC1-*ddh*: ~1.3 Kb PstI-EcoRI fragment of pUC18-*ddh* was cloned into pFC1 cut with PstI and EcoRI.

6. pUC19-P1: ~550 bp HpaI-PvuII fragment (containing the first promoter, P1, of the *argS-lysA* operon) of pRS6 was cloned into pUC19 at the SmaI site.

7. pUC19-P1*lysA*: ~1.45 Kb promoterless PCR product, using primer *LysA*(ATG) and *LysA*3B, of NRRL-B11474 *lysA* coding region is cloned into pUC19-P1 at the HincII site.

8. pFC1-P1*lysA*: ~2 Kb EcoRI-HindIII fragment of pUC19-P1*lysA* was cloned into pFC1 cut with EcoRI and HindIII.

9. pFC1-P1*lysA-ddh*: ~1.3 Kb EcoRI-NotI fragment of pFC1-*ddh* was cloned into pFC1-P1*lysA* cut with EcoRI and NotI.

10. pFC1-*ask-asd-ddh*-P1*lysA*: ~2.6 Kb SmaI-FseI fragment of pFC3-*ask-asd* was cloned into pFC1-*ddh*-P1*lysA* cut with SmaI and FseI.

11. pFC3-*ask-asd-dapB-ORF2-dapA-ddh*-P1*lysA* (pFC3-KDABHP1L): ~5.9 Kb SpeI fragment of pFC1-*ask-asd-ddh*-P1*lysA* was cloned into pFC3-*dapB-ORF2-dapA* at the SpeI site.

12. pDElia2-*ask-asd-dapB-ORF2-dapA-ddh*-P1*lysA* (pDElia2-KDABHP1L): ~8.8 Kb PmeI fragment of pFC3-*ask-asd-dapB-ORF2-dapA-ddh*-P1*lysA* was cloned into pDElia2 at the HincII site.

-64-

Primers used in PCR:

lysA(ATG): CCGGAGAAGATGTAACAATGGCTAC

LysA3B: CCTCGACTGCAGACCCCTAGACACC

The nucleotide sequence (SEQ ID NO:17) of the HpaI-PvuII fragment containing the promoter P1 is shown in figure 20. Results of lysine production in NRRL-B11474 comprising the pDElia2-*ask-asd-dapA-ORF2-dapB-ddh-P1lysA* (pDElia2 KDABHP1L) construct are shown below.

Strain tested	lysine titer	lysine yield (%)	cell deposit
NRRL-B11474	30	35	
NRRL-B11474::pDElia2-KDABHP1L	37	42.8	NRRL B30359

Example 8

This example demonstrates the use of vector pDElia2_{FCS}-*ask-asd-dapB-ddh-lysA* (pDElia2_{FCS}KDBHL) in the construction of the high yield cell lines of the invention. The pDElia2_{FCS}KDBHL vector comprises a truncated ORF2 gene and lacks a *dapA* gene. The ORF2 gene was cleaved at an internal ClaI site, removing the 3' region and the *dapA* gene. A promoterless *lysA* gene was obtained from NRRL-B11474. For cell transformation experiments with the isolated nucleic acid molecules of the invention, the growth preparation of competent cells, and determining of relative growth may be done according to the procedure set forth above. Applicants performed the following steps in constructing the following vectors used in the L-lysine biosynthetic pathway.

1. pGEMT-*ask-asd*: ~2.6 Kb PCR product containing the *ask-asd* operon of ATCC21529 using primers *ask* and *asd* was cloned into pGEM-T (Promega pGEM-T vector systems).

2. pFC3-*ask-asd*: ~2.6 Kb NsiI-ApaI fragment of pGEMT-*ask-asd* was cloned into pFC3 cut with PstI and ApaI.

-65-

3. pFC3-*dapB-ORF2-dapA*: ~2.9 Kb PCR product of NRRL-B11474 *dapB-ORF2-dapA* coding region was cloned into pFC3 at the EcoRV site.

4. pFC3-*dapB*: the large ClaI fragment of pFC3-*dapB-ORF2-dapA* was religated.

5. pUC18-*ddh*: ~1.3 Kb KpnI fragment of pADM21 containing *ddh* (NRRL-B11474 locus) was subcloned into pUC18 at the KpnI site.

6. pFC1-*ddh*: ~1.3 Kb SalI-EcoRI fragment of pUC18-*ddh* was cloned into pFC1 cut with SalI and EcoRI.

7. pFC1-*ddh-lysA*: ~2.1 Kb EcoRI-PstI fragment (containing the intact *lysA* DNA) of pRS6 was clone into pFC1-*ddh* cut with EcoRI and PstI.

8. pFC1-*ask-asd-ddh-lysA*: ~2.6 Kb SwaI-FseI fragment of pFC3-*ask-asd* was cloned into pFC1-*ddh-lysA* cut with SwaI and FseI.

9. pFC3-*ask-asd-dapB-ddh-lysA*: ~6 Kb SpeI fragment of pFC1-*ask-asd-ddh-lysA* was cloned into pFC3-*dapB* at the SpeI site.

10. pDElia2_{FC5}-*ask-asd-dapB-ddh-lysA* (pDElia2_{FC5}-KDBHL): ~7.3 Kb NotI-PmeI fragment of pFC3-*ask-asd-dapB-ddh-lysA* was cloned into pDElia2_{FC5} cut with NotI and PmeI.

11. pDElia2_{FC5}: the small PvuII fragment of pFC5 was ligated with the large PvuII fragment of pDElia2.

Results of lysine production in NRRL-B11474 comprising the pDElia2_{FC5}-*ask-asd-dapB-ddh-lysA* (pDElia2_{FC5}KDBHL) are shown below.

-66-

Strain tested	lysine titer	lysine yield (%)	cell deposit
NRRL-B11474	31	49	
NRRL-B11474::pDElia2 _{PCS} -KDBHL	37.8	58	NRRL B30360

* * * * *

5 Having now fully described the present invention in some detail by way
of illustration and example for purposes of clarity of understanding, it will be
obvious to one of ordinary skill in the art that same can be performed by
modifying or changing the invention with a wide and equivalent range of
conditions, formulations and other parameters thereof, and that such
10 modifications or changes are intended to be encompassed within the scope of the
appended claims.

 All publications, patents and patent applications mentioned in this
specification are indicative of the level of skill of those skilled in the art to which
this invention pertains, and are herein incorporated by reference to the same
15 extent as if each individual publication, patent or patent application was
specifically and individually indicated to be incorporated by reference.

66.1

Applicant's or agent's file reference number: 1533.103PC...	International application No. TBA
--	--------------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>8</u> , line <u>2</u> .	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depository institution Agricultural Research Culture Collection (NRRL)	
Address of depository institution (including postal code and country) 1815 N. University Street Peoria, Illinois 61604 United States of America	
Date of deposit 16 September 1999 (16.09.99)	Accession Number NRRL B-30218
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
A::pK184-KDABDL	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <i>Vonessa E. Clark</i>	Authorized officer

66.2

Applicant's or agent's file reference number 1533.103PC	International application TBA
--	----------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page _8_, line _3_.	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depository institution Agricultural Research Culture Collection (NRRL)	
Address of depository institution (including postal code and country) 1815 N. University Street Peoria, Illinois 61604 United States of America	
Date of deposit 16 September 1999 (16.09.99)	Accession Number NRRL B-30219
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
B::pK184-KDAB	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <i>Vanessa E Clark</i>	Authorized officer

66.3

Applicant's or agent's file reference number: 1533.103PC0.	International application PG TBA
---	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page _8_, line _4_.	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depository institution Agricultural Research Culture Collection (NRRL)	
Address of depository institution (including postal code and country) 1815 N. University Street Peoria, Illinois 61604 United States of America	
Date of deposit 16 September 1999 (16.09.99)	Accession Number NRRL B-30220
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
C::pK184-KDABDL	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (If the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <i>Vonessa E. Clark</i>	Authorized officer

66.4

Applicant's or agent's file reference number: 1533.103PCU	International application No. TBA
--	--------------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page _8_, line _4_.	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depository institution Agricultural Research Culture Collection (NRRL)	
Address of depository institution (including postal code and country) 1815 N. University Street Peoria, Illinois 61604 United States of America	
Date of deposit 16 September 1999 (16.09.99)	Accession Number NRRL B-30221
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D::pK184-KDAB	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <i>Vanessa E Clark</i>	Authorized officer

66.5

Applicant's or agent's file reference number: 1533.103PCU	International application No. 7 TBA
--	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>8</u> , line <u>5</u> .	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depository institution Agricultural Research Culture Collection (NRRL)	
Address of depository institution (including postal code and country) 1815 N. University Street Peoria, Illinois 61604 United States of America	
Date of deposit 16 September 1999 (16.09.99)	Accession Number NRRL B-30222
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
E::2(KDABD'L)	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <i>Vanessa E Clark</i>	Authorized officer

66.6

Applicant's or agent's file reference number: 1533.103PC03	International application No. TBA
---	--------------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page _8_, line _7_.	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depository institution Agricultural Research Culture Collection (NRRL)	
Address of depository institution (including postal code and country) 1815 N. University Street Peoria, Illinois 61604 United States of America	
Date of deposit 29 September 1999 (29.09.99)	Accession Number NRRL B-30228
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
DH5-a MCR pK184-KDABD'L	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer Vanessa E. Clark	Authorized officer

66.7

Applicant's or agent's file reference number: 1533.103PC6,	International application No. TBA
---	--------------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>43</u> , line <u>21</u> .	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depository institution Agricultural Research Culture Collection (NRRL)	
Address of depository institution (including postal code and country) 1815 N. University Street Peoria, Illinois 61604 United States of America	
Date of deposit 16 December 1999 (16.12.99)	Accession Number NRRL B-30233
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
DH5-a MCR pDelia2-KDABdl	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <i>Vanessa E. Clark</i>	Authorized officer

66.8

Applicant's or agent's file reference number: 1533.103P002	International application No. TBA
---	--------------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>8</u> , line <u>5</u> .	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depository institution Agricultural Research Culture Collection (NRRL)	
Address of depository institution (including postal code and country) 1815 N. University Street Peoria, Illinois 61604 United States of America	
Date of deposit 16 December 1999 (16.12.99)	Accession Number NRRL B-30234
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
: : pDeliA2-KDABdL	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <i>Vonessa E. Clark</i>	Authorized officer

66.9

Applicant's or agent's file
reference number: 1533.103PCC.

International application No. ~~56~~
TBA

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 8, line 6.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet ☒

Name of depository institution

Agricultural Research Culture Collection (NRRL)

Address of depository institution (including postal code and country)

1815 N. University Street
Peoria, Illinois 61604
United States of America

Date of deposit 16 December 1999
(16.12.99)

Accession Number
NRRL B-30235

C. ADDITIONAL INDICATIONS (leave blank if not applicable)

This information is continued on an additional sheet ☐

: : pDelia2-KDABdl

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")

For receiving Office use only

☒ This sheet was received with the international application

Authorized officer

Vanessa A. Clark

For International Bureau use only

☐ This sheet was received by the International Bureau on:

Authorized officer

66.10

Applicant's or agent's file reference number: 1533.103PCC	International application No. TBA
--	--------------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>8</u> , line <u>9</u> .	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depository institution Agricultural Research Culture Collection (NRRL)	
Address of depository institution (including postal code and country) 1815 N. University Street Peoria, Illinois 61604 United States of America	
Date of deposit 16 December 1999 (16.12.99)	Accession Number NRRL B-30236
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
: :pK184-KDABd'L	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer Vanessa E. Clark	Authorized officer

66.11

Applicant's or agent's file reference number: 1533.103PCu:	International application No. TBA
---	--------------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>8</u> , line <u>9</u> .	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depository institution Agricultural Research Culture Collection (NRRL)	
Address of depository institution (including postal code and country) 1815 N. University Street Peoria, Illinois 61604 United States of America	
Date of deposit 16 December 1999 (16.12.99)	Accession Number NRRL B-30237
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
: pDelia2-KDABdL	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <i>Venessa E. Clark</i>	Authorized officer

66.12

Applicant's or agent's file reference number: 1533.103PC	International application No. TBA
---	--------------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>9</u> , line <u>23</u> .	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depository institution Agricultural Research Culture Collection (NRRL)	
Address of depository institution (including postal code and country) 1815 N. University Street Peoria, Illinois 61604 United States of America	
Date of deposit 31 October 2000 (31.10.00)	Accession Number NRRL B-30359
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
: pDELia2-KDABHP1L	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <i>Vanessa E Clark</i>	Authorized officer

66.13

Applicant's or agent's file reference number: 1533.103PCL	International application No. TBA
--	--------------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>9</u> , line <u>7</u> .	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depository institution Agricultural Research Culture Collection (NRRL)	
Address of depository institution (including postal code and country) 1815 N. University Street Peoria, Illinois 61604 United States of America	
Date of deposit 31 October 2000 (31.10.00)	Accession Number NRRL B-30360
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
: pDELia2FC5-KDBHL	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <i>Vanesa E. Clark</i>	Authorized officer

-67-

What Is Claimed Is:

1. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2.

2. An isolated polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide sequence of claim 1.

3. The isolated polynucleotide molecule of claim 2 comprising a nucleic acid having the sequence of SEQ ID NO:1.

4. A vector comprising the isolated polynucleotide molecule of claim 2.

5. A host cell comprising the vector of claim 4.

6. A method comprising:

(a) transforming a *Corynebacterium* species host cell with the polynucleotide molecule of claim 2, wherein said isolated polynucleotide molecule is integrated into said host cell's chromosome thereby increasing the total number of said amino acid biosynthetic pathway genes in said host cell chromosome, and

(b) selecting a transformed host cell.

7. The method of claim 6 further comprising screening for increased amino acid production.

8. The method of claim 6 wherein said polynucleotide molecule further comprises at least one of the following:

(a) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *asd* amino acid sequence;

-68-

(b) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *dapA* amino acid sequence;

(c) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *dapB* amino acid sequence;

5 (d) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *ddh* amino acid sequence; and

(e) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *lysA* amino acid sequence;

10 (f) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *lysA* amino acid sequence; and

(g) a nucleic acid molecule encoding a *Corynebacterium species* lysine pathway *ORF2* amino acid sequence.

9. The method of claim 8 further comprising screening for increased amino acid production.

15 10. The method of claim 6, wherein said isolated polynucleotide molecule further comprises at least one of the following:

(a) a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4;

20 (b) a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6;

(c) a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8;

(d) a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10;

25 (e) a nucleic acid molecule encoding the *lysA* amino acid sequence of SEQ ID NO:21;

(f) a nucleic acid molecule encoding the *lysA* amino acid sequence of SEQ ID NO:14;

(g) a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

11. The method of claim 6, wherein said isolated polynucleotide molecule further comprises the following:

5 (a) a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4;

(b) a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6;

10 (c) a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8; and

(d) a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

12. The method of claim 6, wherein said isolated polynucleotide molecule further comprises the following:

15 (a) a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4;

(b) a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6;

20 (c) a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8;

(d) a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10; and

(e) a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

25 13. The method of claim 6, wherein said isolated polynucleotide molecule further comprises the following:

(a) a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4;

-70-

(b) a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6;

(c) a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8;

5 (d) a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10;

(e) a nucleic acid molecule encoding the *lysA* amino acid sequence of SEQ ID NO:21; and

10 (f) a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

14. The method of claim 6, wherein said isolated polynucleotide molecule further comprises the following:

(a) a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4;

15 (b) a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6;

(c) a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8;

20 (d) a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10;

(e) a nucleic acid molecule encoding the *lysA* amino acid sequence of SEQ ID NO:14; and

(f) a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

25 15. The method of claim 6 further comprising:

(a) growing said transformed host cell in a medium; and

(b) purifying an amino acid produced by said transformed host cell.

16. An isolated polynucleotide molecule comprising:

- (a) the polynucleotide molecule of claim 2; and
- (b) at least one additional *Corynebacterium* species lysine pathway

gene selected from the group consisting of:

- 5 (i) a nucleic acid molecule encoding an *asd* polypeptide;
- (ii) a nucleic acid molecule encoding a *dapA* polypeptide;
- (iii) a nucleic acid molecule encoding a *dapB* polypeptide;
- (iv) a nucleic acid molecule encoding a *ddh* polypeptide;
- (v) a nucleic acid molecule encoding a *lysA* polypeptide;
- 10 (vi) a nucleic acid molecule encoding a *lysA* polypeptide; and
- (vii) a nucleic acid molecule encoding an *ORF2* polypeptide.

17. The isolated nucleic acid molecule of claim 16, wherein:

- (a) said *asd* polypeptide is SEQ ID NO:4;
- (b) said *dapA* polypeptide is SEQ ID NO:6;
- 15 (c) said *dapB* polypeptide is SEQ ID NO:8;
- (d) said *ddh* polypeptide is SEQ ID NO:10;
- (e) said *lysA* polypeptide is SEQ ID NO:21;
- (f) said *lysA* polypeptide is SEQ ID NO:14; and
- (g) said *ORF2* polypeptide is SEQ ID NO:16.

20 18. An isolated polynucleotide molecule comprising:

- (a) the polynucleotide molecule of claim 2;
- (b) a nucleic acid molecule encoding the *asd* amino acid sequence of

SEQ ID NO:4;

- (c) a nucleic acid molecule encoding the *dapA* amino acid sequence
- 25 of SEQ ID NO:6;

- (d) a nucleic acid molecule encoding the *dapB* amino acid sequence
- of SEQ ID NO:8; and

- (e) a nucleic acid molecule encoding the *ORF2* amino acid sequence
- of SEQ ID NO:16.

-72-

19. An isolated polynucleotide molecule comprising:

- (a) the polynucleotide molecule of claim 2;
- (b) a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4;

5 (c) a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6;

(d) a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8;

10 (e) a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10; and

(f) a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

20. An isolated polynucleotide molecule comprising:

- (a) the polynucleotide molecule of claim 2;

15 (b) a nucleic acid molecule encoding the *asd* amino acid sequence of SEQ ID NO:4;

(c) a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6;

20 (d) a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8;

(e) a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10;

(f) a nucleic acid molecule encoding the *lysA* amino acid sequence of SEQ ID NO:21; and

25 (g) a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

-73-

21. An isolated polynucleotide molecule comprising:

- (a) the polynucleotide molecule of claim 2;
- (b) a nucleic acid molecule encoding the *asd* amino acid sequence of

SEQ ID NO:4;

5 (c) a nucleic acid molecule encoding the *dapA* amino acid sequence of SEQ ID NO:6;

(d) a nucleic acid molecule encoding the *dapB* amino acid sequence of SEQ ID NO:8;

10 (e) a nucleic acid molecule encoding the *ddh* amino acid sequence of SEQ ID NO:10;

(f) a nucleic acid molecule encoding the *lysA* amino acid sequence of SEQ ID NO:14; and

(g) a nucleic acid molecule encoding the *ORF2* amino acid sequence of SEQ ID NO:16.

15 22. The isolated polynucleotide molecule of claim 18 comprising pK184-KDAB.

23. The isolated polynucleotide molecule of claim 20 comprising pD11-KDABH'L.

20 24. The isolated polynucleotide molecule of claim 21 comprising pD2-KDABHL.

25. A vector comprising the polynucleotide molecule of claim 16.

26. A host cell comprising the vector of claim 25.

25 27. The host cell of claim 26 wherein said host cell is a *Brevibacterium* selected from the group consisting of *Brevibacterium flavum* NRRL-B30218, *Brevibacterium flavum* NRRL-B30219, *Brevibacterium lactofermentum*

-74-

NRRL-B30220, *Brevibacterium lactofermentum* NRRL-B30221, *Brevibacterium lactofermentum* NRRL-B30222, *Brevibacterium flavum* NRRL-30234 and *Brevibacterium lactofermentum* NRRL-30235.

28. The host cell of claim 26 wherein said host cell is *Escherichia coli* DH5 α MCR NRRL-B30228.

29. The host cell of claim 26 wherein said host cell is a *C. glutamicum* selected from the group consisting of *C. glutamicum* NRRL-B30236 and *C. glutamicum* NRRL-B30237.

30. A method of producing lysine comprising culturing the host cells of claim 5 wherein said host cells comprise one or more of:

(a) increased enzyme activity of one or more lysine biosynthetic pathway enzymes compared to the genetically unaltered host cell;

(b) one or more copies of each gene encoding a lysine biosynthetic pathway enzyme; and,

(c) alteration of one or more transcription factors regulating transcription of one or more genes encoding a lysine biosynthetic pathway enzyme, wherein said host cell produces lysine in said culture medium.

31. The method of claim 30 wherein said increased enzyme activity comprises overexpressing one or more genes encoding one or more lysine biosynthetic pathway enzymes.

32. The method of claim 31 wherein said one or more genes are operably linked directly or indirectly to one or more promoter sequences.

33. The method of claim 32 wherein said operably linked promoter sequences are heterologous, endogenous, or hybrid.

-75-

34. The method of claim 33 wherein said promoter sequences are one or more of: a promoter sequence from the 5' end of genes endogenous to *C. glutamicum*, a promoter sequence from plasmids that replicate in *C. glutamicum*, and, a promoter sequence from the genome of phage which infect *C. glutamicum*.

5 35. The method of claim 33 or 34 wherein one or more of said promoter sequences are modified.

10 36. The method of claim 35 wherein said modification comprises truncation at the 5' end, truncation at the 3' end, non-terminal insertion of one or more nucleotides, non-terminal deletion of one or more nucleotides, addition of one or more nucleotides at the 5' end, addition of one or more nucleotides at the 3' end, and, combinations thereof.

15 37. The method of claim 30 wherein said increased enzyme activity results from the activity of one or more modified lysine biosynthetic pathway enzymes wherein said enzyme modification results in a change in kinetic parameters, allosteric regulation, or both, compared to the enzyme lacking said modification.

38. The method of claim 37 wherein said change in kinetic parameters is a change in K_m , V_{max} or both.

39. The method of claim 37 wherein said change in allosteric regulation is a change in one or more enzyme allosteric regulatory sites.

20 40. The method of claim 37 wherein said modification is a result of a change in the nucleotide sequence encoding said enzyme.

41. The method of claim 40 wherein said change in said nucleotide sequence is an addition, insertion, deletion, substitution, or a combination thereof, of one or more nucleotides.

-76-

42. The method of claim 30 wherein said alteration of one or more transcription factors comprises one or more mutations in transcription inhibitor proteins, one or more mutations in transcription activator proteins, or both, wherein said one or more mutations increases transcription of the target nucleotide sequence compared to the transcription by said one or more transcription factors lacking said alteration.

43. The method of claim 42 wherein said one or more mutations is a change in said nucleotide sequence encoding said transcription factor.

44. The method of claim 43 wherein said change in said nucleotide sequence is an addition, insertion, deletion, substitution, or a combination thereof, of one or more nucleotide.

45. An isolated polypeptide, wherein said polypeptide comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:19.

46. The polypeptide of claim 45, wherein said polypeptide has the amino acid sequence of SEQ ID NO:19.

47. An isolated polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide of claim 45.

48. The isolated polynucleotide molecule of claim 47 comprising a nucleic acid having the sequence of SEQ ID NO:18.

49. A vector comprising the polynucleotide molecule of claim 47.

50. A host cell comprising the vector of claim 49.

51. The host cell of claim 50 wherein said host cell is NRRL B30360.

-77-

52. A method comprising:

(a) transforming a *Corynebacterium* species host cell with the polynucleotide molecule of claim 47, and

(b) selecting a transformed host cell.

5 53. An isolated polypeptide wherein said polypeptide comprises a polypeptide having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:21.

54. The polypeptide of claim 53 having the amino acid sequence of SEQ ID NO:21.

10 55. An isolated polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide of claim 53.

56. The isolated polynucleotide molecule of claim 55 comprising a nucleic acid having the sequence of SEQ ID NO: 20.

57. A vector comprising the polynucleotide molecule of claim 55.

15 58. A host cell comprising the vector of claim 57.

59. The host cell of claim 58 wherein said host cell is selected from the group consisting of NRRL B30218, NRRL B30220 and NRRL B30222.

60. A method comprising:

20 (a) transforming a *Corynebacterium* species host cell with the polynucleotide molecule of claim 55, and

(b) selecting a transformed host cell.

-78-

61. The isolated polynucleotide molecule of claim 2 further comprising a promoter sequence where said promoter sequence has at least 95% sequence identity to SEQ ID NO:17.

5

62. The polynucleotide of claim 61 where said promoter sequence has the nucleotide sequence of SEQ ID NO: 17.

63. The isolated polynucleotide molecule of claim 61 wherein said promoter is operably directly linked to the LysA gene.

64. A vector comprising the isolated polynucleotide of claim 61.

65. A host cell comprising the vector of claim 64.

10

66. The host cell of claim 65 wherein said host cell is NRRL B30359.

67. A method comprising:

- (a) transforming a *Corynebacterium* species host cell with the polynucleotide molecule of claim 61, and
- (b) selecting a transformed host cell.




Figure 1

Nucleotide sequence of ATCC21529 ask (SEQ ID NO:1)

```
1 GTGGCCCTGC TCGTACAGAA ATATGCCGGT TCCTCGCTTG AGAGTGCGGA
51 ACGCATTAGA AACGTGCGTG AACGGATCGT TGCCACCAAG AAGGCTGGAA
101 ATGATGTCGT GGTGTCTGTC TCCGCAATGG GAGACACCAC GGATGAACCTT
151 CTAGAACTTG CAGCGGCAGT GAATCCCGTT CCGCCAGCTC GTGAAATGGA
201 TATGCTCCTG ACTGCTGGTG AGCGTATTTC TAACGCTCTC GTCGCCATGG
251 CTATTGAGTC CCTTGGGCGCA GAAGCTCAAT CTTTCACTGG CTCTCAGGCT
301 GGTGTGCTCA CCACCGAGCG CCACGGAAAC GCACGCATTG TTGACGTCAC
351 ACCGGGTCGT GTGCGTGAAG CACTCGATGA GGGCAAGATC TGCATTGTTG
401 CTGGTTTTCA GGGTGTTAAT AAAGAAACCC GCGATGTCAC CAGGTGGGT
451 CGTGGTGGTT CTGACACCAC TGCAGTTGCG TTGGCAGCTG CTTTGAACGC
501 TGATGTGTGT GAGATTACT CGGACGTTGA CGGTGTGTAT ACCGCTGACC
551 CGCGCATCGT TCCTAATGCA CAGAAGCTGG AAAAGCTCAG CTTGGAAGAA
601 ATGCTGGAAC TTGCTGCTGT TGGCTCCAAG ATTTGGTGC TGGCAGTGT
651 TGAATACGCT CGTGCAITCA ATGTCCACT TCGGTACGC TCGTCTATA
701 GTAATGATCC CGGCACITTG ATTGCCGGCT CTATGCAGGA TATTCCTGTG
751 GAAGAAGCAG TCCTTACCGG TGTOGCAACC GACAGTCCG AAGCCAAAGT
801 AACCGTTCTG GGTATTTCCG ATAAGCCAGG CGAGGCTGCC AAGGTTTTCC
851 GTGCGTTGGC TGATGCAGAA ATCAACATTG ACATGGTTCT GCAGAACGTC
901 TCCTCTGTGG AAGACGGCAC CACGACATC ACGTTCACCT GCOCTCGCGC
951 TGACGGACGC CGTGCGATGG AGATCTTGAA GAAGCTTCAG GTTCAGGGCA
1001 ACTGGACCAA TGTGCTTTAC GACGACCAGG TCGGCAAAGT CTCCCTCGTG
1051 GGTGCTGGCA TGAAGTCTCA CCCAGGTGTT ACCGCAGAGT TCATGGAAGC
1101 TCTGCGCGAT GTCAACGTGA ACATCGAATT GATTTCCATC TCTGAGATCC
1151 GCATTTCGGT GCTGATCCGT GAAGATGATC TGGATGCTGC TGCACGTGCA
1201 TTGCATGAGC AGTTCCAGCT GGGCGGCGAA GACGAAGCCG TCGTTTATGC
1251 AGGCACCGGA CGCTAA
```

Fig. 2

SEQ ID NO:2

pro amino acid sequence of ATCC 71529 ank

1 GTGGCCCTGGTGTACAGAAATATGGGGTTCCTGGCTTGACAGTGGGAACGATTAGA 60
K A L V V O N Y G C S L E S A E P I R
61 AAGTGGCTGAACGATCGTTGCCACCAAGAAGCTCGAAATGATGTGTGGTGTCTGCG 120
R V A E R I V A T K K A G N D V V V V C
121 TCCCAATGGGAGACACCGGATGAACCTCTAGAACTTCAGCGGCGAGTGAATCCCGTT 180
S A H G D T T D E L L E L A A A V N P V
CCGCCAGCTCGTGAATGGATATGCTCTGACTGCTGGTGAGCGTATTTCTAACGCTCTC
181 240
P P A R E N D M L L T A G E R I S N A L
241 GTGCCCATGGCTATTGAGTCCCTTGGCGCAGAAGCTCAATCTTCACTGGCTCTCAGGCT 300
V A H A I E S L G A E A Q S F T G S Q A
301 GGTGTGCTCACACCGAGCGGCCAGGAACGCACGCATTGTTGACGTGCACACCGGGTGTG 360
G V L T T E R H G N A R I V D V T P G R
361 GTGCGTGAAGCACTCGATGAGGGCAAGATCTGCATTGTTGCTGGTTTTCAGGGTGTAAAT 420
V R E A L D E G K I C I V A G F Q G V N
421 AAAGAAACCCGCGATGTCACACGTTGGGTGCTGGTGGTCTTGACACCACTGCAGTTGCG 480
K E T R D V T T L G R G G S D T T A V A
481 TTGGCAGCTGCTTTGAACGCTGATGTGTGTGAGATTACTCGGACGTTGACGGTGTGTAT 540
L A A A L N A D V C E I Y S D V D G V Y
541 ACCGCTGACCGCGCATCGTTCTAATGCACAGAGCTGGAAAAGCTCAGCTTCCAAGAA 600
T A D P R I V P N A Q K L E K L S F E E
601 ATGCTGGAACCTTGCTGCTGTTGGCTCCAAGATTTGGTGTGCGCAGTGTGAATACGCT 660
M L E L A A V G S K I L V L R S V E Y A
661 CGTGCATTCAATGTGCCACTTCGGGTACGCTCGTCTTATAGTAATGATCCCGGCACTTTG 720
R A F N V P L R V R S S Y S N D P G T L
721 ATTGCCGGCTCTATGGAGGATATTCCTGTGGAAGAGCAGTCTTACCGGTGTGCGCAACC 780
I A G S M E D I P V E E A V L T G V A T
781 GACAAGTCCGAAGCCAAAGTAACCGTTCTGGGTATTTCGATAAGCCAGGCGAGGCTGCC 840
D K S E A K V T V L G I S D K P G E A A

Fig 3A

290x
114

3

Nucleotide. sequence of ATCC21529 asd (SEQ ID NO: 2)

```
1  ATGACCACCA TCGCAGTTGT TGETGCAACC GGCCAGGTGG GCCAGGTTAT
51  GCGCACCTTT TTGGAAGAGC GCAATTTCCC AGCTGACACT GTTGGTTTCT
101 TTGCTTCCCC GCGTTCCGCA GGCCGTAAGA TTGAATTCGG TGGCACGGAA
151 ATCGAGGTAG AAGACATTAC TCAGGCAACC GAGGAGTCCC TCAGGGGCAT
201 CGACGTTGCG TTGTTCTCTG CTGGAGGCAC CGCTTCCAG CAGTACGCTC
251 CACTGTTTGC TGCTGCAGGC GCGACTGTTG TGGATAACTC TTCTGCTTGG
301 CGCAAGGAAG ACGAGGTTCC ACTAATCGTC TCTGAGGTGA ACCCTTCCGA
351 CAAGGATTCC CTGGTCAAGG GCATTATTGC GAATCCTAAC TGCACACCA
401 TGGCTGCAAT GCCAGTGTG AAGCCACTGC ACGATGCCGC TGGTCTTGTA
451 AAGCTTCACG TTCTCTCTA CCAGGCTGTT TCCGTTCTG GTCTTGCAGG
501 TGTGAAACC TTGGCAAGC AGGTTGCTGC AGTTGGCGAC CACAACGTTG
551 AGTTGCTCCA TGATGGACAG GCTGCTGACG CAGGCGATGT CGGACCTTAC
601 GTTTCOCCAA TCGTTACAA CGTGTGCCA TCGCCGGAA ACCTGCTCGA
651 TGACGGCACC TTCGAAACCG ACGAGAGCA GAAGCTGCGC AACGAATCCC
701 GCAAGATTCT CGGCCTCCCA GACCTCAAGG TCTCAGGCAC CTGCTCCGC
751 GTGCCGGTTT TCACCGGCCA CACGCTGACC ATTACGCGG AATTGACAA
801 GGCAATCACC GTCGAGCAGG CGCAAGAGAT CTTGGGTGOC GCTTCAGGCG
851 TCGAGCTTGT CGACGTCCA ACCCACTTG CAGCTGCCGG CATTGACGAA
901 TCCCTCGTTG GACGCATCG TCAGGACTCC ACTGTCGAGG ACAACCGCGG
951 TCTGTTCTC GTCGTATCTG GCGATAACCT TCGCAAGGGC GCAGCACTGA
1001 ACACCATTC AATTGCTGAG CTGCTGGTTA AGTAA
```

Fig. 4

SEQ ID NO:4
(CON4)

TCCCTCGTTGGA⁺CGCATCCGTCAGGACTCCACTGTCGACGACAACCGCGGTCTGGTTCTC
901 -----+-----+-----+-----+-----+ 960
S L V G R I R Q D S T V D D N R G L V L
GTCGTATCTGGCGATAACCTTCGCAAGGGCCGAGCACTGAACACCATTTCAGATTGCTGAG
961 -----+-----+-----+-----+-----+ 1020
V V S G D N L R K G A A L N T I Q I A E
CTGCTGGTTAAGTAA
1021 -----+----- 1035
L L V K *

Fig 5B

Nucleotide.	sequence of	dapA (SEQ ID NO:5)
1	ATGAGCACAG	GTTTAACAGC TAAGACCGGA GTAGAGCACT TCGGCACCGT
51	TGGAGTAGCA	ATGGTTACTC CATTACGGA ATCCGGAGAC ATCGATATCG
101	CTGCTGGCCG	CGAAGTCGCG GCTTATTTGG TTGATAAGGG CTGGGATTCT
151	TTGGTTCTCG	CGGGCACCAC TGGTGAATCC CCAACGACAA CCGCGCTGA
201	AAACTAGAA	CTGCTCAAGG OCGTTCTGTA GGAAGTTGGG GATCGGGCGA
251	AGCTCATCGC	CGGTGTCGGA ACCAACAACA CGCGGACATC TGTGGAACCT
301	GCGGAAGCTG	CTGCTTCTGC TGGCGCAGAC GGCTTTTAG TTGTAACCTC
351	TTATTACTCC	AAGCCGAGCC AAGAGGGATT GCTGGGCGAC TTCGGTGCAA
401	TTGCTGCAGC	AACAGAGGTT CCAATTTGTC TCTATGACAT TCCTGGTCGG
451	TCAGGTATTC	CAATTGAATC TGATACCATG AGACGCTGA GTGAATTACC
501	TACGATTTTG	GCGGTCAAGG ACGCCAAGGG TGACCTCGTT GCAGCCACGT
551	CATTGATCAA	AGAAACGGGA CTTGCTTGGT ATTCAGGCGA TGACCCACTA
601	AACTTGTTT	GGCTTGCTTT GGGCGGATCA GGTTCATTT CCGTAATTGG
651	ACATGCAGCC	CCCACAGCAT TACGTGAGTT GTACACAAGC TTCGAGGAAG
701	GCGACCTCGT	CGGTGCGCGG GAAATCAACG CCAAACTATC ACCGCTGGTA
751	GCTGCCCAAG	GTGCTTGGG TGGAGTCAGC TTGGCAAAAG CTGCTCTGCG
801	TCTGCAGGGC	ATCAACGTAG GAGATCCTCG ACTTCCAAAT ATGGCTCCAA
851	ATGAGCAGGA	ACTTGAGGCT CTCCGAGAAG ACATGAAAAA AGCTGGAGTT
901	CTATAA	

Fig 6

9/33

SEQ ID:6 Amino acid sequence of dapA

ATGAGCACAGGTTTAAACAGCTAAGACCGGAGTAGAGCACTTCGGCACCGTTGGAGTAGCA
1 -----+-----+-----+-----+-----+ 60
M S T G L T A K T G V E H F G T V G V A
ATGGTTACTCCATTACGGAATCCGGAGACATCGATATCGCTGCTGGCCGCGAAGTCGCG
61 -----+-----+-----+-----+-----+ 120
M V T P F T E S G D I D I A A G R E V A
GCTTATTTGGTTGATAAGGGCTTGGATTCTTTGGTTCTCGCGGGCACCCTGGTGAATCC
121 -----+-----+-----+-----+-----+ 180
A Y L V D K G L D S L V L A G T T G E S
CCAACGACAACCGCCGCTGAAAACTAGAACTGCTCAAGGCCGTTCTGTGAGGAAGTTGGG
181 -----+-----+-----+-----+-----+ 240
P T T T A A E K L E L L K A V R E E V G
GATCGGGCGAAGCTCATCGCCGGTGTGCGAACCAACAACACGCGGACATCTGTGGAACCTT
241 -----+-----+-----+-----+-----+ 300
D R A K L I A G V G T N N T R T S V E L
GCGGAAGCTGCTGCTTCTGCTGGCGCAGACGGCCCTTTAGTTGTAACCTCCTTATTACTCC
301 -----+-----+-----+-----+-----+ 360
A E A A A S A G A D G L L V V T P Y Y S
AAGCCGAGCCAAGAGGGATTGCTGGCGCACTTCGGTGCAATTGCTGCAGCAACAGAGGTT
361 -----+-----+-----+-----+-----+ 420
K P S Q E G L L A H F G A I A A A T E V
CCAATTTGTCTCTATGACATTCTGGTTCGGTCAGGTATTCCAATTGAATCTGATACCATG
421 -----+-----+-----+-----+-----+ 480
P I C L Y D I P G R S G I P I E S D T M
AGACGCCTGAGTGAATTACCTACGATTTTGGCGGTCAAGGACGCCAAGGGTGACCTCGTT
481 -----+-----+-----+-----+-----+ 540
R R L S E L P T I L A V K D A K G D L V
GCAGCCACGTCATTGATCAAAGAAACGGGACTTGCCTGGTATTCAGGCGATGACCCACTA
541 -----+-----+-----+-----+-----+ 600
A A T S L I K E T G L A W Y S G D D P L
AACCTTGTTTGGCTTGCTTTGGGCGGATCAGGTTTCATTTCCGTAATTGGACATGCAGCC

Fig. 7A

601 -----+-----+-----+-----+-----+ 660
N L V W L A L G G S G F I S V I G H A A
CCCACAGCATTACGTGAGTTGTACACAAGCTTCGAGGAAGGCGACCTCGTCCGTGCGCGG
661 -----+-----+-----+-----+-----+ 720
P T A L R E L Y T S F E E G D L V R A R
GAAATCAACGCCAAACTATCACCGCTGGTAGCTGCCCAAGGTCGCTTGGGTGGAGTCAGC
721 -----+-----+-----+-----+-----+ 780
E I N A K L S P L V A A Q G R L G G V S
TTGGCAAAAGCTGCTctGCGTCTGCAGGGCATCAACGTAGGAGATCCTCGACTTCCAATT
781 -----+-----+-----+-----+-----+ 840
L A K A A L R L Q G I N V G D P R L P I
ATGGCTCCAAATGAGCAGGAACCTTGAGGCTCTCCGAGAAGACATGAAAAAAGCTGGAGTT
841 -----+-----+-----+-----+-----+ 900
M A P N E Q E L E A L R E D M K K A G V
CTATAA
901 ----- 906
L * -

Fig. 7B

dapB (SEQ ID NO: 7)

Nucleotide	sequence of
1	ATGGGAATCA AGGTTGGCGT TCTCGGAGCC AATGGCGGTG TTGGTCAAAC
51	TATTGTGGCA GCAGTCAATG AGTCCGACGA TCTGGAGCTT GTTGCAAGGA
101	TCGGCGTGA CGATGATTG AGCCTTCTGG TAGACAACGG CGCTGAAGTT
151	GTOGTTGACT TCACCACTOC TAACGCTGTG ATGGGCAACC TGGAGTTCTG
201	CATCAACAAC GGCATTCTG CGGTTGTTGG AACCACGGGC TTCGATaATG
251	CTOGTTTGA GCAGGTTGCG GcCTGGCTTG AAGGAARA GA CAATGTCCGT
301	GTCTGATCG CACCTAATT TGCTATCTCT GCGGTGTTGA CCATGGTCTT
351	TTCCAAGCAG GCTGCCCGCT TCTTGAATC AGCTGAAGTT ATTGAGCTGC
401	ACCACCCCA CAAGCTGGAT GCACTTCAG GCACCGGAT CCACACTGCT
451	CAGGGCATTG CTGCGGCACG CAAAGAAGCA GGCATGGAAG CACAGCCAGA
501	TGCGACCGAG CAGGCACTTG AGGTTCCCG TGGCGCAAGC GTAGATGGAA
551	TCCCAGTTCA cGCAGTCCGC ATGTCCGGCA TGGTTGCTCA CGAGCAAGTT
601	ATCTTTGGCA CCCAGGGTCA GACCTTGACC ATCAAGCAGG ACTCCTATGA
651	TCGCAACTCA TTTGCAACAG GTGTCTTGGT GGGTGTGCGC AACATTGCAC
701	AGCAACCAGG CCTAGTCGTA GGAATTGAGC ATTACCTAGG CCTGTAA

Fig 8

12/33

SEQID NO. 8

[illegible]

Fig. 9

9

Nucleotide. sequence of ddh (SEQ ID NO: 1)

```

1  ATGCATTTCG GTAAGCTCGA CCAGGACAGT GCCACCACAA TTTTGGAGGA
51  TTACAAGAAC ATGACCAACA TCCGCGTAGC TATCGTGGC TACGGAAACC
101 TGGGACGCAG CGTCGAAAAG CTTATTGCCA AGCAGCCCGA CATGGACCTT
151 GTAGGAATCT TCTCGCGCCG GGCCACCCCTC GACACAAAGA CGCCAGTCTT
201 TGATGTGCGC GACGTGGACA AGCAGCCCGA CGACGTGGAC GTGCTGTTCG
251 TGTGCATGGG CTCGCGCCACC GACATCCCTG AGCAGGCACC AAAGTTCCGG
301 CAGTTCGCTT GCACCGTAGA CACCTACGAC AACCACCGCG ACATCCCAGG
351 CCACCGCCAG GTCATGAACG AAGCCGCCAC CGCAGCCGGC AACGTTGCAC
401 TGGTCTCTAC CGGCTGGGAT CCAGGAATGT TCTCCATCAA CCGCTCTAC
451 GCAGCGGCAG TCTTAGCCGA GCACCAGCAG CACACCTTCT GGGGCCCAGG
501 TTTGTACACG GGCCACTCCG ATGCTTTGCG ACGCATCCCT GCGGTTCAA
551 AGGCcGTCCA GTACACCCCTC CCATCCGAAG AaGCCCTGGA AAAGGCCCGC
601 CGTGGCGAAG CCGGCGACCT cACCGGAAAG CAAACCCACA AGCGCCAAAG
651 CTTCGTGGTT GCCGACGCGG CCGAcCACGA GCGCATCGAA AACGACATCC
701 GCACCATGCC TGATTACTTC GTTGGCTACG AAGTCGAAGT CAACCTCATC
751 GACGAAGCAA CCTTgGACgC CGAGCACACC GGCATGCCAC ACGCcGGaCA
801 CGTGATcACC ACCGGCGACA CCGGTGGCTT CAACCACACC GTGGAATACA
851 TCCTgAAGCT GGACCGAAAC CCAGATTTCa CCGCTTcTC ACAGATCGCT
901 TTCGGcCGCG CAGCTCACCG CATGAAGCAG CAGGGCCAAA GCGGtGCTTT
951 CACCGTCTC GAAGTTGCTC CATAcTGCT CTCCCCgGAG AACTTGCAtg
1001 ATCTGATCGC ACGCGACGTC TAA

```

Fig 10

SEQ ID 10: amino acid sequence of ddh.

SEQ ID
NO: 10

```

ATGATTTCTGTAATCTCGACCGGAAAGTGGCAGGCAATTTCAGCATTACAGAAC
60
M E F G F L D Q D S A T T I L E D Y K N
ATTAGCAACATCTGGTAGCTATCTAGGCTACCGCAACCTGGACCCAGCTGGAAAAG
120
M T N I F V A I V G Y C H L G R S V E K
CTTATTGCAAGCAGCGGACATGGACCTTGTAGGAATCTTCTGCGCGCGCGCCACCGTC
180
L I A K Q P D M D L V G I F S R R A T L
GACACAAAGACCGCGCTCTTGATGTGGCGACCTGGACAAGCGCGGACCGGTGGAG
240
D I K Y P V F D V A D V D K N A D D V D
GTGCTCTTCTCTGTCATGGCTCGCGCACCGACCTGCTGAGCAGGCAACCAAGTTCGGC
300
V L F L C H G R A T D I F C Q A P K E A
CAGTTCGCGCTGACCGTAGACAGCTACGACAAACCGCGGACATCCGACCGCGCGGACG
360
D F A C T V D T Y O M H R D I P R H R Q
GTGATGAACGAGCGCGCACCGCGCGGCAACCTTGCACCTGCTCTACCGGCTGGGAT
420
V H N E A A T A A C N V A L V S T G W D
CCAGCAATGTCTTCATCAACCGGCTCTACCGCGCGGCACTCTTAGCGGACACCGAGCAG
480
P G H F S I M R V Y A A A V L A E H O Q
CACACCTTCTGGGCGCGGCTTGTGACAGGGCGGCTCGATGCTTTCGCACTGATCGCT
540
H T F W G P G L S Q G H S D A L R P T P
GGGCTTCGAAAGGCGGTCCAGTACACCGCTCCATCTCGAAGAAGCGCTGCGAAGGCGCGG
600
C T Q K A V Q T T L F S E E A L E H A R
CGTGGGAGCGCGCGGACCTACCGGAAGCAAGCGCAACCGCGCAATGCTTGGTGGT
660
R G E A G D L T G K Q T H N R O C F V V
CGCGAGCGCGCGGACGAGGCGGATCGAAACGACATCGCCACCATCGCTTATTACTTC
720
A D A A D H E R I E N D I R T H F D Y F
GTTGGCTAGGAGTGGAGTCAACTTCATGACGAGGAGGACCTTGGACCTGAGCAGCC
780
V G Y E V E V M F I D E A T L D A E M T
GGCAGCGCACAGCGCGGACAGCTGATGACCGCGCGGACACCGTGGCTTAAACGACCC
840
G M P U G C H V I T T C D T G C F H E T
GTGGATACATCTGAAGCTGGACCGAAGCCAGATTTACCGCTTCTCTAGATCGCT
900
V E Y I L K L O R N P D F T A S S Q I A
TTGGCGCGCGGAGCTACCGCATGAGCAGCGCGGCAAGCGGCTGCTTACCGCTGCTC

```

Fig 11A

SEQ ID NO:10
(cont)

```
901 ----- 960
      F G R A A H R M K Q Q G Q S G A F I V L
      GAAGTTGCTCCATACCTGCTCTCCCCGAGAACTTGGATGATCTGATCGCACCGACGTC
961 ----- 1020
      E V A P Y L L S P E N L D D L I A R D V
      TAA
1021 --- 1023
```

Fig. 11B

Sequence of full length *lysA* from MRR1 B-11474 (SEQ ID NO: 11); Underlined region: the priming site for *lysA* primer

ATGGCTACAGTTGAAAAATTCAATGAACCTCCCGCACACGATGCCCAGGCAATGCAGTG
CGCCAAAGAAGACGGCGTTGTCAACCGTTCGCTGATGTGCTCTGCTGAOCTCGCTGAAGAA
TACGGAAACCCACTGTTCTGAGTCCGACGAGGACGATTTCCGTTCCCGCTGTCCGACATG
GCTACCGCATTCGGTGGACCAAGGCAATGTGCACACGCAATCCAAAGCGTTCTGACCAAG
ACCATTTGCACGTTGGGTTGATGAAGAGGGCTGGCACTGGACATTGGTTCATCAATGAA
CTGGGCATTCGCTCGCCGCTGGTTTCCTCCGCGCAGCGGTATCACCGCGCACGGCAACAC
AAAGGCGTAGCTTCTTCCCGCGCTTGGTTCAAAACCGTGTCCGGCAATGTGTCTGGAC
TCCCGCGCAGGAATTGGAACCTGCTGGATTACGTTGCGCTGGTGAAGGCAAGATCCAGGAC
GTCTTGATCCGCGTGAAGCCAGGCTATCGAAGGCCACACCCACGAGTTTCATCGCCACTAGC
CACGAAGACCAAGATTCCGATTCCTCCCTGGCATCCGTTCCGCTTCGAAGCAGCGAAA
GCAGCCAACTATGCAGAGAACTTGACCTGGTTGGTCTGCACTGCCATGTTGGTTCCAG
GTGTTCCGACCGCGAAGCGCTTCAAGCTGGCAGCAGAGCGCGTGTGGGCTGTACTACAG
ATCCACAGCGAACTAGGTGTCCCGCTTCTGAGCTGGACCTCCGAGGCGGATACGGCATC
GCCTACACTGCAGATGAGGAACCACTCAACGTCGCAGATGCGCTCCGACCTACTCACC
GCAGTCGGAAAAATGGCAGCGGAACTAGGCATCGACGCCAACCAACCGTGTCTGTGAGCC
GGCCCGCTATCCGACGGCCCTCCACCGTGACCATCTACGAAGTCCGCCACCAAAAAC
GTCCACGTAGACGACGACAAAACCGCGCTACGTTAGCGGTCCGACGGGCAATGTCCGAC
AACATCCGCGCCAGCACTCTACCGCTCCGANTACGACGCGCGGTAGTATCCCGCTTGGC
GAAGGAGACCCAGTAGCAACCGCATCGTGGGCTCCCACTGGGAATCCGGCGAATCCG
ATCAACGATGAATCTACCCATCTGACATCACGAGCGGCGACTTCTCCGCACTCGCAGCC
ACCGCGCATACTGCTACCGCATGAGCTCCCGCTACACGCTTCACAGCGCGCGCGT
GTGTCGCTCCGCGCTGGCAGCTCCCGCTCATGCTGGCGCGGAACCCCTCGACGACATC
CTCTCACTAGAGGCATAA

Fig. 12

Full length sequence of LysA (UDEL-B11474)
DIAMINOPIMELATE DECARBOXYLASE (Lys A) SEQ ID NO:12

MATVENFNELPARVMPFNAVHQEDGVVTVAGVFLPDLAEYGTPLFVVDKDDFRRCRDM
ATAFGGPGNVHYASKAFLATETIARWVDEEGHALDTASINELGIALAAGFPASRTAHGNN
KGVFPLRALVQNGVGHVVLDSAQEELLDYVAAGEGKIQDVLIRVKPGIEARTHEFLATS
HEDQKPGFSLASGSAPFAAKAANNAENLALVGLCHVGSQVFDAGFPLAAERVLGLYSQ
IHSELGVALFELDLGGGYGLAYTADERFLNVAEVASDLITAVGKMAAELGIDAPTVLVER
GRATAGPSTVTIYEVGTTKNVHVDDKTRRYVAVDGMSDNIRPALYGSEYDARVVSRA
EGDPVSTRIVGSHCESGDLINDEIYPSDITSGDFLALAATGAYCYAMSSRYNAFTRPV
VSVRAGSSRLMLRRETLDLILSLA

Fig. 13

Nucleotide sequences of AS019 lysA (SEQ ID NO.13) (p 256)

1 ATGGCTACAG TTGAAAATTT CAATGACTT CCGGCACAG TATGGCCAG
51 CAATGCCGTG CGCCAAGAAG ACGGTTTGT CACCGTCGCT GGTGTGCCTC
101 TGCCTGACCT CGCTGAAGAA TACGGACCC CACTGTTCT AGTCGACGAG
151 GACGATTTC GTTCCCGCTG TCGGCACATG GCTACCGCAT TCGGTGGACC
201 AGGCAATGTG CACTACGCAT CTAAGCGTT CCTGACCAAG ACCATTGCAC
251 GTTGGGTTGA TGAAGAGGGG CTGGCACTGG ACATTGCATC CATCAACGAA
301 CTGGGCATTG CCCTGGCCCG TGGTTTCCCC GCCAGCCGTA TCACCGGCA
351 CGGCAACAAC AAAGGCGTAG AGTTCTGCG CGGTTGGTT CAAAACGGTG
401 TGGGACACGT GGTGCTGGAC TCCGCACAGG AACTAGAACT GTTGGATTAC
451 GTTGCCTGTG GTGAAGGCAA GATTCAAGAC GTGTGATCC GCGTAAAGCC
501 AGGCATCGAA GCACACACCC ACGAGTTCAT CGCCACTAGC CACGAGACC
551 AGAAGTTGG ATTCTCCTG GCATCCGTT CGGCATTGA AGCAGCAAAA
601 GCGCCAAACA ACGCAGAAAA CCTGAACCTG GTTGGCCTGC ACTGCCAGT
651 TGGTTCCAG GTGTTGACG CCGAAGGCTT CAAGCTGGCA GCAGAACCG
701 TGTGGGCCT GTACTCACAG ATCCACAGG AACTGGGCGT TGGCCTTCCT
751 GAACTGGATC TCGGTGGCG ATACGTCATT GCCTATACG CAGCTGAAGA
801 ACCACTCAAC GTGCAGAGG TTGCTCCGA CCTGCTCAC GCAGTCGGAA
851 AAATGGCAGC GGAAGTAGG ATCGACGCAC CAACCGTGCT TGTGAGGCC
901 GGCCGGGCTA TCGAGGCC CCGACCGTG ACCATCTACG AAGTCGGCAC
951 CACCAAGAC GTCCACGTAG ACGACACAA AACCGCGGT TACATCGCCG
1001 TGGACGGAGG CATGTCCGAC AACATCGCC CAGCACTTA CGGCTCCGA
1051 TACGACGCCC GCGTAGTATC CCGCTCGCC GAAGGAGACC CAGTAAGCAC
1101 CCGCATCGTG GGCTCCCACT CGGAACCGG CGATATCCTG ATCAACGATG
1151 AAATCTACCC ATCTGACATC ACCAGCGCG ACTTCCTGC ACTCGCAGCC
1201 ACCGGCGCAT ACTGCTAGC CATGAGCTCC CGCTACAACG CCTTCACAGC
1251 GCGCGCCGTC GTGTCCGTCC GCGCTGACG CTCGCGCTC ATGCTGCGCC
1301 GCGAAGCGT CGACGACATC CTCTCCTAG AGGCATAA

Fig. 14

SEQ ID NO: 14 Full length amino acid sequence of LysA (pRSL6)

```

ATGGCTACAGTTGAAAAATTCAATGAACCTCCCGCACACGTATGGCCACGCAATGCCGTG
1  -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 60
M A T V E N F N E L P A H V W P R E A V
CGCCAAGAAGACGGCGTTGTCAACCGTCGCTGGTGTGCTCTGCTGACCTCGCTGAAGAA
61  -----+-----+-----+-----+-----+-----+-----+-----+-----+ 120
R Q E D G V V T V A G V P L P D L A E E
TACGGAACCCCACTGTTCTAGTCGACGAGGACGATTTCGGTTCCCGCTGTGCGGACATG
121 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 180
Y G T P L F V V D E D D F R S R C R D M
GCTACCGCATTTCGGTGGACAGGCAATGTGCACTACGCATCTAAAGCGTTCCCTGACCAAG
181 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 240
A T A F G G P G N V H Y A S K A F L T K
ACCATTGCACGTTGGGTTGATGAAGAGGGGCTGGCACTGGACATTGCATCCATCAACGAA
241 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 300
T I A R W V D E E G L A L D I A S E N E
CTGGGCATTGCGCTGGCGCTGGTTTCCCGGCCAGCGGTATCACCGCGCACGGCAACAAC
301 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 360
L G I A L A A G F P A S R I T A H G N N
AAAGGCGTAGAGTTCTCGCGCGGTGGTTCAAAACGGTGTGGGACACGTGGTGGTGGAC
361 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 420
K G V E F L R A L V Q N G V G H V V L D
TCCGCACAGGAAGTAGAAGTGTGGATTACGTTGCCGCTGGTGAAGGCAAGATTCAGGAC
421 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 480
S A Q E L E L L D Y V A A G E G K I Q D
GTGTTGATCGCGTAAAGCCAGGCATCGAAGCACACCCACGAGTTCATCGCCACTAGC
481 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 540
V L I R V K P G I E A H T H E F I A T S
CACGAAGACCAGAAGTTCGGATTCTCCCTGGCATCCGGTTCGGCATTGGAAGCAGCAAAA
541 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 600
H E D Q K F G F S L A S G S A F E A A K
GCCGCCAACAACGCAGAAAACCTGAACCTGGTGGCTGCACTGCCACGTTGGTTCACAG
601 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 660
A A N N A E N L N L V G L H C H V G S Q

```

Fig 15A

SEQ ID NO: 14 Lys A (pRS6)
(cont)

GTGTTTCGACGCCGAAGGCTTCAAGCTGGCAGCAGAACGGGTGTTGGGCTGTACTCACAG
661-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 720
V F D A E G F K L A A E R V L G L Y S Q
ATCCACAGCGAACTGGGCGTTGCCCTTCTGAACTGGATCTCGGTGGCGGATACGGCATT
721-----+-----+-----+-----+-----+-----+-----+-----+-----+ 780
I H S E L G V A L P E L D L G G G Y G I
GCCTATACCGCAGCTGAAGAACCCTCAACGTCGCAGAAGTTGCTCCGACCTGCTCAOC
781-----+-----+-----+-----+-----+-----+-----+-----+-----+ 840
A Y T A A E E P L N V A E V A S D L L T
GCAGTCGGAAAAATGGCAGCGGAAGTACGATCGACGCCAACCCTGCTTGTGAGCCC
841-----+-----+-----+-----+-----+-----+-----+-----+-----+ 900
A V G K M A A E L G I D A P T V L V E P
GGCCGCGCTATCGCAGGCCCTCCACCGTGACCATCTACGAAGTCGGCACCACCAAGAC
901-----+-----+-----+-----+-----+-----+-----+-----+-----+ 960
G R A I A G P S T V T I Y E V G T T K D
GTCCACGTAGACGACGACAAAACCGCCGTACATCGCCGTGGACGGAGCATGTCCGAC
961-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1020
V H V D D D K T R R Y I A V D G G M S D
AACATCCGCCAGCACTCTACGGCTCCGAATACGACGCCCGCTAGTATCCCGCTTCGCC
1021-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1080
N I R P A L Y G S E Y D A R V V S R F A
GAAGGAGACCCAGTAAGCACCCGCATCGTGGGCTCCCACTGCGAATCCGGCGATATCCTG
1081-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1140
E G D P V S T R I V G S H C E S G D I L
ATCAACGATGAAATCTACCATCTGACATCACCAGCGGCGACTTCCTTGCACTCGCAGCC
1141-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1200
I N D E I Y P S D I T S G D F L A L A A
ACCGGCGCATACTGCTACGCCATGAGCTCCCGCTACAACGCCCTTCACACGGCCCGCGTC
1201-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1260
T G A Y C Y A M S S R Y N A F T R P A V
GTGTCCGTCCGCGCTGGCAGTCCCGCTCATGCTGCCCGCGAAACGCTCGACGACATC
1261-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1320
V S V R A G S S R L M L R R E T L D D I

Fig 15B

Seq ID NO: 14 Lys A (PRS6)
(cont)
CTCTCACTAGAGGCATTA
1321 ----- 1338
L S L E A *

fig 15C

Nucleotide. sequence of orf2 in dapBA operon SEQ ID NO: 15

```
1 GTGGCCGAAC AAGTTAAATT GAGCGTGGAG TTGATAGCGT GCAGTTCTTT
51 TACTCCACCC GCTGATGTTG AGTGGTCAAC TGATGTTGAG GCGCGGAAG
101 CACTCGTCGA GTTTGCGGGT CGTGCCTGCT ACGAACTTT TGATAAGCCG
151 AACCTCGAA CTGCTTCCAA TGCTGCGTAT CTGCGCCACA TCATGGAAGT
201 GGGGCACACT GCTTTGCTTG AGCATGCCAA TGCCACGATG TATATCCGAG
251 GCATTTCTCG GTCCGCGACC CATGAATTGG TCCGACACCG CCATTTTCC
301 TTCTCTCAAC TGTCTCAGCG TTTGCTGCAC AGCGGAGAAT CGGAAGTAGT
351 GGTGCCCACT CTCATCGATG AAGATCCGCA GTTGCGTGAA CTTTTCATGC
401 ACGCCATGGA TGAGTCTCGG TTGCTTTCA ATGAGCTGCT TAATGCGCTG
451 GAAGAAAAAC TTGGCGATGA ACCGAATGCA CTTTAAAGGA AAAAGCAGGC
501 TCGTCAAGCA GCTCGCGCTG TGCTGCCCAA CGCTACAGAG TCCAGAATCG
551 TGGTGTCTGG AAACCTCCGC ACCTGGAGGC ATTTCAATTG CATCGAGCC
601 AGTGAACATG CAGACGTGCA AATCCGCGAA GTAGCGGTAG GATGTTAAG
651 AAAGCTGCAG GTAGCAGCGC CAACTGTTT CCGTGATTTT GAGATTGAAA
701 CTTTGGCAGA CGGATCGCAA ATGGCAACAA GCCCGTATGT CATGGACTTT
751 TAA
```

Fig 1b

fig 17

ATCC 13032					50
N13					
ATCC 21529					
Consensus	HALVVQKYCG	SSLESAERIR	NVAERIVATY	KAGND/VVCC	SAXGUTDEL
ATCC 13032	51				100
N13					
ATCC 21529					
Consensus	LELAAAVNPV	PPAREMDMLL	TAGERISNAL	VAMAIESLGA	ELQSFTGSQA
ATCC 13032	101				150
N13					
ATCC 21529					
Consensus	GVLTERHGN	ARIVDUTPGR	VREALDEGKI	CIVAGFGVN	KETRDVTTLG
ATCC 13032	151				200
N13					
ATCC 21529					
Consensus	RGGSDTTAVA	LAAALNADVC	EIYSODGVY	TADPRIVFNA	QZLEKLSFEE
ATCC 13032	201				250
N13					
ATCC 21529					
Consensus	MLELAAVGSK	ILVLSVEYA	RAFNVPLRV	SSYSNDPQTL	IASSMEDIPV
ATCC 13032	251				300
N13					
ATCC 21529					
Consensus	EEAVLTGVAT	DKSEAKVTVL	GISDKPGEAA	KVFRALADAE	INIDMVLQNV
ATCC 13032	301				350
N13					
ATCC 21529					
Consensus	SSVEDGTTDI	TFTCPRADGR	RAKEILKKLQ	VEGNWTVLY	DCQVGEVSLV
ATCC 13032	351				400
N13					
ATCC 21529					
Consensus	GAGMKSHPGV	TAEFMEALRD	VNVNIELIST	SEIRISVLIR	EDDLQAAARA
ATCC 13032	401				421
N13					
ATCC 21529					
Consensus	LHEQFQLGGE	DEAVVYACTG	R		

Fig. 19

HpaI - PvuII fragment comprising the P1 promoter

AACCGGTGTGGAGCCGACCATTCGGGAGGCTGCACTGCAAAGAGGTCGTAGTITTTGGTACATGGCTTCTG
GCCAGTTCATGGATTGGCTGCCAAGAAAGCTATAGGCATCGCCACCAGGGCCACCGGAGTTACCGAAGAT
GGTGCCGTGCTTTTCGGCTTGGGCAGGGACCTTGACAAAAGCCACGCTGATATCGCCAAGTGAGGGATCAG
AATAGTGCATGGGCAAGTCGATGCTGCCACATTAAGCGGAGGCAATATCTACCTGAGGTGGGCATTCTTCC
CAGCGGATGTTTTCTTGGCTGCTGCACTGGGCATTGATACCAAAAAGGGGCTAAGCCAGTCGAGGCGG
CAAGAACTGCTACTACCTTTTTTATTGTCGAACGGGGCATTACGGCTCCAAGGACGTTTGTTCCTGGGTCA
GTTACCCCAAAAAGCATATACAGAGACCAATGATTTTTCATTA AAAAGGCAGGGATTGTTATAAGTATGG
GTCGTATTCTGTGCGACGGGTGTACCTCGGCTAGAATTTCTCCCATGACAACAG

Fig. 20 (SEQ ID NO: 17)

Making pFC1-ddh-*lysA*






Fig. 21A

Making pDEla2-KDABHPL

Making pDEla2Fc5-KDBHL



nucleotide sequence of truncated ORF2

Seq ID no: 18

```
1  GTGGCCGAAC AAGTTAAATT GAGCGTGGAG TTGATAGCGT GCAGTTCTTT
51  TACTCCACCC GCTGATGTTG AGTGGTCAAC TGATGTTGAG GGCGCGGAAG
101 CACTCGTCGA GTTGCGGGT CGTGCCTGCT ACGAACTTT TGATAAGCCG
151 AACCTCGAA CTGCTTCCAA TGCTGCGTAT CTGCGCCA CA TCATGGAAGT
201 GGGGCACACT GCTTGCTTG AGCATGCCAA TGCCACGATG TATATCCGAG
251 GCATTTCTOG GTCGCGACC CATGAATTGG TCCGACACCG CCATTTTTC
301 TTCTCTCAAC TGTCTCAGCG TTTCGTGCAC AGCGGAGAAT CGGAAGTAGT
351 GGTGCCCACT CTCAT
```

Fig. 23

Truncated ORF2 amino acid sequence (SEQ ID NO:19)

GTGGCCGAACAAGTTAAATTGAGCGTGGAGTTGATAGCGTGCAGTTCTTTTACTCCACCC
1 -----+-----+-----+-----+-----+-----+ 60
M A E Q V K L S V E L I A C S S F T P P
GCTGATGTTGAGTGGTCAACTGATGTTGAGGGCGCGGAAGCACTCGTCGAGTTTGCGGGT
61 -----+-----+-----+-----+-----+-----+ 120
A D V E W S T D V E G A E A L V E F A G
CGTGCCTGCTACGAACTTTTGATAAGCCGAACCCCTCGAACTGCTTCCAATGCTGCGTAT
121 -----+-----+-----+-----+-----+-----+ 180
R A C Y E T F D K P N P R T A S N A A Y
CTGCGCCACATCATGGAAGTGGGGCACACTGCTTTGCTTGAGCATGCCAATGCCACGATG
181 -----+-----+-----+-----+-----+-----+ 240
L R H I M E V G H T A L L E H A N A T M
TATATCCGAGGCATTTCTCGGTCCGCGACCCATGAATTGGTCCGACACCGCCATTTTCC
241 -----+-----+-----+-----+-----+-----+ 300
Y I R G I S R S A T H E L V R H R H F S
TTCTCTCAACTGTCTCAGCGTTTCGTGCACAGCGGAGAATCGGAAGTAGTGGTGCCCACT
301 -----+-----+-----+-----+-----+-----+ 360
F S Q L S Q R F V H S G E S E V V V P T
CTCAT ...
361 -----
L (I)

FIG. 24

See Fig. 20

Sequence of truncated Lys A (Lys A) (NRRL-B11474)

ATGGCTACAGTTGAAAATTTCAATGAACTTCCCGCACACGTATGGCCACGCAATGCCAGTG
CGCCAGGAAGACGGGCGTTGTACCGTGGCTGGTGGCTCTGGCTGACCTGGCTGAAGAA
TACGGAAACCCCACTGTTCTGTAGTGGACGAGGACGATTTCCGTTCCCGCTGTGGGACATG
GCTACCGCATTCGGTGGACACGCAATGTGCACTACGCATCCAAAGCGTTCTTGAACCAAG
ACCATTTGCACTGTTGGGTTGATGAAGAGGGGCTGGCACTGGACATTGGCTCCATCAATGAA
CTGGGCATTTGCCCTGGCCGCTGGTTTCCCGGCCAGCCGTATCACCGCCACGGCAACAC
AAAGGCGTAGAGTTCCCTGGCGCGCTGGTTCAAAAACGGTGTGGGCGATGTGGTGTGGAC
TCCGCGCAGGAATTGGAACTGCTGGATTACGTTGCCGCTGGTGAAGGCAAGATCCAGGAC
GTGTTGATCCCGTGAAGCCAGGTATCGAAGCCACACCCACGAGTTTCATCGCCACTAGC
CACGAAGACCAAGATTGGATTCTCCCTGGCATTCGGTTCCGCAATCGAAGCAGCGAAA
GCAGCCAAACAATGCAGAGAACTTGAACCTGGTTGGTCTGCACTGCCATGTTGGTTCCAG
GTGTTGACGCGGAAGGCTTCAAGCTGGCAGCAGAGCGGTTGTTGGGCTGTACTCACAG
ATCCACAGCGAACTAGGTGTGGCCCTTCTGTAGCTGGACCTCGGTGGCGGATAACGGCATC
GCCTACACTGCAGATGAGGAACCACTCAACGTCGCAGAAAGTGGCTCCGACCT.

Fig. 25

Truncated sequence of LysA (UDEL-B11474).

DIAMINOPIMELATE DECARBOXYLASE (Lys A) SEQ ID NO: 21

NATVENFNELEPAHVWPRNAVROEDGVVTVAGVFLPDLAEEYGTFLFVVDEDDFRSRCRM
ATAFGGPGNVHYASKAFLAKTLARWVDESGLAIDTASTNELGTALAAGFEASRTAHGNN
KGVEFLRALVQNGVGHVVLDQAQELKLLQYVAAGEGKIQDVLIRVKPGDAAHTEPTATS
HEQQRKFGFSLASGSAPFAAKAANNAENLNLVGLCHVGSQVFDREGFKLAARVLGLYSQ
IHSELGVALPELILGGCYGLATTADEEPLNVAEVASDL

Fig. 26

-1-

<110> Archer-Daniels-Midland Company

Li-D'Elia, Lhing-Yew

Rayapati, John

<120> Increased Lysine Production by Gene Amplification

<130> 1533.103PC03

<150> US 60/173,707

<151> 1999-12-30

<150> US 60/184,130

<151> 2000-02-22

<160> 21

<170> PatentIn version 3.0

<210> 1

<211> 1266

<212> DNA

<213> ask

<220>

<221> CDS

<222> (1) .. (1266)

<400> 1

<400> 1
gtg gcc ctg gtc gta cag aaa tat ggc ggt tcc tgc ctt gag agt gcg 48
Met Ala Leu Val Val Gln Lys Tyr Gly Gly Ser Ser Leu Glu Ser Ala
1 5 10 15

gaa cgc att aga aac gtc gct gaa cgg atc gtt gcc acc aag aag gct 96
Glu Arg Ile Arg Asn Val Ala Glu Arg Ile Val Ala Thr Lys Lys Ala
20 25 30

-2-

gga aat gat gtc gtg gtt gtc tgc tcc gca atg gga gac acc acg gat Gly Asn Asp Val Val Val Val Cys Ser Ala Met Gly Asp Thr Thr Asp 35 40 45	144
gaa ctt cta gaa ctt gca gcg gca gtg aat ccc gtt ccg cca gct cgt Glu Leu Leu Glu Leu Ala Ala Val Asn Pro Val Pro Pro Ala Arg 50 55 60	192
gaa atg gat atg ctc ctg act gct ggt gag cgt att tct aac gct ctc Glu Met Asp Met Leu Leu Thr Ala Gly Glu Arg Ile Ser Asn Ala Leu 65 70 75 80	240
gtc gcc atg gct att gag tcc ctt ggc gca gaa gct caa tct ttc act Val Ala Met Ala Ile Glu Ser Leu Gly Ala Glu Ala Gln Ser Phe Thr 85 90 95	288
ggc tct cag gct ggt gtg ctc acc acc gag cgc cac gga aac gca cgc Gly Ser Gln Ala Gly Val Leu Thr Thr Glu Arg His Gly Asn Ala Arg 100 105 110	336
att gtt gac gtc aca ccg ggt cgt gtg cgt gaa gca ctc gat gag ggc Ile Val Asp Val Thr Pro Gly Arg Val Arg Glu Ala Leu Asp Glu Gly 115 120 125	384
aag atc tgc att gtt gct ggt ttt cag ggt gtt aat aaa gaa acc cgc Lys Ile Cys Ile Val Ala Gly Phe Gln Gly Val Asn Lys Glu Thr Arg 130 135 140	432
gat gtc acc acg ttg ggt cgt ggt ggt tct gac acc act gca gtt gcg Asp Val Thr Thr Leu Gly Arg Gly Gly Ser Asp Thr Thr Ala Val Ala 145 150 155 160	480
ttg gca gct gct ttg aac gct gat gtg tgt gag att tac tcg gac gtt Leu Ala Ala Ala Leu Asn Ala Asp Val Cys Glu Ile Tyr Ser Asp Val 165 170 175	528
gac ggt gtg tat acc gct gac ccg cgc atc gtt cct aat gca cag aag Asp Gly Val Tyr Thr Ala Asp Pro Arg Ile Val Pro Asn Ala Gln Lys 180 185 190	576
ctg gaa aag ctc agc ttc gaa gaa atg ctg gaa ctt gct gct gtt ggc Leu Glu Lys Leu Ser Phe Glu Glu Met Leu Glu Leu Ala Ala Val Gly 195 200 205	624
tcc aag att ttg gtg ctg cgc agt gtt gaa tac gct cgt gca ttc aat Ser Lys Ile Leu Val Leu Arg Ser Val Glu Tyr Ala Arg Ala Phe Asn 210 215 220	672
gtg cca ctt cgc gta cgc tcg tct tat agt aat gat ccc ggc act ttg Val Pro Leu Arg Val Arg Ser Ser Tyr Ser Asn Asp Pro Gly Thr Leu 225 230 235 240	720
att gcc ggc tct atg gag gat att cct gtg gaa gaa gca gtc ctt acc Ile Ala Gly Ser Met Glu Asp Ile Pro Val Glu Glu Ala Val Leu Thr 245 250 255	768
ggt gtc gca acc gac aag tcc gaa gcc aaa gta acc gtt ctg ggt att Gly Val Ala Thr Asp Lys Ser Glu Ala Lys Val Thr Val Leu Gly Ile 260 265 270	816
tcc gat aag cca ggc gag gct gcc aag gtt ttc cgt gcg ttg gct gat Ser Asp Lys Pro Gly Glu Ala Ala Lys Val Phe Arg Ala Leu Ala Asp 275 280 285	864

-3-

gca gaa atc aac att gac atg gtt ctg cag aac gtc tcc tct gtg gaa 912
 Ala Glu Ile Asn Ile Asp Met Val Leu Gln Asn Val Ser Ser Val Glu
 290 295 300

gac ggc acc acc gac atc acg ttc acc tgc cct cgc gct gac gga cgc 960
 Asp Gly Thr Thr Asp Ile Thr Phe Thr Cys Pro Arg Ala Asp Gly Arg
 305 310 315 320

cgt gcg atg gag atc ttg aag aag ctt cag gtt cag ggc aac tgg acc 1008
 Arg Ala Met Glu Ile Leu Lys Lys Leu Gln Val Gln Gly Asn Trp Thr
 325 330 335

aat gtg ctt tac gac gac cag gtc ggc aaa gtc tcc ctc gtg ggt gct 1056
 Asn Val Leu Tyr Asp Asp Gln Val Gly Lys Val Ser Leu Val Gly Ala
 340 345 350

ggc atg aag tct cac cca ggt gtt acc gca gag ttc atg gaa gct ctg 1104
 Gly Met Lys Ser His Pro Gly Val Thr Ala Glu Phe Met Glu Ala Leu
 355 360 365

cgc gat gtc aac gtg aac atc gaa ttg att tcc atc tct gag atc cgc 1152
 Arg Asp Val Asn Val Asn Ile Glu Leu Ile Ser Ile Ser Glu Ile Arg
 370 375 380

att tcc gtg ctg atc cgt gaa gat gat ctg gat gct gct gca cgt gca 1200
 Ile Ser Val Leu Ile Arg Glu Asp Asp Leu Asp Ala Ala Ala Arg Ala
 385 390 395 400

ttg cat gag cag ttc cag ctg ggc ggc gaa gac gaa gcc gtc gtt tat 1248
 Leu His Glu Gln Phe Gln Leu Gly Gly Glu Asp Glu Ala Val Val Tyr
 405 410 415

gca ggc acc gga cgc taa 1266
 Ala Gly Thr Gly Arg
 420

<210> 2

<211> 421

<212> PRT

<213> ask

<400> 2

Met Ala Leu Val Val Gln Lys Tyr Gly Gly Ser Ser Leu Glu Ser Ala
 1 5 10 15

Glu Arg Ile Arg Asn Val Ala Glu Arg Ile Val Ala Thr Lys Lys Ala
 20 25 30

Gly Asn Asp Val Val Val Val Cys Ser Ala Met Gly Asp Thr Thr Asp
 35 40 45

Glu Leu Leu Glu Leu Ala Ala Ala Val Asn Pro Val Pro Pro Ala Arg
 50 55 60

-4-

Glu Met Asp Met Leu Leu Thr Ala Gly Glu Arg Ile Ser Asn Ala Leu
65 70 75 80

Val Ala Met Ala Ile Glu Ser Leu Gly Ala Glu Ala Gln Ser Phe Thr
85 90 95

Gly Ser Gln Ala Gly Val Leu Thr Thr Glu Arg His Gly Asn Ala Arg
100 105 110

Ile Val Asp Val Thr Pro Gly Arg Val Arg Glu Ala Leu Asp Glu Gly
115 120 125

Lys Ile Cys Ile Val Ala Gly Phe Gln Gly Val Asn Lys Glu Thr Arg
130 135 140

Asp Val Thr Thr Leu Gly Arg Gly Gly Ser Asp Thr Thr Ala Val Ala
145 150 155 160

Leu Ala Ala Ala Leu Asn Ala Asp Val Cys Glu Ile Tyr Ser Asp Val
165 170 175

Asp Gly Val Tyr Thr Ala Asp Pro Arg Ile Val Pro Asn Ala Gln Lys
180 185 190

Leu Glu Lys Leu Ser Phe Glu Glu Met Leu Glu Leu Ala Ala Val Gly
195 200 205

Ser Lys Ile Leu Val Leu Arg Ser Val Glu Tyr Ala Arg Ala Phe Asn
210 215 220

Val Pro Leu Arg Val Arg Ser Ser Tyr Ser Asn Asp Pro Gly Thr Leu
225 230 235 240

Ile Ala Gly Ser Met Glu Asp Ile Pro Val Glu Glu Ala Val Leu Thr
245 250 255

Gly Val Ala Thr Asp Lys Ser Glu Ala Lys Val Thr Val Leu Gly Ile
260 265 270

Ser Asp Lys Pro Gly Glu Ala Ala Lys Val Phe Arg Ala Leu Ala Asp
275 280 285

Ala Glu Ile Asn Ile Asp Met Val Leu Gln Asn Val Ser Ser Val Glu
290 295 300

Asp Gly Thr Thr Asp Ile Thr Phe Thr Cys Pro Arg Ala Asp Gly Arg
305 310 315 320

Arg Ala Met Glu Ile Leu Lys Lys Leu Gln Val Gln Gly Asn Trp Thr
325 330 335

Asn Val Leu Tyr Asp Asp Gln Val Gly Lys Val Ser Leu Val Gly Ala
340 345 350

Gly Met Lys Ser His Pro Gly Val Thr Ala Glu Phe Met Glu Ala Leu
355 360 365

Arg Asp Val Asn Val Asn Ile Glu Leu Ile Ser Ile Ser Glu Ile Arg
370 375 380

Ile Ser Val Leu Ile Arg Glu Asp Asp Leu Asp Ala Ala Ala Arg Ala
385 390 395 400

Leu His Glu Gln Phe Gln Leu Gly Gly Glu Asp Glu Ala Val Val Tyr
405 410 415

Ala Gly Thr Gly Arg
420

<210> 3

<211> 1035

<212> DNA

<213> asd

<220>

<221> CDS

<222> (1) .. (1035)

<400> 3

<400> 3
atg acc acc atc gca gtt gtt ggt gca acc ggc cag gtc ggc cag gtt 48
Met Thr Thr Ile Ala Val Val Gly Ala Thr Gly Gln Val Gly Gln Val
1 5 10 15

atg cgc acc ttt ttg gaa gag cgc aat ttc cca gct gac act gtt cgt 96
Met Arg Thr Phe Leu Glu Glu Arg Asn Phe Pro Ala Asp Thr Val Arg
20 25 30

ttc ttt gct tcc ccg cgt tcc gca ggc cgt aag att gaa ttc cgt ggc 144
Phe Phe Ala Ser Pro Arg Ser Ala Gly Arg Lys Ile Glu Phe Arg Gly
35 40 45

acg gaa atc gag gta gaa gac att act cag gca acc gag gag tcc ctc 192
Thr Glu Ile Glu Val Glu Asp Ile Thr Gln Ala Thr Glu Glu Ser Leu
50 55 60

-6-

aag ggc atc gac gtt gcg ttg ttc tct gct gga ggc acc gct tcc aag Lys Gly Ile Asp Val Ala Leu Phe Ser Ala Gly Gly Thr Ala Ser Lys 65 70 75 80	240
cag tac gct cca ctg ttt gct gct gca ggc gcg act gtt gtg gat aac Gln Tyr Ala Pro Leu Phe Ala Ala Ala Gly Ala Thr Val Val Asp Asn 85 90 95	288
tct tct gct tgg cgc aag gac gac gag gtt cca cta atc gtc tct gag Ser Ser Ala Trp Arg Lys Asp Asp Glu Val Pro Leu Ile Val Ser Glu 100 105 110	336
gtg aac cct tcc gac aag gat tcc ctg gtc aag ggc att att gcg aat Val Asn Pro Ser Asp Lys Asp Ser Leu Val Lys Gly Ile Ile Ala Asn 115 120 125	384
cct aac tgc acc acc atg gct gca atg cca gtg ctg aag cca ctg cac Pro Asn Cys Thr Thr Met Ala Ala Met Pro Val Leu Lys Pro Leu His 130 135 140	432
gat gcc gct ggt ctt gta aag ctt cac gtt tcc tct tac cag gct gtt Asp Ala Ala Gly Leu Val Lys Leu His Val Ser Ser Tyr Gln Ala Val 145 150 155 160	480
tcc ggt tct ggt ctt gca ggt gtg gaa acc ttg gca aag cag gtt gct Ser Gly Ser Gly Leu Ala Gly Val Glu Thr Leu Ala Lys Gln Val Ala 165 170 175	528
gca gtt ggc gac cac aac gtt gag ttc gtc cat gat gga cag gct gct Ala Val Gly Asp His Asn Val Glu Phe Val His Asp Gly Gln Ala Ala 180 185 190	576
gac gca ggc gat gtc gga cct tac gtt tcc cca atc gct tac aac gtg Asp Ala Gly Asp Val Gly Pro Tyr Val Ser Pro Ile Ala Tyr Asn Val 195 200 205	624
ctg cca ttc gcc gga aac ctc gtc gat gac ggc acc ttc gaa acc gac Leu Pro Phe Ala Gly Asn Leu Val Asp Asp Gly Thr Phe Glu Thr Asp 210 215 220	672
gaa gag cag aag ctg cgc aac gaa tcc cgc aag att ctc ggc ctc cca Glu Glu Gln Lys Leu Arg Asn Glu Ser Arg Lys Ile Leu Gly Leu Pro 225 230 235 240	720
gac ctc aag gtc tca ggc acc tgc gtc cgc gtg ccg gtt ttc acc ggc Asp Leu Lys Val Ser Gly Thr Cys Val Arg Val Pro Val Phe Thr Gly 245 250 255	768
cac acg ctg acc att cac gcc gaa ttc gac aag gca atc acc gtc gag His Thr Leu Thr Ile His Ala Glu Phe Asp Lys Ala Ile Thr Val Glu 260 265 270	816
cag gcg cag gag atc ttg ggt gcc gct tca ggc gtc gag ctt gtc gac Gln Ala Gln Glu Ile Leu Gly Ala Ala Ser Gly Val Glu Leu Val Asp 275 280 285	864
gtc cca acc cca ctt gca gct gcc ggc att gac gaa tcc ctc gtt gga Val Pro Thr Pro Leu Ala Ala Ala Gly Ile Asp Glu Ser Leu Val Gly 290 295 300	912

-7-

cgc atc cgt cag gac tcc act gtc gac gac aac cgc ggt ctg gtt ctc 960
 Arg Ile Arg Gln Asp Ser Thr Val Asp Asp Asn Arg Gly Leu Val Leu
 305 310 315 320

gtc gta tct ggc gat aac ctt cgc aag ggc gca gca ctg aac acc att 1008
 Val Val Ser Gly Asp Asn Leu Arg Lys Gly Ala Ala Leu Asn Thr Ile
 325 330 335

cag att gct gag ctg ctg gtt aag taa 1035
 Gln Ile Ala Glu Leu Leu Val Lys
 340

<210> 4

<211> 344

<212> PRT

<213> asd

<400> 4

Met Thr Thr Ile Ala Val Val Gly Ala Thr Gly Gln Val Gly Gln Val
 1 5 10 15

Met Arg Thr Phe Leu Glu Glu Arg Asn Phe Pro Ala Asp Thr Val Arg
 20 25 30

Phe Phe Ala Ser Pro Arg Ser Ala Gly Arg Lys Ile Glu Phe Arg Gly
 35 40 45

Thr Glu Ile Glu Val Glu Asp Ile Thr Gln Ala Thr Glu Glu Ser Leu
 50 55 60

Lys Gly Ile Asp Val Ala Leu Phe Ser Ala Gly Gly Thr Ala Ser Lys
 65 70 75 80

Gln Tyr Ala Pro Leu Phe Ala Ala Ala Gly Ala Thr Val Val Asp Asn
 85 90 95

Ser Ser Ala Trp Arg Lys Asp Asp Glu Val Pro Leu Ile Val Ser Glu
 100 105 110

Val Asn Pro Ser Asp Lys Asp Ser Leu Val Lys Gly Ile Ile Ala Asn
 115 120 125

Pro Asn Cys Thr Thr Met Ala Ala Met Pro Val Leu Lys Pro Leu His
 130 135 140

-8-

Asp Ala Ala Gly Leu Val Lys Leu His Val Ser Ser Tyr Gln Ala Val
 145 150 155 160

Ser Gly Ser Gly Leu Ala Gly Val Glu Thr Leu Ala Lys Gln Val Ala
 165 170 175

Ala Val Gly Asp His Asn Val Glu Phe Val His Asp Gly Gln Ala Ala
 180 185 190

Asp Ala Gly Asp Val Gly Pro Tyr Val Ser Pro Ile Ala Tyr Asn Val
 195 200 205

Leu Pro Phe Ala Gly Asn Leu Val Asp Asp Gly Thr Phe Glu Thr Asp
 210 215 220

Glu Glu Gln Lys Leu Arg Asn Glu Ser Arg Lys Ile Leu Gly Leu Pro
 225 230 235 240

Asp Leu Lys Val Ser Gly Thr Cys Val Arg Val Pro Val Phe Thr Gly
 245 250 255

His Thr Leu Thr Ile His Ala Glu Phe Asp Lys Ala Ile Thr Val Glu
 260 265 270

Gln Ala Gln Glu Ile Leu Gly Ala Ala Ser Gly Val Glu Leu Val Asp
 275 280 285

Val Pro Thr Pro Leu Ala Ala Ala Gly Ile Asp Glu Ser Leu Val Gly
 290 295 300

Arg Ile Arg Gln Asp Ser Thr Val Asp Asp Asn Arg Gly Leu Val Leu
 305 310 315 320

Val Val Ser Gly Asp Asn Leu Arg Lys Gly Ala Ala Leu Asn Thr Ile
 325 330 335

Gln Ile Ala Glu Leu Leu Val Lys
 340

<210> 5

<211> 906

<212> DNA

<213> dapA

-9-

<220>

<221> CDS

<222> (1)..(906)

<400> 5

atg agc aca ggt tta aca gct aag acc gga gta gag cac ttc ggc acc	48
Met Ser Thr Gly Leu Thr Ala Lys Thr Gly Val Glu His Phe Gly Thr	
1 5 10 15	
ggt gga gta gca atg gtt act cca ttc acg gaa tcc gga gac atc gat	96
Val Gly Val Ala Met Val Thr Pro Phe Thr Glu Ser Gly Asp Ile Asp	
20 25 30	
atc gct gct ggc cgc gaa gtc gcg gct tat ttg gtt gat aag ggc ttg	144
Ile Ala Ala Gly Arg Glu Val Ala Ala Tyr Leu Val Asp Lys Gly Leu	
35 40 45	
gat tct ttg gtt ctc gcg ggc acc act ggt gaa tcc cca acg aca acc	192
Asp Ser Leu Val Leu Ala Gly Thr Thr Gly Glu Ser Pro Thr Thr Thr	
50 55 60	
gcc gct gaa aaa cta gaa ctg ctc aag gcc gtt cgt gag gaa gtt ggg	240
Ala Ala Glu Lys Leu Glu Leu Leu Lys Ala Val Arg Glu Glu Val Gly	
65 70 75 80	
gat cgg gcg aag ctc atc gcc ggt gtc gga acc aac aac acg cgg aca	288
Asp Arg Ala Lys Leu Ile Ala Gly Val Gly Thr Asn Asn Thr Arg Thr	
85 90 95	
tct gtg gaa ctt gcg gaa gct gct gct tct gct ggc gca gac ggc ctt	336
Ser Val Glu Leu Ala Glu Ala Ala Ser Ala Gly Ala Asp Gly Leu	
100 105 110	
tta gtt gta act cct tat tac tcc aag ccg agc caa gag gga ttg ctg	384
Leu Val Val Thr Pro Tyr Tyr Ser Lys Pro Ser Gln Glu Gly Leu Leu	
115 120 125	
gcg cac ttc ggt gca att gct gca gca aca gag gtt cca att tgt ctc	432
Ala His Phe Gly Ala Ile Ala Ala Ala Thr Glu Val Pro Ile Cys Leu	
130 135 140	
tat gac att cct ggt cgg tca ggt att cca att gaa tct gat acc atg	480
Tyr Asp Ile Pro Gly Arg Ser Gly Ile Pro Ile Glu Ser Asp Thr Met	
145 150 155 160	
aga cgc ctg agt gaa tta cct acg att ttg gcg gtc aag gac gcc aag	528
Arg Arg Leu Ser Glu Leu Pro Thr Ile Leu Ala Val Lys Asp Ala Lys	
165 170 175	
ggt gac ctc gtt gca gcc acg tca ttg atc aaa gaa acg gga ctt gcc	576
Gly Asp Leu Val Ala Ala Thr Ser Leu Ile Lys Glu Thr Gly Leu Ala	
180 185 190	
tgg tat tca ggc gat gac cca cta aac ctt gtt tgg ctt gct ttg ggc	624
Trp Tyr Ser Gly Asp Asp Pro Leu Asn Leu Val Trp Leu Ala Leu Gly	
195 200 205	

-10-

gga tca ggt ttc att tcc gta att gga cat gca gcc ccc aca gca tta 672
 Gly Ser Gly Phe Ile Ser Val Ile Gly His Ala Ala Pro Thr Ala Leu
 210 215 220
 cgt gag ttg tac aca agc ttc gag gaa ggc gac ctc gtc cgt gcg cgg 720
 Arg Glu Leu Tyr Thr Ser Phe Glu Glu Gly Asp Leu Val Arg Ala Arg
 225 230 235 240
 gaa atc aac gcc aaa cta tca ccg ctg gta gct gcc caa ggt cgc ttg 768
 Glu Ile Asn Ala Lys Leu Ser Pro Leu Val Ala Ala Gln Gly Arg Leu
 245 250 255
 ggt gga gtc agc ttg gca aaa gct gct ctg cgt ctg cag gcc atc aac 816
 Gly Gly Val Ser Leu Ala Lys Ala Ala Leu Arg Leu Gln Gly Ile Asn
 260 265 270
 gta gga gat cct cga ctt cca att atg gct cca aat gag cag gaa ctt 864
 Val Gly Asp Pro Arg Leu Pro Ile Met Ala Pro Asn Glu Gln Glu Leu
 275 280 285
 gag gct ctc cga gaa gac atg aaa aaa gct gga gtt cta taa 906
 Glu Ala Leu Arg Glu Asp Met Lys Lys Ala Gly Val Leu
 290 295 300

<210> 6

<211> 301

<212> PRT

<213> dapA

<400> 6

Met Ser Thr Gly Leu Thr Ala Lys Thr Gly Val Glu His Phe Gly Thr
 1 5 10 15
 Val Gly Val Ala Met Val Thr Pro Phe Thr Glu Ser Gly Asp Ile Asp
 20 25 30
 Ile Ala Ala Gly Arg Glu Val Ala Ala Tyr Leu Val Asp Lys Gly Leu
 35 40 45
 Asp Ser Leu Val Leu Ala Gly Thr Thr Gly Glu Ser Pro Thr Thr Thr
 50 55 60
 Ala Ala Glu Lys Leu Glu Leu Leu Lys Ala Val Arg Glu Glu Val Gly
 65 70 75 80
 Asp Arg Ala Lys Leu Ile Ala Gly Val Gly Thr Asn Asn Thr Arg Thr
 85 90 95

-11-

Ser Val Glu Leu Ala Glu Ala Ala Ala Ser Ala Gly Ala Asp Gly Leu
 100 105 110

Leu Val Val Thr Pro Tyr Tyr Ser Lys Pro Ser Gln Glu Gly Leu Leu
 115 120 125

Ala His Phe Gly Ala Ile Ala Ala Ala Thr Glu Val Pro Ile Cys Leu
 130 135 140

Tyr Asp Ile Pro Gly Arg Ser Gly Ile Pro Ile Glu Ser Asp Thr Met
 145 150 155 160

Arg Arg Leu Ser Glu Leu Pro Thr Ile Leu Ala Val Lys Asp Ala Lys
 165 170 175

Gly Asp Leu Val Ala Ala Thr Ser Leu Ile Lys Glu Thr Gly Leu Ala
 180 185 190

Trp Tyr Ser Gly Asp Asp Pro Leu Asn Leu Val Trp Leu Ala Leu Gly
 195 200 205

Gly Ser Gly Phe Ile Ser Val Ile Gly His Ala Ala Pro Thr Ala Leu
 210 215 220

Arg Glu Leu Tyr Thr Ser Phe Glu Glu Gly Asp Leu Val Arg Ala Arg
 225 230 235 240

Glu Ile Asn Ala Lys Leu Ser Pro Leu Val Ala Ala Gln Gly Arg Leu
 245 250 255

Gly Gly Val Ser Leu Ala Lys Ala Ala Leu Arg Leu Gln Gly Ile Asn
 260 265 270

Val Gly Asp Pro Arg Leu Pro Ile Met Ala Pro Asn Glu Gln Glu Leu
 275 280 285

Glu Ala Leu Arg Glu Asp Met Lys Lys Ala Gly Val Leu
 290 295 300

<210> 7

<211> 747

<212> DNA

<213> BF100 dapB

-12-

<220>

<221> CDS

<222> (1)..(747)

<400> 7

atg gga atc aag gtt ggc gtt ctc gga gcc aaa ggc cgt gtt ggt caa	48
Met Gly Ile Lys Val Gly Val Leu Gly Ala Lys Gly Arg Val Gly Gln	
1 5 10 15	
act att gtg gca gca gtc aat gag tcc gac gat ctg gag ctt gtt gca	96
Thr Ile Val Ala Ala Val Asn Glu Ser Asp Asp Leu Glu Leu Val Ala	
20 25 30	
gag atc ggc gtc gac gat gat ttg agc ctt ctg gta gac aac ggc gct	144
Glu Ile Gly Val Asp Asp Asp Leu Ser Leu Leu Val Asp Asn Gly Ala	
35 40 45	
gaa gtt gtc gtt gac ttc acc act cct aac gct gtg atg ggc aac ctg	192
Glu Val Val Val Asp Phe Thr Thr Pro Asn Ala Val Met Gly Asn Leu	
50 55 60	
gag ttc tgc atc aac aac ggc att tct gcg gtt gtt gga acc acg ggc	240
Glu Phe Cys Ile Asn Asn Gly Ile Ser Ala Val Val Gly Thr Thr Gly	
65 70 75 80	
ttc gat aat gct cgt ttg gag cag gtt cgc gcc tgg ctt gaa gga aaa	288
Phe Asp Asn Ala Arg Leu Glu Gln Val Arg Ala Trp Leu Glu Gly Lys	
85 90 95	
gac aat gtc ggt gtt ctg atc gca cct aac ttt gct atc tct gcg gtg	336
Asp Asn Val Gly Val Leu Ile Ala Pro Asn Phe Ala Ile Ser Ala Val	
100 105 110	
ttg acc atg gtc ttt tcc aag cag gct gcc cgc ttc ttc gaa tca gct	384
Leu Thr Met Val Phe Ser Lys Gln Ala Ala Arg Phe Phe Glu Ser Ala	
115 120 125	
gaa gtt att gag ctg cac cac ccc aac aag ctg gat gca cct tca ggc	432
Glu Val Ile Glu Leu His His Pro Asn Lys Leu Asp Ala Pro Ser Gly	
130 135 140	
acc gcg atc cac act gct cag ggc att gct gcg gca cgc aaa gaa gca	480
Thr Ala Ile His Thr Ala Gln Gly Ile Ala Ala Ala Arg Lys Glu Ala	
145 150 155 160	
ggc atg gac gca cag cca gat gcg acc gag cag gca ctt gag ggt tcc	528
Gly Met Asp Ala Gln Pro Asp Ala Thr Glu Gln Ala Leu Glu Gly Ser	
165 170 175	
cgt ggc gca agc gta gat gga atc cca gtt cac gca gtc cgc atg tcc	576
Arg Gly Ala Ser Val Asp Gly Ile Pro Val His Ala Val Arg Met Ser	
180 185 190	
ggc atg gtt gct cac gag caa gtt atc ttt ggc acc cag ggt cag acc	624
Gly Met Val Ala His Glu Gln Val Ile Phe Gly Thr Gln Gly Gln Thr	
195 200 205	
ttg acc atc aag cag gac tcc tat gat cgc aac tca ttt gca cca ggt	672
Leu Thr Ile Lys Gln Asp Ser Tyr Asp Arg Asn Ser Phe Ala Pro Gly	
210 215 220	

-13-

gtc ttg gtg ggt gtg cgc aac att gca cag cac cca ggc cta gtc gta 720
 Val Leu Val Gly Val Arg Asn Ile Ala Gln His Pro Gly Leu Val Val
 225 230 235 240

gga ctt gag cat tac cta ggc ctg taa 747
 Gly Leu Glu His Tyr Leu Gly Leu
 245

<210> 8

<211> 248

<212> PRT

<213> BF100 dapB

<400> 8

Met Gly Ile Lys Val Gly Val Leu Gly Ala Lys Gly Arg Val Gly Gln
 1 5 10 15

Thr Ile Val Ala Ala Val Asn Glu Ser Asp Asp Leu Glu Leu Val Ala
 20 25 30

Glu Ile Gly Val Asp Asp Asp Leu Ser Leu Leu Val Asp Asn Gly Ala
 35 40 45

Glu Val Val Val Asp Phe Thr Thr Pro Asn Ala Val Met Gly Asn Leu
 50 55 60

Glu Phe Cys Ile Asn Asn Gly Ile Ser Ala Val Val Gly Thr Thr Gly
 65 70 75 80

Phe Asp Asn Ala Arg Leu Glu Gln Val Arg Ala Trp Leu Glu Gly Lys
 85 90 95

Asp Asn Val Gly Val Leu Ile Ala Pro Asn Phe Ala Ile Ser Ala Val
 100 105 110

Leu Thr Met Val Phe Ser Lys Gln Ala Ala Arg Phe Phe Glu Ser Ala
 115 120 125

Glu Val Ile Glu Leu His His Pro Asn Lys Leu Asp Ala Pro Ser Gly
 130 135 140

Thr Ala Ile His Thr Ala Gln Gly Ile Ala Ala Ala Arg Lys Glu Ala
 145 150 155 160

Gly Met Asp Ala Gln Pro Asp Ala Thr Glu Gln Ala Leu Glu Gly Ser
 165 170 175

-14-

Arg Gly Ala Ser Val Asp Gly Ile Pro Val His Ala Val Arg Met Ser
 180 185 190

Gly Met Val Ala His Glu Gln Val Ile Phe Gly Thr Gln Gly Gln Thr
 195 200 205

Leu Thr Ile Lys Gln Asp Ser Tyr Asp Arg Asn Ser Phe Ala Pro Gly
 210 215 220

Val Leu Val Gly Val Arg Asn Ile Ala Gln His Pro Gly Leu Val Val
 225 230 235 240

Gly Leu Glu His Tyr Leu Gly Leu
 245

<210> 9

<211> 1023

<212> DNA

<213> BF 100 ddh

<220>

<221> CDS

<222> (1)..(1023)

<400> 9

atg cat ttc ggt aag ctc gac cag gac agt gcc acc aca att ttg gag 48
 Met His Phe Gly Lys Leu Asp Gln Asp Ser Ala Thr Thr Ile Leu Glu
 1 5 10 15

gat tac aag aac atg acc aac atc cgc gta gct atc gta ggc tac gga 96
 Asp Tyr Lys Asn Met Thr Asn Ile Arg Val Ala Ile Val Gly Tyr Gly
 20 25 30

aac ctg gga cgc agc gtc gaa aag ctt att gcc aag cag ccc gac atg 144
 Asn Leu Gly Arg Ser Val Glu Lys Leu Ile Ala Lys Gln Pro Asp Met
 35 40 45

gac ctt gta gga atc ttc tcg cgc cgg gcc acc ctc gac aca aag acg 192
 Asp Leu Val Gly Ile Phe Ser Arg Arg Ala Thr Leu Asp Thr Lys Thr
 50 55 60

cca gtc ttt gat gtc gcc gac gtg gac aag cac gcc gac gac gtg gac 240
 Pro Val Phe Asp Val Ala Asp Val Asp Lys His Ala Asp Asp Val Asp
 65 70 75 80

gtg ctg ttc ctg tgc atg ggc tcc gcc acc gac atc cct gag cag gca 288
 Val Leu Phe Leu Cys Met Gly Ser Ala Thr Asp Ile Pro Glu Gln Ala
 85 90 95

-15-

cca aag ttc gcg cag ttc gcc tgc acc gta gac acc tac gac aac cac Pro Lys Phe Ala Gln Phe Ala Cys Thr Val Asp Thr Tyr Asp Asn His 100 105 110	336
cgc gac atc cca cgc cac cgc cag gtc atg aac gaa gcc gcc acc gca Arg Asp Ile Pro Arg His Arg Gln Val Met Asn Glu Ala Ala Thr Ala 115 120 125	384
gcc gcc aac gtt gca ctg gtc tct acc ggc tgg gat cca gga atg ttc Ala Gly Asn Val Ala Leu Val Ser Thr Gly Trp Asp Pro Gly Met Phe 130 135 140	432
tcc atc aac cgc gtc tac gca gcg gca gtc tta gcc gag cac cag cag Ser Ile Asn Arg Val Tyr Ala Ala Val Leu Ala Glu His Gln Gln 145 150 155 160	480
cac acc ttc tgg ggc cca ggt ttg tca cag ggc cac tcc gat gct ttg His Thr Phe Trp Gly Pro Gly Leu Ser Gln Gly His Ser Asp Ala Leu 165 170 175	528
cga cgc atc cct ggc gtt caa aag gcc gtc cag tac acc ctc cca tcc Arg Arg Ile Pro Gly Val Gln Lys Ala Val Gln Tyr Thr Leu Pro Ser 180 185 190	576
gaa gaa gcc ctg gaa aag gcc cgc cgt ggc gaa gcc ggc gac ctc acc Glu Glu Ala Leu Glu Lys Ala Arg Gly Glu Ala Gly Asp Leu Thr 195 200 205	624
gga aag caa acc cac aag cgc caa tgc ttc gtg gtt gcc gac gcg gcc Gly Lys Gln Thr His Lys Arg Gln Cys Phe Val Val Ala Asp Ala Ala 210 215 220	672
gac cac gag cgc atc gaa aac gac atc cgc acc atg cct gat tac ttc Asp His Glu Arg Ile Glu Asn Asp Ile Arg Thr Met Pro Asp Tyr Phe 225 230 235 240	720
gtt ggc tac gaa gtc gaa gtc aac ttc atc gac gaa gca acc ttg gac Val Gly Tyr Glu Val Glu Val Asn Phe Ile Asp Glu Ala Thr Leu Asp 245 250 255	768
gcc gag cac acc ggc atg cca cac ggc gga cac gtg atc acc acc ggc Ala Glu His Thr Gly Met Pro His Gly Gly His Val Ile Thr Thr Gly 260 265 270	816
gac acc ggt ggc ttc aac cac acc gtg gaa tac atc ctg aag ctg gac Asp Thr Gly Gly Phe Asn His Thr Val Glu Tyr Ile Leu Lys Leu Asp 275 280 285	864
cga aac cca gat ttc acc gct tct tca cag atc gct ttc ggc cgc gca Arg Asn Pro Asp Phe Thr Ala Ser Ser Gln Ile Ala Phe Gly Arg Ala 290 295 300	912
gct cac cgc atg aag cag cag ggc caa agc ggt gct ttc acc gtc ctc Ala His Arg Met Lys Gln Gln Gly Gln Ser Gly Ala Phe Thr Val Leu 305 310 315 320	960
gaa gtt gct cca tac ttg ctc tcc ccg gag aac ttg gat gat ctg atc Glu Val Ala Pro Tyr Leu Leu Ser Pro Glu Asn Leu Asp Asp Leu Ile 325 330 335	1008
gca cgc gac gtc taa Ala Arg Asp Val 340	1023

-16-

<210> 10

<211> 340

<212> PRT

<213> BF 100 qdh

<400> 10

Met His Phe Gly Lys Leu Asp Gln Asp Ser Ala Thr Thr Ile Leu Glu
1 5 10 15

Asp Tyr Lys Asn Met Thr Asn Ile Arg Val Ala Ile Val Gly Tyr Gly
20 25 30

Asn Leu Gly Arg Ser Val Glu Lys Leu Ile Ala Lys Gln Pro Asp Met
35 40 45

Asp Leu Val Gly Ile Phe Ser Arg Arg Ala Thr Leu Asp Thr Lys Thr
50 55 60

Pro Val Phe Asp Val Ala Asp Val Asp Lys His Ala Asp Asp Val Asp
65 70 75 80

Val Leu Phe Leu Cys Met Gly Ser Ala Thr Asp Ile Pro Glu Gln Ala
85 90 95

Pro Lys Phe Ala Gln Phe Ala Cys Thr Val Asp Thr Tyr Asp Asn His
100 105 110

Arg Asp Ile Pro Arg His Arg Gln Val Met Asn Glu Ala Ala Thr Ala
115 120 125

Ala Gly Asn Val Ala Leu Val Ser Thr Gly Trp Asp Pro Gly Met Phe
130 135 140

Ser Ile Asn Arg Val Tyr Ala Ala Ala Val Leu Ala Glu His Gln Gln
145 150 155 160

His Thr Phe Trp Gly Pro Gly Leu Ser Gln Gly His Ser Asp Ala Leu
165 170 175

Arg Arg Ile Pro Gly Val Gln Lys Ala Val Gln Tyr Thr Leu Pro Ser
180 185 190

Glu Glu Ala Leu Glu Lys Ala Arg Arg Gly Glu Ala Gly Asp Leu Thr
195 200 205

-17-

Gly Lys Gln Thr His Lys Arg Gln Cys Phe Val Val Ala Asp Ala Ala
 210 215 220

Asp His Glu Arg Ile Glu Asn Asp Ile Arg Thr Met Pro Asp Tyr Phe
 225 230 235 240

Val Gly Tyr Glu Val Glu Val Asn Phe Ile Asp Glu Ala Thr Leu Asp
 245 250 255

Ala Glu His Thr Gly Met Pro His Gly Gly His Val Ile Thr Thr Gly
 260 265 270

Asp Thr Gly Gly Phe Asn His Thr Val Glu Tyr Ile Leu Lys Leu Asp
 275 280 285

Arg Asn Pro Asp Phe Thr Ala Ser Ser Gln Ile Ala Phe Gly Arg Ala
 290 295 300

Ala His Arg Met Lys Gln Gln Gly Gln Ser Gly Ala Phe Thr Val Leu
 305 310 315 320

Glu Val Ala Pro Tyr Leu Leu Ser Pro Glu Asn Leu Asp Asp Leu Ile
 325 330 335

Ala Arg Asp Val
 340

<210> 11

<211> 1338

<212> DNA

<213> full length LysA

<220>

<221> CDS

<222> (1)..(1338)

<400> 11

atg gct aca gtt gaa aat ttc aat gaa ctt ccc gca cac gta tgg cca
 Met Ala Thr Val Glu Asn Phe Asn Glu Leu Pro Ala His Val Trp Pro
 1 5 10 15

48

cgc aat gca gtg cgc caa gaa gac ggc gtt gtc acc gtc gct ggt gtg
 Arg Asn Ala Val Arg Gln Glu Asp Gly Val Val Thr Val Ala Gly Val
 20 25 30

96

-18-

cct ctg cct gac ctc gct gaa gaa tac gga acc cca ctg ttc gta gtc Pro Leu Pro Asp Leu Ala Glu Tyr Gly Thr Pro Leu Phe Val Val 35 40 45	144
gac gag gac gat ttc cgt tcc cgc tgt cgc gac atg gct acc gca ttc Asp Glu Asp Asp Phe Arg Ser Arg Cys Arg Asp Met Ala Thr Ala Phe 50 55 60	192
ggt gga cca ggc aat gtg cac tac gca tcc aaa gcg ttc ctg acc aag Gly Gly Pro Gly Asn Val His Tyr Ala Ser Lys Ala Phe Leu Thr Lys 65 70 75 80	240
acc att gca cgt tgg gtt gat gaa gag ggg ctg gca ctg gac att gcg Thr Ile Ala Arg Trp Val Asp Glu Glu Gly Leu Ala Leu Asp Ile Ala 85 90 95	288
tcc atc aat gaa ctg ggc att gcc ctg gcc gct ggt ttc ccg gcc agc Ser Ile Asn Glu Leu Gly Ile Ala Leu Ala Ala Gly Phe Pro Ala Ser 100 105 110	336
cgt atc acc gcg cac ggc aac aac aaa ggc gta gag ttc ctg cgc gcg Arg Ile Thr Ala His Gly Asn Asn Lys Gly Val Glu Phe Leu Arg Ala 115 120 125	384
ttg gtt caa aac ggt gtc ggg cat gtg gtg ctg gac tcc gcg cag gaa Leu Val Gln Asn Gly Val Gly His Val Val Leu Asp Ser Ala Gln Glu 130 135 140	432
ttg gaa ctg ctg gat tac gtt gcc gct ggt gaa ggc aag atc cag gac Leu Glu Leu Leu Asp Tyr Val Ala Ala Gly Glu Gly Lys Ile Gln Asp 145 150 155 160	480
gtg ttg atc cgc gtg aag cca ggt atc gaa gcc cac acc cac gag ttc Val Leu Ile Arg Val Lys Pro Gly Ile Glu Ala His Thr His Glu Phe 165 170 175	528
atc gcc act agc cac gaa gac cag aag ttc gga ttc tcc ctg gca tcc Ile Ala Thr Ser His Glu Asp Gln Lys Phe Gly Phe Ser Leu Ala Ser 180 185 190	576
ggt tcc gca ttc gaa gca gcg aaa gca gcc aac aat gca gag aac ttg Gly Ser Ala Phe Glu Ala Ala Lys Ala Ala Asn Asn Ala Glu Asn Leu 195 200 205	624
aac ctg gtt ggt ctg cac tgc cat gtt ggt tcc cag gtg ttc gac gcc Asn Leu Val Gly Leu His Cys His Val Gly Ser Gln Val Phe Asp Ala 210 215 220	672
gaa ggc ttc aag ctg gca gca gag cgc gtg ttg ggc ctg tac tca cag Glu Gly Phe Lys Leu Ala Ala Glu Arg Val Leu Gly Leu Tyr Ser Gln 225 230 235 240	720
atc cac agc gaa cta ggt gtc gcc ctt cct gag ctg gac ctc ggt ggc Ile His Ser Glu Leu Gly Val Ala Leu Pro Glu Leu Asp Leu Gly Gly 245 250 255	768
gga tac ggc atc gcc tac act gca gat gag gaa cca ctc aac gtc gca Gly Tyr Gly Ile Ala Tyr Thr Ala Asp Glu Glu Pro Leu Asn Val Ala 260 265 270	816
gaa gtc gcc tcc gac cta ctc acc gca gtc gga aaa atg gca gcg gaa Glu Val Ala Ser Asp Leu Leu Thr Ala Val Gly Lys Met Ala Ala Glu 275 280 285	864

-19-

cta ggc atc gac gca cca acc gtg ctt gtt gag ccc ggc cgc gct atc 912
 Leu Gly Ile Asp Ala Pro Thr Val Leu Val Glu Pro Gly Arg Ala Ile
 290 295 300

gca ggc ccc tcc acc gtg acc atc tac gaa gtc ggc acc acc aaa aac 960
 Ala Gly Pro Ser Thr Val Thr Ile Tyr Glu Val Gly Thr Thr Lys Asn
 305 310 315 320

gtc cac gta gac gac gac aaa acc cgc cgc tac gta gcc gtc gac gga 1008
 Val His Val Asp Asp Asp Lys Thr Arg Arg Tyr Val Ala Val Asp Gly
 325 330 335

ggc atg tcc gac aac atc cgc cca gca ctc tac ggc tcc gaa tac gac 1056
 Gly Met Ser Asp Asn Ile Arg Pro Ala Leu Tyr Gly Ser Glu Tyr Asp
 340 345 350

gcc cgc gta gta tcc cgc ttc gcc gaa gga gac cca gta agc acc cgc 1104
 Ala Arg Val Val Ser Arg Phe Ala Glu Gly Asp Pro Val Ser Thr Arg
 355 360 365

atc gtg ggc tcc cac tgc gaa tcc ggc gat atc ctg atc aac gat gaa 1152
 Ile Val Gly Ser His Cys Glu Ser Gly Asp Ile Leu Ile Asn Asp Glu
 370 375 380

atc tac cca tct gac atc acc agc ggc gac ttc ctc gca ctc gca gcc 1200
 Ile Tyr Pro Ser Asp Ile Thr Ser Gly Asp Phe Leu Ala Leu Ala Ala
 385 390 395 400

acc ggc gca tac tgc tac gcc atg agc tcc cgc tac aac gcc ttc aca 1248
 Thr Gly Ala Tyr Cys Tyr Ala Met Ser Ser Arg Tyr Asn Ala Phe Thr
 405 410 415

cgg ccc gcc gtc gtg tcc gtc cgc gct ggc agc tcc cgc ctc atg ctg 1296
 Arg Pro Ala Val Val Ser Val Arg Ala Gly Ser Ser Arg Leu Met Leu
 420 425 430

cgc cgc gaa acc ctc gac gac atc ctc tca cta gag gca taa 1338
 Arg Arg Glu Thr Leu Asp Asp Ile Leu Ser Leu Glu Ala
 435 440 445

<210> 12

<211> 445

<212> PRT

<213> full length LysA

<400> 12

Met Ala Thr Val Glu Asn Phe Asn Glu Leu Pro Ala His Val Trp Pro
 1 5 10 15

Arg Asn Ala Val Arg Gln Glu Asp Gly Val Val Thr Val Ala Gly Val
 20 25 30

Pro Leu Pro Asp Leu Ala Glu Glu Tyr Gly Thr Pro Leu Phe Val Val
 35 40 45

-20-

Asp Glu Asp Asp Phe Arg Ser Arg Cys Arg Asp Met Ala Thr Ala Phe
50 55 60

Gly Gly Pro Gly Asn Val His Tyr Ala Ser Lys Ala Phe Leu Thr Lys
65 70 75 80

Thr Ile Ala Arg Trp Val Asp Glu Glu Gly Leu Ala Leu Asp Ile Ala
85 90 95

Ser Ile Asn Glu Leu Gly Ile Ala Leu Ala Ala Gly Phe Pro Ala Ser
100 105 110

Arg Ile Thr Ala His Gly Asn Asn Lys Gly Val Glu Phe Leu Arg Ala
115 120 125

Leu Val Gln Asn Gly Val Gly His Val Val Leu Asp Ser Ala Gln Glu
130 135 140

Leu Glu Leu Leu Asp Tyr Val Ala Ala Gly Glu Gly Lys Ile Gln Asp
145 150 155 160

Val Leu Ile Arg Val Lys Pro Gly Ile Glu Ala His Thr His Glu Phe
165 170 175

Ile Ala Thr Ser His Glu Asp Gln Lys Phe Gly Phe Ser Leu Ala Ser
180 185 190

Gly Ser Ala Phe Glu Ala Ala Lys Ala Ala Asn Asn Ala Glu Asn Leu
195 200 205

Asn Leu Val Gly Leu His Cys His Val Gly Ser Gln Val Phe Asp Ala
210 215 220

Glu Gly Phe Lys Leu Ala Ala Glu Arg Val Leu Gly Leu Tyr Ser Gln
225 230 235 240

Ile His Ser Glu Leu Gly Val Ala Leu Pro Glu Leu Asp Leu Gly Gly
245 250 255

Gly Tyr Gly Ile Ala Tyr Thr Ala Asp Glu Glu Pro Leu Asn Val Ala
260 265 270

Glu Val Ala Ser Asp Leu Leu Thr Ala Val Gly Lys Met Ala Ala Glu
275 280 285

Leu Gly Ile Asp Ala Pro Thr Val Leu Val Glu Pro Gly Arg Ala Ile
290 295 300

-21-

Ala Gly Pro Ser Thr Val Thr Ile Tyr Glu Val Gly Thr Thr Lys Asn
305 310 315 320

Val His Val Asp Asp Asp Lys Thr Arg Arg Tyr Val Ala Val Asp Gly
325 330 335

Gly Met Ser Asp Asn Ile Arg Pro Ala Leu Tyr Gly Ser Glu Tyr Asp
340 345 350

Ala Arg Val Val Ser Arg Phe Ala Glu Gly Asp Pro Val Ser Thr Arg
355 360 365

Ile Val Gly Ser His Cys Glu Ser Gly Asp Ile Leu Ile Asn Asp Glu
370 375 380

Ile Tyr Pro Ser Asp Ile Thr Ser Gly Asp Phe Leu Ala Leu Ala Ala
385 390 395 400

Thr Gly Ala Tyr Cys Tyr Ala Met Ser Ser Arg Tyr Asn Ala Phe Thr
405 410 415

Arg Pro Ala Val Val Ser Val Arg Ala Gly Ser Ser Arg Leu Met Leu
420 425 430

Arg Arg Glu Thr Leu Asp Asp Ile Leu Ser Leu Glu Ala
435 440 445

<210> 13

<211> 1338

<212> DNA

<213> AS019 lysA (PRS6)

<220>

<221> CDS

<222> (1)..(1338)

<400> 13

atg gct aca gtt gaa aat ttc aat gaa ctt ccc gca cac gta tgg cca
Met Ala Thr Val Glu Asn Phe Asn Glu Leu Pro Ala His Val Trp Pro
1 5 10 15

48

cgc aat gcc gtg cgc caa gaa gac ggc gtt gtc acc gtc gct ggt gtg
Arg Asn Ala Val Arg Gln Glu Asp Gly Val Val Thr Val Ala Gly Val
20 25 30

96

-22-

cct ctg cct gac ctc gct gaa gaa tac gga acc cca ctg ttc gta gtc Pro Leu Pro Asp Leu Ala Glu Glu Tyr Gly Thr Pro Leu Phe Val Val 35 40 45	144
gac gag gac gat ttc cgt tcc cgc tgt cgc gac atg gct acc gca ttc Asp Glu Asp Asp Phe Arg Ser Arg Cys Arg Asp Met Ala Thr Ala Phe 50 55 60	192
ggc gga cca ggc aat gtg cac tac gca tct aaa gcg ttc ctg acc aag Gly Gly Pro Gly Asn Val His Tyr Ala Ser Lys Ala Phe Leu Thr Lys 65 70 75 80	240
acc att gca cgt tgg gtt gat gaa gag ggg ctg gca ctg gac att gca Thr Ile Ala Arg Trp Val Asp Glu Glu Gly Leu Ala Leu Asp Ile Ala 85 90 95	288
tcc atc aac gaa ctg ggc att gcc ctg gcc gct ggt ttc ccc gcc agc Ser Ile Asn Glu Leu Gly Ile Ala Leu Ala Gly Phe Pro Ala Ser 100 105 110	336
cgt atc acc gcg cac ggc aac aac aaa ggc gta gag ttc ctg cgc gcg Arg Ile Thr Ala His Gly Asn Asn Lys Gly Val Glu Phe Leu Arg Ala 115 120 125	384
ttg gtt caa aac ggt gtg gga cac gtg gtg ctg gac tcc gca cag gaa Leu Val Gln Asn Gly Val Gly His Val Val Leu Asp Ser Ala Gln Glu 130 135 140	432
cta gaa ctg ttg gat tac gtt gcc gct ggt gaa ggc aag att cag gac Leu Glu Leu Leu Asp Tyr Val Ala Ala Gly Glu Gly Lys Ile Gln Asp 145 150 155 160	480
gtg ttg atc cgc gta aag cca ggc atc gaa gca cac acc cac gag ttc Val Leu Ile Arg Val Lys Pro Gly Ile Glu Ala His Thr His Glu Phe 165 170 175	528
atc gcc act agc cac gaa gac cag aag ttc gga ttc tcc ctg gca tcc Ile Ala Thr Ser His Glu Asp Gln Lys Phe Gly Phe Ser Leu Ala Ser 180 185 190	576
ggc tcc gca ttc gaa gca gca aaa gcc gcc aac aac gca gaa aac ctg Gly Ser Ala Phe Glu Ala Ala Lys Ala Ala Asn Asn Ala Glu Asn Leu 195 200 205	624
aac ctg gtt ggc ctg cac tgc cac gtt ggt tcc cag gtg ttc gac gcc Asn Leu Val Gly Leu His Cys His Val Gly Ser Gln Val Phe Asp Ala 210 215 220	672
gaa ggc ttc aag ctg gca gca gaa cgc gtg ttg ggc ctg tac tca cag Glu Gly Phe Lys Leu Ala Ala Glu Arg Val Leu Gly Leu Tyr Ser Gln 225 230 235 240	720
atc cac agc gaa ctg ggc gtt gcc ctt cct gaa ctg gat ctc ggt ggc Ile His Ser Glu Leu Gly Val Ala Leu Pro Glu Leu Asp Leu Gly Gly 245 250 255	768
gga tac ggc att gcc tat acc gca gct gaa gaa cca ctc aac gtc gca Gly Tyr Gly Ile Ala Tyr Thr Ala Ala Glu Glu Pro Leu Asn Val Ala 260 265 270	816
gaa gtt gcc tcc gac ctg ctc acc gca gtc gga aaa atg gca gcg gaa Glu Val Ala Ser Asp Leu Leu Thr Ala Val Gly Lys Met Ala Ala Glu 275 280 285	864

-23-

cta ggc atc gac gca cca acc gtg ctt gtt gag ccc ggc cgc gct atc 912
 Leu Gly Ile Asp Ala Pro Thr Val Leu Val Glu Pro Gly Arg Ala Ile
 290 295 300

gca ggc ccc tcc acc gtg acc atc tac gaa gtc ggc acc acc aaa gac 960
 Ala Gly Pro Ser Thr Val Thr Ile Tyr Glu Val Gly Thr Thr Lys Asp
 305 310 315 320

gtc cac gta gac gac gac aaa acc cgc cgt tac atc gcc gtg gac gga 1008
 Val His Val Asp Asp Asp Lys Thr Arg Arg Tyr Ile Ala Val Asp Gly
 325 330 335

ggc atg tcc gac aac atc cgc cca gca ctc tac ggc tcc gaa tac gac 1056
 Gly Met Ser Asp Asn Ile Arg Pro Ala Leu Tyr Gly Ser Glu Tyr Asp
 340 345 350

gcc cgc gta gta tcc cgc ttc gcc gaa gga gac cca gta agc acc cgc 1104
 Ala Arg Val Val Ser Arg Phe Ala Glu Gly Asp Pro Val Ser Thr Arg
 355 360 365

atc gtg ggc tcc cac tgc gaa tcc ggc gat atc ctg atc aac gat gaa 1152
 Ile Val Gly Ser His Cys Glu Ser Gly Asp Ile Leu Ile Asn Asp Glu
 370 375 380

atc tac cca tct gac atc acc agc ggc gac ttc ctt gca ctc gca gcc 1200
 Ile Tyr Pro Ser Asp Ile Thr Ser Gly Asp Phe Leu Ala Leu Ala Ala
 385 390 395 400

acc ggc gca tac tgc tac gcc atg agc tcc cgc tac aac gcc ttc aca 1248
 Thr Gly Ala Tyr Cys Tyr Ala Met Ser Ser Arg Tyr Asn Ala Phe Thr
 405 410 415

cgg ccc gcc gtc gtg tcc gtc cgc gct ggc agc tcc cgc ctc atg ctg 1296
 Arg Pro Ala Val Val Ser Val Arg Ala Gly Ser Ser Arg Leu Met Leu
 420 425 430

cgc cgc gaa acg ctc gac gac atc ctc tca cta gag gca taa 1338
 Arg Arg Glu Thr Leu Asp Asp Ile Leu Ser Leu Glu Ala
 435 440 445

<210> 14

<211> 445

<212> PRT

<213> AS019 lysA (pRS6)

<400> 14

Met Ala Thr Val Glu Asn Phe Asn Glu Leu Pro Ala His Val Trp Pro
 1 5 10 15

Arg Asn Ala Val Arg Gln Glu Asp Gly Val Val Thr Val Ala Gly Val
 20 25 30

Pro Leu Pro Asp Leu Ala Glu Glu Tyr Gly Thr Pro Leu Phe Val Val
 35 40 45

-24-

Asp Glu Asp Asp Phe Arg Ser Arg Cys Arg Asp Met Ala Thr Ala Phe
50 55 60

Gly Gly Pro Gly Asn Val His Tyr Ala Ser Lys Ala Phe Leu Thr Lys
65 70 75 80

Thr Ile Ala Arg Trp Val Asp Glu Glu Gly Leu Ala Leu Asp Ile Ala
85 90 95

Ser Ile Asn Glu Leu Gly Ile Ala Leu Ala Ala Gly Phe Pro Ala Ser
100 105 110

Arg Ile Thr Ala His Gly Asn Asn Lys Gly Val Glu Phe Leu Arg Ala
115 120 125

Leu Val Gln Asn Gly Val Gly His Val Val Leu Asp Ser Ala Gln Glu
130 135 140

Leu Glu Leu Leu Asp Tyr Val Ala Ala Gly Glu Gly Lys Ile Gln Asp
145 150 155 160

Val Leu Ile Arg Val Lys Pro Gly Ile Glu Ala His Thr His Glu Phe
165 170 175

Ile Ala Thr Ser His Glu Asp Gln Lys Phe Gly Phe Ser Leu Ala Ser
180 185 190

Gly Ser Ala Phe Glu Ala Ala Lys Ala Ala Asn Asn Ala Glu Asn Leu
195 200 205

Asn Leu Val Gly Leu His Cys His Val Gly Ser Gln Val Phe Asp Ala
210 215 220

Glu Gly Phe Lys Leu Ala Ala Glu Arg Val Leu Gly Leu Tyr Ser Gln
225 230 235 240

Ile His Ser Glu Leu Gly Val Ala Leu Pro Glu Leu Asp Leu Gly Gly
245 250 255

Gly Tyr Gly Ile Ala Tyr Thr Ala Ala Glu Glu Pro Leu Asn Val Ala
260 265 270

Glu Val Ala Ser Asp Leu Leu Thr Ala Val Gly Lys Met Ala Ala Glu
275 280 285

-25-

Leu Gly Ile Asp Ala Pro Thr Val Leu Val Glu Pro Gly Arg Ala Ile
 290 295 300

Ala Gly Pro Ser Thr Val Thr Ile Tyr Glu Val Gly Thr Thr Lys Asp
 305 310 315 320

Val His Val Asp Asp Asp Lys Thr Arg Arg Tyr Ile Ala Val Asp Gly
 325 330 335

Gly Met Ser Asp Asn Ile Arg Pro Ala Leu Tyr Gly Ser Glu Tyr Asp
 340 345 350

Ala Arg Val Val Ser Arg Phe Ala Glu Gly Asp Pro Val Ser Thr Arg
 355 360 365

Ile Val Gly Ser His Cys Glu Ser Gly Asp Ile Leu Ile Asn Asp Glu
 370 375 380

Ile Tyr Pro Ser Asp Ile Thr Ser Gly Asp Phe Leu Ala Leu Ala Ala
 385 390 395 400

Thr Gly Ala Tyr Cys Tyr Ala Met Ser Ser Arg Tyr Asn Ala Phe Thr
 405 410 415

Arg Pro Ala Val Val Ser Val Arg Ala Gly Ser Ser Arg Leu Met Leu
 420 425 430

Arg Arg Glu Thr Leu Asp Asp Ile Leu Ser Leu Glu Ala
 435 440 445

<210> 15

<211> 753

<212> DNA

<213> orf2 in dapBA operon

<220>

<221> CDS

<222> (1)..(753)

<400> 15
 gtg gcc gaa caa gtt aaa ttg agc gtg gag ttg ata gcg tgc agt tct
 Met Ala Glu Gln Val Lys Leu Ser Val Glu Leu Ile Ala Cys Ser Ser
 1 5 10 15 48

-26-

ttt act cca ccc gct gat gtt gag tgg tca act gat gtt gag ggc gcg Phe Thr Pro Pro Ala Asp Val Glu Trp Ser Thr Asp Val Glu Gly Ala 20 25 30	96
gaa gca ctc gtc gag ttt gcg ggt cgt gcc tgc tac gaa act ttt gat Glu Ala Leu Val Glu Phe Ala Gly Arg Ala Cys Tyr Glu Thr Phe Asp 35 40 45	144
aag ccg aac cct cga act gct tcc aat gct gcg tat ctg cgc cac atc Lys Pro Asn Pro Arg Thr Ala Ser Asn Ala Ala Tyr Leu Arg His Ile 50 55 60	192
atg gaa gtg ggg cac act gct ttg ctt gag cat gcc aat gcc acg atg Met Glu Val Gly His Thr Ala Leu Leu Glu His Ala Asn Ala Thr Met 65 70 75 80	240
tat atc cga ggc att tct cgg tcc gcg acc cat gaa ttg gtc cga cac Tyr Ile Arg Gly Ile Ser Arg Ser Ala Thr His Glu Leu Val Arg His 85 90 95	288
cgc cat ttt tcc ttc tct caa ctg tct cag cgt ttc gtg cac agc gga Arg His Phe Ser Phe Ser Gln Leu Ser Gln Arg Phe Val His Ser Gly 100 105 110	336
gaa tcg gaa gta gtg gtg ccc act ctc atc gat gaa gat ccg cag ttg Glu Ser Glu Val Val Val Pro Thr Leu Ile Asp Glu Asp Pro Gln Leu 115 120 125	384
cgt gaa ctt ttc atg cac gcc atg gat gag tct cgg ttc gct ttc aat Arg Glu Leu Phe Met His Ala Met Asp Glu Ser Arg Phe Ala Phe Asn 130 135 140	432
gag ctg ctt aat gcg ctg gaa gaa aaa ctt ggc gat gaa ccg aat gca Glu Leu Leu Asn Ala Leu Glu Glu Lys Leu Gly Asp Glu Pro Asn Ala 145 150 155 160	480
ctt tta agg aaa aag cag gct cgt caa gca gct cgc gct gtg ctg ccc Leu Leu Arg Lys Lys Gln Ala Arg Gln Ala Ala Arg Ala Val Leu Pro 165 170 175	528
aac gct aca gag tcc aga atc gtg gtg tct gga aac ttc cgc acc tgg Asn Ala Thr Glu Ser Arg Ile Val Val Ser Gly Asn Phe Arg Thr Trp 180 185 190	576
agg cat ttc att ggc atg cga gcc agt gaa cat gca gac gtc gaa atc Arg His Phe Ile Gly Met Arg Ala Ser Glu His Ala Asp Val Glu Ile 195 200 205	624
cgc gaa gta gcg gta gga tgt tta aga aag ctg cag gta gca gcg cca Arg Glu Val Ala Val Gly Cys Leu Arg Lys Leu Gln Val Ala Ala Pro 210 215 220	672
act gtt ttc ggt gat ttt gag att gaa act ttg gca gac gga tcg caa Thr Val Phe Gly Asp Phe Glu Ile Glu Thr Leu Ala Asp Gly Ser Gln 225 230 235 240	720
atg gca aca agc ccg tat gtc atg gac ttt taa Met Ala Thr Ser Pro Tyr Val Met Asp Phe 245 250	753

-27-

<210> 16

<211> 250

<212> PRT

<213> orf2 in dapBA operon

<400> 16

Met Ala Glu Gln Val Lys Leu Ser Val Glu Leu Ile Ala Cys Ser Ser
1 5 10 15

Phe Thr Pro Pro Ala Asp Val Glu Trp Ser Thr Asp Val Glu Gly Ala
20 25 30

Glu Ala Leu Val Glu Phe Ala Gly Arg Ala Cys Tyr Glu Thr Phe Asp
35 40 45

Lys Pro Asn Pro Arg Thr Ala Ser Asn Ala Ala Tyr Leu Arg His Ile
50 55 60

Met Glu Val Gly His Thr Ala Leu Leu Glu His Ala Asn Ala Thr Met
65 70 75 80

Tyr Ile Arg Gly Ile Ser Arg Ser Ala Thr His Glu Leu Val Arg His
85 90 95

Arg His Phe Ser Phe Ser Gln Leu Ser Gln Arg Phe Val His Ser Gly
100 105 110

Glu Ser Glu Val Val Val Pro Thr Leu Ile Asp Glu Asp Pro Gln Leu
115 120 125

Arg Glu Leu Phe Met His Ala Met Asp Glu Ser Arg Phe Ala Phe Asn
130 135 140

Glu Leu Leu Asn Ala Leu Glu Glu Lys Leu Gly Asp Glu Pro Asn Ala
145 150 155 160

Leu Leu Arg Lys Lys Gln Ala Arg Gln Ala Ala Arg Ala Val Leu Pro
165 170 175

Asn Ala Thr Glu Ser Arg Ile Val Val Ser Gly Asn Phe Arg Thr Trp
180 185 190

Arg His Phe Ile Gly Met Arg Ala Ser Glu His Ala Asp Val Glu Ile
195 200 205

-28-

Arg Glu Val Ala Val Gly Cys Leu Arg Lys Leu Gln Val Ala Ala Pro
 210 215 220

Thr Val Phe Gly Asp Phe Glu Ile Glu Thr Leu Ala Asp Gly Ser Gln
 225 230 235 240

Met Ala Thr Ser Pro Tyr Val Met Asp Phe
 245 250

<210> 17

<211> 551

<212> DNA

<213> HpaI-PvuII fragment comprising the P1 promoter

<400> 17
 aaccggtgtg gagccgacca ttccgcgagg ctgcactgca acgaggtcgt agtttttgta 60
 catggcttct ggccagttca tggattggct gccgaagaag ctataggcat cgccaccagg 120
 gccaccggag ttaccgaaga tggtgccgtg cttttgcct tgggcaggga ccttgacaaa 180
 gcccacgctg atatcgccaa gtgagggatc agaatagtgc atgggcacgt cgatgctgcc 240
 acattgagcg gaggcaatat ctacctgagg tgggcattct tcccagcgga tgttttcttg 300
 cgctgctgca gtgggcattg ataccaaaaa ggggctaagc gcagtcgagg cggcaagaac 360
 tgctactacc ttttttattg tcgaacgggg cattacggct ccaaggacgt ttgttttctg 420
 ggtcagttac cccaaaaagc atatacagag accaatgatt tttcattaaa aaggcaggga 480
 tttgttataa gtatgggtcg tattctgtgc gacgggtgta cctcggctag aatttctccc 540
 catgacacca g 551

<210> 18

<211> 365

<212> DNA

<213> truncated ORF2

<220>

<221> CDS

<222> (1) .. (365)

-29-

<400> 18
 gtg gcc gaa caa gtt aaa ttg agc gtg gag ttg ata gcg tgc agt tct 48
 Met Ala Glu Gln Val Lys Leu Ser Val Glu Leu Ile Ala Cys Ser Ser
 1 5 10 15

ttt act cca ccc gct gat gtt gag tgg tca act gat gtt gag ggc gcg 96
 Phe Thr Pro Pro Ala Asp Val Glu Trp Ser Thr Asp Val Glu Gly Ala
 20 25 30

gaa gca ctc gtc gag ttt gcg ggt cgt gcc tgc tac gaa act ttt gat 144
 Glu Ala Leu Val Glu Phe Ala Gly Arg Ala Cys Tyr Glu Thr Phe Asp
 35 40 45

aag ccg aac cct cga act gct tcc aat gct gcg tat ctg cgc cac atc 192
 Lys Pro Asn Pro Arg Thr Ala Ser Asn Ala Ala Tyr Leu Arg His Ile
 50 55 60

atg gaa gtg ggg cac act gct ttg ctt gag cat gcc aat gcc acg atg 240
 Met Glu Val Gly His Thr Ala Leu Leu Glu His Ala Asn Ala Thr Met
 65 70 75 80

tat atc cga ggc att tct cgg tcc gcg acc cat gaa ttg gtc cga cac 288
 Tyr Ile Arg Gly Ile Ser Arg Ser Ala Thr His Glu Leu Val Arg His
 85 90 95

cgc cat ttt tcc ttc tct caa ctg tct cag cgt ttc gtg cac agc gga 336
 Arg His Phe Ser Phe Ser Gln Leu Ser Gln Arg Phe Val His Ser Gly
 100 105 110

gaa tcg gaa gta gtg gtg ccc act ctc at 365
 Glu Ser Glu Val Val Val Pro Thr Leu Ile
 115 120

<210> 19

<211> 122

<212> PRT

<213> truncated ORF2

<400> 19
 Met Ala Glu Gln Val Lys Leu Ser Val Glu Leu Ile Ala Cys Ser Ser
 1 5 10 15

Phe Thr Pro Pro Ala Asp Val Glu Trp Ser Thr Asp Val Glu Gly Ala
 20 25 30

Glu Ala Leu Val Glu Phe Ala Gly Arg Ala Cys Tyr Glu Thr Phe Asp
 35 40 45

Lys Pro Asn Pro Arg Thr Ala Ser Asn Ala Ala Tyr Leu Arg His Ile
 50 55 60

Met Glu Val Gly His Thr Ala Leu Leu Glu His Ala Asn Ala Thr Met
 65 70 75 80

-30-

Tyr Ile Arg Gly Ile Ser Arg Ser Ala Thr His Glu Leu Val Arg His
85 90 95

Arg His Phe Ser Phe Ser Gln Leu Ser Gln Arg Phe Val His Ser Gly
100 105 110

Glu Ser Glu Val Val Val Pro Thr Leu Ile
115 120

<210> 20

<211> 833

<212> DNA

<213> truncated LysA ('LysA)

<220>

<221> CDS

<222> (1)..(833)

<400> 20

atg gct aca gtt gaa aat ttc aat gaa ctt ccc gca cac gta tgg cca 48
Met Ala Thr Val Glu Asn Phe Asn Glu Leu Pro Ala His Val Trp Pro
1 5 10 15

cgc aat gca gtg cgc caa gaa gac ggc gtt gtc acc gtc gct ggt gtg 96
Arg Asn Ala Val Arg Gln Glu Asp Gly Val Val Thr Val Ala Gly Val
20 25 30

cct ctg cct gac ctc gct gaa gaa tac gga acc cca ctg ttc gta gtc 144
Pro Leu Pro Asp Leu Ala Glu Tyr Gly Thr Pro Leu Phe Val Val
35 40 45

gac gag gac gat ttc cgt tcc cgc tgt cgc gac atg gct acc gca ttc 192
Asp Glu Asp Asp Phe Arg Ser Arg Cys Arg Asp Met Ala Thr Ala Phe
50 55 60

ggt gga cca ggc aat gtg cac tac gca tcc aaa gcg ttc ctg acc aag 240
Gly Gly Pro Gly Asn Val His Tyr Ala Ser Lys Ala Phe Leu Thr Lys
65 70 75 80

acc att gca cgt tgg gtt gat gaa gag ggg ctg gca ctg gac att gcg 288
Thr Ile Ala Arg Trp Val Asp Glu Glu Gly Leu Ala Leu Asp Ile Ala
85 90 95

tcc atc aat gaa ctg ggc att gcc ctg gcc gct ggt ttc ccg gcc agc 336
Ser Ile Asn Glu Leu Gly Ile Ala Leu Ala Ala Gly Phe Pro Ala Ser
100 105 110

cgt atc acc gcg cac ggc aac aac aaa ggc gta gag ttc ctg cgc gcg 384
Arg Ile Thr Ala His Gly Asn Asn Lys Gly Val Glu Phe Leu Arg Ala
115 120 125

-31-

ttg gtt caa aac ggt gtc ggg cat gtg gtg ctg gac tcc gcg cag gaa 432
 Leu Val Gln Asn Gly Val Gly His Val Val Leu Asp Ser Ala Gln Glu
 130 135 140

ttg gaa ctg ctg gat tac gtt gcc gct ggt gaa ggc aag atc cag gac 480
 Leu Glu Leu Leu Asp Tyr Val Ala Ala Gly Glu Gly Lys Ile Gln Asp
 145 150 155 160

gtg ttg atc cgc gtg aag cca ggt atc gaa gcc cac acc cac gag ttc 528
 Val Leu Ile Arg Val Lys Pro Gly Ile Glu Ala His Thr His Glu Phe
 165 170 175

atc gcc act agc cac gaa gac cag aag ttc gga ttc tcc ctg gca tcc 576
 Ile Ala Thr Ser His Glu Asp Gln Lys Phe Gly Phe Ser Leu Ala Ser
 180 185 190

ggt tcc gca ttc gaa gca gcg aaa gca gcc aac aat gca gag aac ttg 624
 Gly Ser Ala Phe Glu Ala Ala Lys Ala Ala Asn Asn Ala Glu Asn Leu
 195 200 205

aac ctg gtt ggt ctg cac tgc cat gtt ggt tcc cag gtg ttc gac gcc 672
 Asn Leu Val Gly Leu His Cys His Val Gly Ser Gln Val Phe Asp Ala
 210 215 220

gaa ggc ttc aag ctg gca gca gag cgc gtg ttg ggc ctg tac tca cag 720
 Glu Gly Phe Lys Leu Ala Ala Glu Arg Val Leu Gly Leu Tyr Ser Gln
 225 230 235 240

atc cac agc gaa cta ggt gtc gcc ctt cct gag ctg gac ctc ggt ggc 768
 Ile His Ser Glu Leu Gly Val Ala Leu Pro Glu Leu Asp Leu Gly Gly
 245 250 255

gga tac ggc atc gcc tac act gca gat gag gaa cca ctc aac gtc gca 816
 Gly Tyr Gly Ile Ala Tyr Thr Ala Asp Glu Glu Pro Leu Asn Val Ala
 260 265 270

gaa gtc gcc tcc gac ct 833
 Glu Val Ala Ser Asp Leu
 275

<210> 21

<211> 278

<212> PRT

<213> truncated LysA ('LysA)

<400> 21

Met Ala Thr Val Glu Asn Phe Asn Glu Leu Pro Ala His Val Trp Pro
 1 5 10 15

Arg Asn Ala Val Arg Gln Glu Asp Gly Val Val Thr Val Ala Gly Val
 20 25 30

Pro Leu Pro Asp Leu Ala Glu Glu Tyr Gly Thr Pro Leu Phe Val Val
 35 40 45

-32-

Asp Glu Asp Asp Phe Arg Ser Arg Cys Arg Asp Met Ala Thr Ala Phe
50 55 60

Gly Gly Pro Gly Asn Val His Tyr Ala Ser Lys Ala Phe Leu Thr Lys
65 70 75 80

Thr Ile Ala Arg Trp Val Asp Glu Glu Gly Leu Ala Leu Asp Ile Ala
85 90 95

Ser Ile Asn Glu Leu Gly Ile Ala Leu Ala Ala Gly Phe Pro Ala Ser
100 105 110

Arg Ile Thr Ala His Gly Asn Asn Lys Gly Val Glu Phe Leu Arg Ala
115 120 125

Leu Val Gln Asn Gly Val Gly His Val Val Leu Asp Ser Ala Gln Glu
130 135 140

Leu Glu Leu Leu Asp Tyr Val Ala Ala Gly Glu Gly Lys Ile Gln Asp
145 150 155 160

Val Leu Ile Arg Val Lys Pro Gly Ile Glu Ala His Thr His Glu Phe
165 170 175

Ile Ala Thr Ser His Glu Asp Gln Lys Phe Gly Phe Ser Leu Ala Ser
180 185 190

Gly Ser Ala Phe Glu Ala Ala Lys Ala Ala Asn Asn Ala Glu Asn Leu
195 200 205

Asn Leu Val Gly Leu His Cys His Val Gly Ser Gln Val Phe Asp Ala
210 215 220

Glu Gly Phe Lys Leu Ala Ala Glu Arg Val Leu Gly Leu Tyr Ser Gln
225 230 235 240

Ile His Ser Glu Leu Gly Val Ala Leu Pro Glu Leu Asp Leu Gly Gly
245 250 255

Gly Tyr Gly Ile Ala Tyr Thr Ala Asp Glu Glu Pro Leu Asn Val Ala
260 265 270

Glu Val Ala Ser Asp Leu
275